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1 INTRODUCTION 
1.1 Molybdenum cofactor (MoCo) deficiency 
Molybdenum cofactor (MoCo) deficiency (complementation group A, B and C; OMIM# 
252150, #252160 and #615501) is a rare, autosomal recessive disease leading to a 
combined deficiency of all MoCo-dependent enzymes. The usual phenotype includes 
untreatable neonatal seizures, mental retardation in association with elevated levels of 
xanthine in the plasma and urine, and elevated urine sulphites, particularly S-
sulphocysteine (Macaya et al., 2005), as well as feeding difficulties and dysmorphic facial 
features. Most infants die in early childhood, those who survive the neonatal period have 
a profound developmental delay with abnormal tone, lens dislocation, and renal stones 
(Carmi-Nawi et al., 2011). Additionally, computed tomography (CT) and magnetic 
resonance imaging (MRI) often reveals dramatic and progressive loss of white matter in 
the brain (Reiss and Johnson, 2003). Although in MoCo deficiency all MoCo-dependent 
enzymes are inactive, the clinical findings are attributable to the loss of sulphite oxidase 
activity and the subsequent neurotoxic effect of sulphite accumulation (Reiss et al., 2005). 
Both diseases MoCo deficiency and sulphite oxidase (SUOX) deficiency are clinically 
indistinguishable, and only biochemical tests can differentiate these two disorders. 
Besides an elevated sulphite level, MoCo-deficient patients present a diminished uric acid 
level, and an elevated xanthine concentration in the plasma and urine caused by the loss 
of xanthine dehydrogenase activity (Reiss and Johnson, 2003). In contrast to SUOX 
deficiency, therapy for type A of MoCo deficiency is available so the appropriate diagnosis 
increases the chances to rescue MoCo-deficient patients. Since MoCo is synthesised in a 
multi-step biosynthesis pathway, disease-causing mutations can occur in different genes. 
Dependent on the mutated gene, one can distinguish between three types of MoCo 
deficiency: type A, B and C (Fig. 1.1). In type A deficiency, mutations are present in the 
MOCS1 gene and abolish the formation of cyclic pyranopterin monophosphate (cPMP). 
The type B deficiency of the disease is characterised by mutations present in the MOCS2 
gene, thus blocking the conversion of cPMP to molybdopterin (MPT). In the last type of 
the deficiency, type C, the GPHN gene is affected preventing MPT from adenylation and 
further incorporation of molybdate to the pterin moiety (Arenas et al., 2009). To date, 
mutations in the MOCS3 gene have not been described (Reiss and Hahnewald, 2011). As 
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type A of the disease is the most frequent form (Reiss et al., 1998), a murine Mocs1 
knockout mouse model was developed. Mocs1 knockout mice represent a similar 
phenotype observed in MoCo deficiency type A patients, but without morphological 
changes in the brain and ectopic lenses. In addition, the Mocs1 knockout animals 
reflected biochemical abnormalities typical for MoCo deficiency type A such as elevated 
level of sulphite and xanthine, and also exhibited early postnatal death (Lee et al., 2002). 
 
1.2 Molybdenum cofactor (MoCo) 
Molybdenum (Mo) is an essential trace element for several enzymes important for 
metabolism processes in almost all living organisms (Zhang et al., 2011). To date, more 
than 50 molybdenum-containing enzymes have been described. The vast majority of 
these enzymes have been found in bacteria and only seven in eukaryotes (Zhang and 
Gladyshev, 2008; Hille et al., 2011). Bacteria as well as eukaryotic cells take up Mo in the 
form of its oxyanion molybdate (MoO42-) (Bortels, 1930). The mechanism of this action is 
well studied in bacteria, where ABC- (ATP-binding cassette) type transporters consisting 
of three proteins encoded by modA, modB, and modC genes are required (Hagen, 2011). 
In eukaryotes, the molecular nature of the transporters is not well studied. The first 
molybdate transporter, MOT1, was identified in algae (Chlamydomonas reinhardtii) and 
plants (Arabidopsis thaliana) (Tejada-Jimenez et al., 2007; Tomatsu et al., 2007); 
however, it is not present in the animal kingdom. Recently, the MOT2 protein has been 
identified as a putative Mo transporter present in all eukaryotes, including human 
(Tejada-Jimenez et al., 2011). Figure 1.1 presents the summary of biosynthesis of human 
MoCo. Once molybdenum entered the cell as oxyanion, it has to be coordinated by a 
unique scaffold to become biologically active. This special function is performed by 
molybdopterin (MPT), a tricyclic pyranopterin containing a cis-dithiolene group needed 
for molybdenum ligation (Daniels et al., 2008). Together the metal and pterin moiety 
form the molybdenum cofactor (MoCo) (Mendel, 2013). Cofactors are non-protein 
compounds required for the catalytic activity of enzymes (Eagleson, 1993). In contrast to 
bacteria, there are only four molybdenum cofactor-dependent enzymes in humans: [1] 
aldehyde oxidase (Mahler et al., 1954), [2] xanthine oxidoreductase (De Renzo et al., 
1954), [3] sulphite oxidase (Cohen et al., 1971) and [4] mitochondrial amidoxime reducing 
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component (mARC) (Wahl et al., 2010). The biosynthetic pathway of MoCo is evolutionary 
conserved, and can be divided into four steps, according to the biosynthetic 
intermediates: cPMP (cyclic pyranopterin monophosphate), MPT (molybdopterin), 
adenylated MPT and MoCo (Mendel, 2013). This pathway begins in mitochondria with 5’-
guanosine triphosphate (GTP), which is converted by products of MOCS1A and MOCS1AB 
genes to cPMP. The gene MOCS1A belongs to the superfamily of S-adenosylmethionine 
(SAM)-dependent radical enzymes. It catalyses the formation of radicals by a protein 
bound [4Fe-4S] cluster (Hanzelmann et al., 2004), while the B domain of MOCS1AB fusion 
protein might function as a radical acceptor (Teschner et al., 2010). Furthermore, cPMP 
has to pass the mitochondrial membranes, as all subsequent steps are localised in the 
cytosol (Kaufholdt et al., 2013). A heterotetrameric complex of two small sulphur carriers 
and two large catalytic subunits of MPT-synthase (MOCS2A and MOCS2B, respectively) 
catalyses the sulphur transfer into cPMP leading to MPT formation. The sulphur group is 
delivered by the product of the MOCS3 gene, which is believed to catalyse both the 
adenyl transfer, and subsequent thiocarboxylation at the C-terminus of the MOCS2A 
subunit within MPT-synthase (Matthies et al., 2004). Once the MPT moiety is synthesised, 
the chemical backbone is ready to bind and coordinate the molybdenum atom. This step 
is subdivided into two separate steps. In bacteria each step is catalysed by separate MogA 
and MoeA proteins (Nichols and Rajagopalan, 2002), which were combined during 
evolution to form a single two-domain molybdenum insertase (Cnx1 in plant and 
Gephyrin in mammals) (Mendel, 2013). In the first step, MPT has to be activated by 
adenylation, which is carried out by the MogA or G-domain of the Gephyrin (GPHN) gene 
in a Mg2+ and ATP-dependent manner (Llamas et al., 2004). Furthermore, the MPT-AMP 
serves as a substrate for the molybdenum insertion, which is catalysed by MoeA or the E-
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Fig. 1.1. Schematic representation of the molybdenum cofactor (MoCo) biosynthesis pathway and 
function in human cells. The biosynthesis pathway is divided into four steps, presented in violet (1st step), 
grey (2nd step) and yellow (3rd and 4th steps) squares, respectively. In the first step, guanosine thriphosphate 
(GTP) is converted to cyclic pyranopterin monophosphate (cPMP) by products of MOCS1A and MOCS1AB 
genes. Subsequently, molybdopterin-synthase consisting of two MOCS2A and two MOCS2B subunits 
catalyses sulphur incorporation into cPMP, leading to the formation of molybdopterin (MPT). The sulphur 
group required for this reaction is provided by the product of the MOCS3 gene. Finally, MPT is converted 
into MoCo. This process is performed by Gephyrin (GPHN). In eukaryotes G domain of GPHN activates MPT 
by adenylation, while the E domain catalyses molybdenum incorporation. The first reaction occurs in a Mg2+ 
and ATP-dependent manner, while the second reaction requires only Mg2+. The lack of MoCo leads to 
molybdenum cofactor deficiency disease. Depending on the mutation affecting MoCo synthesis, MoCo 
deficiency was classified into three types: A, B and C, as shown on the right site of the squares. The last, 
green square presents the function of MoCo in human. So far, four MoCo-dependent enzymes were 
characterised: aldehyde oxidase, xanthine oxidoreductase, sulphite oxidase and mitochondrial amidoxime 
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reducing component. MoCo deficiency in human attributes to the loss of sulphite oxidase. Scheme modified 
from Reiss and Hahnewald (2011). 
 
1.3 Characteristics of the MOCS2 gene 
1.3.1 Genomic structure of the human MOCS2 and mouse Mocs2 genes 
Products of the human MOCS2 gene, involved in the second step of the MoCo 
biosynthesis pathway, form a complex called molybdopterin synthase, an enzyme 
required for the conversion of cyclic pyranopterin monophosphate (cPMP) to 
molybdopterin (MPT). It is a heterotetrameric complex consisting of two small MOCS2A 
(10 kDa) and two large MOCS2B (21 kDa) subunits. In humans, the MOCS2 gene is 
localised on the long arm of chromosome 5 (5q11.2) and it encodes two transcripts 
corresponding to spliceform I (MOCS2A) and spliceform III (MOCS2B), respectively (Reiss 
and Hahnewald, 2011). Each transcript contains seven exons, with overlapping open 
reading frames (ORFs) in exon 3. Both ORFs are shifted relative to each other, thus do not 
share identical codons (Stallmeyer et al., 1999). The translation start of the MOCS2A 
transcript is localised in exon 1a and the stop codon in exon 3. The MOCS2B transcription 
start site is localised in the alternative exon 1b, although the ORF for the MOCS2B protein 
starts in exon 3 and it is terminated in exon 7 (Fig. 1.2a). The murine Mocs2 gene is 
localised on chromosome 13 (13D2.2). In contrast to the human MOCS2 gene, the mouse 
Mocs2 gene encodes for three spliceforms: I-III. Spliceform I consists of 7 exons, while 
both spliceforms II and III contain 6 exons. Figure 1.2b presents the genomic structure of 
the mouse Mocs2 gene together with the corresponding splice variants. Spliceform I, 
encodes the Mocs2a subunit or both Mocs2a and Mocs2b subunits of molybdopterin-
(MPT) synthase. It expands on exons 1-7 with the start codon localised in exon 1 and the 
stop codon in exon 3 for Mocs2a or with the start codon in exon 3 and stop codon in exon 
7 for Mocs2b, respectively. The gene products of Mosc2a and Mocs2b are evolutionary 
conserved, with 91% and 90% homology between mouse and human (Stallmeyer et al., 
1999). The Mocs2b transcript encoded by spliceform II includes exons 1 and 3-7. The 
translation start is localised in exon 3 and is terminated in exon 7, leading to Mocs2b 
protein formation. Analogous to the human MOCS2 transcripts, mouse spliceforms I, II 
and III overlap in exon 3, and their ORFs are shifted relative to each other, thereby not 
sharing identical amino acids. 
5 
 




Fig. 1.2. Genomic structures of human MOCS2 and mouse Mocs2 genes and their alternative splicing 
products. (a) Gene structure of the human MOCS2 gene together with corresponding transcripts encoding 
MOCS2A and MOCS2B proteins. Exons 1a and 1b of the human MOCS2 gene are mutually exclusive and 
lead to the expression of two distinct proteins via spliceforms I (MOCS2A) and III (MOCS2B), respectively. 
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Spliceform I contains 7 exons, with the start codon (Start) localised in exon 1a and the stop codon in exon 3 
(Stop). The ORF of spliceform I (presented in violet) expands on exons 1-3 and encodes the MOCS2A 
protein. Spliceform III comprises also 7 exons; however, the transcription start point is located in the 
alternative exon 1b. In contrast, its translation starts (Start) in exon 3 and is terminated (Stop) in exon 7. It 
expands on exons 3-7 (shown in orange) and encodes for the MOCS2B protein. The ORFs of MOCS2A and 
MOCS2B transcripts overlap in exon 3 by 77 nucleotides (nt), and they are shifted relative to each other, 
thereby not encoding for identical amino acids. (b) Genomic structure of the murine Mocs2 gene together 
with alternative spliceforms. Spliceform I contains 7 exons, with start codon in exon 1 and stop codon in 
exon 3 for Mocs2a or with start codon in exon 3 and stop codon in exon 7 for Mocs2b transcripts, 
respectively. ORFs of these spliceforms encode Mocs2a protein (presented in violet) or Mocs2b protein 
(shown in orange). Both ORFs overlap in exon 3 by 77 nucleotides (nt). Spliceform II and III comprise 6 
exons, as exon 2 is spiced out. The transcription starts in exon 1, however its translation begins in exon 3 
and is terminated in exon 7. Additionally, in spliceform III part of the exon 5 is spliced out leading to a 
smaller isoform of the Mocs2b protein. Scheme modified from Hahnewald (2009), Reiss and Hahnewald 
(2011). 
 
1.3.2 MOCS2 expression pattern 
The expression profiles of mouse Mocs2 transcripts and proteins have not been studied 
so far. Besides a single Northern blot analysis performed on a human RNA library, little is 
known about the specific localisation of human MOCS2 transcripts and proteins 
(Stallmeyer et al., 1999). This former study has shown ubiquitous expression of MOCS2 
transcripts with the strongest expression detected in human skeletal muscle, kidney, 
pancreas and heart (Reiss et al., 1998).  
 
1.4 MoCo-dependent enzymes 
In humans, there are four MoCo-dependent enzymes described so far: aldehyde oxidase, 
xanthine oxidoreductase, sulphite oxidase and mitochondrial amidoxime reducing 
component (Reiss and Hahnewald, 2011). 
 
1.4.1 Aldehyde oxidase (AO) 
AO is a flavoenzyme present ubiquitously in the cytosol in all vertebrates (Garattini et al., 
2008). It is a homodimer composed of two subunits of about 150 kDa. Each subunit has a 
typical tripartite structure, in which the N-terminal domain of 20 kDa includes two iron-
containing clusters, the central domain corresponding to 40 kDa and harbours a flavin 
adenine dinucleotide (FAD) binding-site, and the last 85 kDa C-terminal domain 
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accommodates the molybdenum cofactor (Garattini et al., 2008) (Fig. 1.3). As soon as 
MoCo binds to the apoenzyme, AO becomes biologically active (Rajagopalan and Johnson, 
1992). However, prior to that MoCo requires post-translational sulphuration to become 
catalytically active (Sagi et al., 2002; Heidenreich et al., 2005; Mendel and Bittner, 2006). 
The reaction is catalysed by sulphurase (Ichida et al., 2001), which substitutes one of the 
oxo groups with the sulpho double bound in MoCo (Bittner et al., 2001; Xiong et al., 
2001). AO proteins are present throughout evolution, from bacteria to man (Kurosaki et 
al., 2013). In the human genome, AO is encoded by the AOX1 gene. It is located on 
chromosome 2 (2q33.1), and consists of 35 exons (Terao et al., 1998). In contrast, rodents 
have four Aox genes (Aox1-4) clustered on chromosome 1 (1C1.3) in mice, and 
chromosome 9 (9q31) in rats (Kurosaki et al., 2004). 
 
 
Fig. 1.3. Structure of the human aldehyde oxidase (AO) and the xanthine oxidoreductase (XOR) monomer. 
Each AO/XOR subunit consists of three domains: a 20 kDa N-terminal domain with two iron-containing [2Fe-
2S] redox clusters, a 40 kDa FAD-binding domain with a flavin adenine dinucleotide (FAD) binding site, and a 
85 kDa C-terminal domain hosting the molybdenum cofactor (MoCo) site adjacent to the substrate binding 
pocket. Domains were determined using Simple Modular Architecture Research Tool (http://smart.embl-
heidelberg.de). 
 
The biological function of the enzyme is not well known. It has been described to oxidise a 
broad range of substrates, mainly aldehydes, nitro/nitroso compounds or N-heterocycles 
(Beedham, 1985; Kitamura et al., 2006). Recently, it has been recognised as regulator of 
drug metabolism (Pryde et al., 2010; Garattini and Terao, 2012). AO is ubiquitously 
expressed, although the highest expression occurs in the liver (Garattini et al., 2008). The 
activity of AO differs between species, e.g. it is high in monkeys and human, low in rats 
and absent in dogs (Kitamura et al., 1999). Moreover, the activity varies within the same 
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species, like in different mouse or rat strains (Al-Salmy, 2002). Furthermore, in human, AO 
activity is detected in the trachea and bronchium epithelia and also in alveolar cells. In the 
gastrointestinal tract AO is active primarily in the epithelia of small and large intestines, 
while in the kidney the highest AO activity was shown in the proximal, distal and 
collecting tubules (Moriwaki et al., 2001). To date, a gender-related difference in AO 
activity has not been reported in humans, but male mice present 2- to 4-fold higher AO 
activity than females (Al-Salmy, 2002). Additionally, other factors such as age, cigarette 
smoking, drug usage, and disease (e.g. cancer), may also alter AO activity (Beedham, 
1985). To date, 5 mutations have been described in the human AOX1 gene (Human Gene 
Mutation Database (HGMD) Professional 2015.1). Although these mutations influence AO 
catalytic efficiency, patients do not present a correlated phenotype (Hartmann et al., 
2012). 
 
1.4.2 Xanthine oxidoreductase (XOR) 
XOR, another MoCo-dependent enzyme, is a homolog of AO and belongs to the same 
family of flavoenzymes. Similar to AO, XOR exists as a homodimer composed of two 150 
kDa subunits. Each subunit consists of three redox centres: a MoCo binding site, a FAD 
binding site, and a Fe/S cluster (Fig. 1.3). The enzyme is active only in the presence of 
MoCo, however, MoCo must be first activated by sulphuration (Sagi et al., 2002; 
Heidenreich et al., 2005; Mendel and Bittner, 2006). Like AO, XOR is also present in the 
cytosol of all vertebrates (Garattini et al., 2008). It exists in two interconvertible forms, 
xanthine oxidase (XOD) and xanthine dehydrogenase (XDH) which transfer electrons to 
both oxygen and nicotinamide adenine dinucleotides (NAD), respectively. Both act on the 
same substrates, hypoxanthine and xanthine, but XOD utilises substrates and O2 as a 
cofactor to produce superoxide (O2−) and uric acid, and XDH acts on the same substrates 
utilising NAD as a cofactor to produce NADH instead of·O2− and uric acid (Chung et al., 
1997). 
The XOR gene is localised on the short arm of human chromosome 2 (2p23.1) and on 
chromosome 17 (17E2) in mice. In both cases the XOR gene is composed of 36 exons. In 
mammals, the presence of XOR has been demonstrated in many organs, albeit at 
different levels and most cells show little enzyme activity. In humans the highest activity 
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is present in the intestine (Riario-Sforza et al., 1969; Auscher et al., 1979) and liver 
(Sarnesto et al., 1996). Additionally, it can be found in human milk (Abadeh et al., 1992). 
It has been shown that in mice Xor expression occurs in the mammary gland, where it is 
necessary as a structural component for milk fat droplet envelopment and secretion 
(McManaman et al., 2002). XOR is one of the best-studied flavoproteins which catalyses 
two terminal reactions in purine degradation in primates: oxidation of hypoxanthine to 
xanthine and the subsequent oxidation of xanthine to uric acid (Hille and Nishino, 1995). 
These reactions and presumably other metabolic reactions of XOR have a far-reaching 
impact on cellular homeostasis, cellular protection from toxic compounds and also 
systemic protection, known as innate immunity. 
The disease associated with XOR dysfunction in humans is termed xanthinuria, because of 
the excretion of xanthine in the urine (Dent and Philpot, 1954). Xanthinuria can be 
classified into two subtypes: type I (isolated form) in which XOR deficiency is observed 
due to a genetic defect in the XOR gene, and type II which involves dual deficiency of XOR 
and the homolog enzyme AO, due to a genetic defect in the MoCo or sulphurase required 
for MoCo activation (Peretz et al., 2007; Ichida et al., 2012). In higher animals other than 
primates, xanthinuria is lethal due to kidney damage, caused by the formation of xanthine 
stones (urolithiasis) in the urinary track (Kucera et al., 1997; van Zuilen et al., 1997; 
Tsuchida et al., 2007; Miranda et al., 2010). Xor knockout mice fail to thrive after 10 to 14 
days, and die within the first month due to renal failure caused by the accumulation of 
triglyceride-rich substances as well as xanthine and hypoxanthine in the renal tubules 
(Ohtsubo et al., 2009). The first month of life is a period, when the murine kidney 
undergoes maturation and remodelling, and is characterised by elevated activity of renal 
Xor (Ohtsubo et al., 2004). In contrast to this report, another group showed that Xor+/- 
female mice, although with healthy appearance and normal fertility, are unable to 
maintain lactation and their pups die within two weeks after birth (Vorbach et al., 2002). 
In human, xanthine urolithiasis is usually benign and easy to prevent or cure by 
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1.4.3 Sulphite oxidase (SO) 
SO is an enzyme encoded by the SUOX gene, which is localised on human chromosome 
12q13.2 and contains 3 exons, while in mice it is found on chromosome 10 with 4 exons. 
The enzyme is a homodimer complex where each subunit contains three domains: a N-
terminal cytochrome b(5) domain (8.5 kDa), a central domain harbouring the 
molybdenum cofactor (MoCo) binding site (20 kDa), and a C-terminal dimerisation 
domain (14 kDa) (Rudolph et al., 2003) (Fig. 1.4).  
 
 
Fig. 1.4. Structure of the human sulphite oxidase monomer. The monomer of the sulphite oxidase consists 
of three domains: a 8.5 kDa N-terminal cytochrome b(5) domain, a 20 kDa MoCo-hosting domain, and a 14 
kDa C-terminal dimerisation domain. Domains were determined using Simple Modular Architecture 
Research Tool (http://smart.embl-heidelberg.de). 
 
The enzyme is localised in the intermembrane space of mitochondria, and catalyses the 
oxidation of sulphite to sulphate, the terminal reaction in the pathway of degradation of 
sulphur-containing amino acids (Johnson, 2003). In humans, the highest expression of 
SUOX occurs in the liver, kidney, skeletal muscles, heart, placenta, and brain (with the 
strongest signal in the cerebral cortex), while the thymus, spleen, peripheral blood 
leukocytes, colon, small intestine, and lung show little expression. In rats, the highest 
expression is present in the liver, kidney, heart, brain, and lung, but not in the skeletal 
muscle. Additionally, weak expression is present in the spleen and testis (Woo et al., 
2003). An isolated sulphite oxidase deficiency is a rare (25 cases described worldwide), 
autosomal recessive disorder with a very poor prognosis. The clinical symptoms, usually 
present in the neonatal period, include neurological abnormalities such as refractory 
seizures, abnormal muscle tone, abnormal movements, marked developmental delay and 
dislocation of ocular lenses (Lam et al., 2002; Basheer et al., 2007; Westerlinck et al., 
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2014). In accordance with these studies, the rat model of the disease shows loss of 
pyramidal neurons in the hippocampus due to a neurotoxic effect of sulphite (Kocamaz et 
al., 2012). 
 
1.4.4 Mitochondrial amidoxime reducing component (mARC) 
Recently, mitochondrial amidoxime reducing component (mARC) was discovered as a 
molybdenum-containing enzyme in mammals. All mammalian genomes studied to date 
contain two mARC genes: MARC1 and MARC2. In humans, they are localised on 
chromosome 1q. The proteins encoded by these genes are mARC-1 and mARC-2, 
respectively (Ott et al., 2014). Each protein contains three domains: a mitochondrial 
targeting signal (~2 kDa), a transmembrane domain (~13.5 kDa) and a catalytic core (~16 
kDa) (Fig. 1.5). It has been shown that mARC1 is localised in the outer mitochondrial 
membrane, with its catalytic domain facing to the cytosol (Klein et al., 2012).  
 
 
Fig. 1.5. Schematic representation of the human mitochondrial amidoxime reducing component (mARC). 
The enzyme consists of three domains: a 2 kDa transmembrane region, a 13.5 kDa central domain with 
unknown function, and a 16 kDa MoCo-sulphurase domain (catalytic core). Domains were determined using 
Simple Modular Architecture Research Tool (http://smart.embl-heidelberg.de). 
 
In mammals, the highest mARC activity was found in the liver, kidney, thyroid and 
pancreas (Krompholz et al., 2012). Although the endogenous function of the mARC 
protein is not fully understood, it was shown that the enzyme is linked with drug and lipid 
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1.5 Substitution therapy for Molybdenum Cofactor Deficiency Type A 
Since MoCo is extremely unstable (Kramer et al., 1987), a substitution therapy using a 
synthetic cofactor is not possible. However, cyclic pyranopterin monophosphate (cPMP), 
the first intermediate of the MoCo biosynthesis pathway, is a more stable one with a half-
life of several hours at low pH (Fay et al., 2007). Due to the fact that the biosynthesis 
pathway is conserved in plants, bacteria and humans it was possible to isolate large 
quantities of cPMP from Escherichia coli by a high-performance liquid chromatography 
(HPLC) procedure. Repeated intrahepatic injections of cPMP into Mocs1 knockout mice 
normalised the phenotype and reconstituted MoCo biosynthesis as well as an activity of 
MoCo-dependent enzymes (Schwarz et al., 2004). In 2009 the first MoCo-deficient patient 
suffering from type A of the disease, received intravenous injections with cPMP isolated 
from E. coli. Shortly after that, all markers of MoCo deficiency were normalised, including 
sulphite, S-sulphocysteine, thiosulphate, xanthine and uric acid. Clinically, the infant 
became more alert, convulsions and twitching disappeared within the first 2 weeks, and 
an electroencephalogram showed the return of rhythmic elements and markedly reduced 
epileptic form discharges (Veldman et al., 2010). 
 
1.6 Gene therapy 
Although, an effective therapy for MoCo deficiency type A has already been established, 
all other types of the deficiency remain incurable. Instability of intermediates other than 
cyclic pyranopterin monophosphate (cPMP) excludes them as potential drugs in 
substitution therapies. To overcome this problem a gene therapy approach could be 
employed. Gene therapy is designed to introduce a functional copy of the gene into the 
appropriate cells of the patient, in order to produce sufficient amounts of the missing 
protein, and rescue the phenotype of the disorder. The gene of interest can be delivered 
into the target cells by physical, chemical or viral vectors. It can target somatic cells (only 
the recipient’s genome is changed), as well as germ cells (the changes passing to the 
offspring through modified parent’s egg or sperm). However, the second scenario is not 
being actively investigated, at least in larger animals and humans, because of the 
associated ethical controversy (Sharma et al., 2004). To date, two different approaches 
for gene therapy exist: the ex vivo therapy and the in vivo therapy (Fig 1.6). In the ex vivo 
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therapy approach cells are modified outside the patient's body and subsequently cells 
with the corrected gene of interest are transplanted back into the patient. In case of the 
in vivo therapy approach, genetic material is directly introduced to the recipient 
(Mulligan, 1993; Flotte and Ferkol, 1997). 
 
 
Fig. 1.6. Schematic illustration of ex vivo and in vivo techniques used in gene therapy approaches. The ex 
vivo technique involves tissue/cell biopsies, in vitro genetic manipulations, and re-implantation of corrected 
cells. The in vivo gene therapy is based on the direct introduction of genetically modified material to the 
recipient. Scheme modified from Kaji and Leiden (2001). 
 
Generally, there are three methods used for gene therapy approaches: [1] a physical 
method which refers to the delivery of the gene via the application of physical force to 
increase the permeability of the cell membrane. The most common methods include 
microinjection, electroporation, ultrasound, gene gun and hydrodynamic application. [2] 
a chemical method utilising natural or synthetic carriers to deliver genes into cells. Here, 
calcium phosphate, DEAE-dextran, liposomes and lipoplexes are used for oral gene 
delivery, and surfactants and perflurochemical liquids for aerosol gene delivery (Sharma 
et al., 2004; Miyazaki et al., 2006; Prokop and Davidson, 2007). The last gene delivery 
system [3] is viral-based, where the therapeutic gene is delivered by modified, 
replication-deficient viruses, including retroviruses, adenoviruses (Ad), lentiviruses and 
adeno-associated viruses (AAV) (Escors and Breckpot, 2010). AAV vectors are currently 
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among the most frequently used viral vectors, and seem to be the most promising tool for 
gene therapy applications (Gauttier et al., 2013). 
 
1.6.1 Adeno-associated virus (AAV) 
The first AAV was discovered in 1965 as a contaminant during adenovirus (Ad) 
preparation (Atchison et al., 1965). It is a small, non-enveloped, single-stranded DNA 
(~4.7 kb) virus, with an icosahedral capsid of approximately 22 nm in diameter. It belongs 
to the family of Parvoviridae, placed in the genus Dependovirus, as its infection occurs 
only in the presence of a helper virus (adenovirus or herpesvirus). AAV integrates into the 
human genome in a site-specific manner on chromosome 19q14.4 (Daya and Berns, 
2008). It can infect dividing and non-dividing cells (Samulski et al., 1999). Although 80% of 
the human population is seropositive for AAV2 (the most extensively examined serotype), 
the virus has not been linked with any disease (Goncalves, 2005). The genome of the virus 
consists of two open reading frames (ORFs) flanked by 145 bp long inverted terminal 
repeats (ITRs) which are important for replication, genome packaging, transcription and 
site-specific integration of the viral DNA. The first ORF encodes for replication-associated 
protein (Rep) proteins, and is transcribed giving rise to four proteins: two larger Rep78 
and Rep68 proteins expressed from the P5 promoter, and two smaller Rep52 and Rep40 
proteins expressed from the P19 promoter. The larger Rep proteins positively and 
negatively regulate AAV gene expression in the presence or absence of a helper virus, 
respectively, and are required for DNA replication (Pereira et al., 1997). Products of 
Rep52 and Rep40 genes are required for efficient packaging of the AAV genome into the 
capsid. All Rep proteins possess helicase/ATP-activity and additionally, the larger proteins 
possess a strand- and site-specific endonuclease activity, plus a site-specific DNA binding 
activity (Young et al., 2000; King et al., 2001). The second ORF encodes two proteins, 
driven by the P40 promoter. As a result of alternative spicing, three viral capsid (Cap) 
proteins, VP1, VP2, and VP3, are produced. All three proteins are necessary for the 
generation of infectious particles; however, VP2 and VP3 are sufficient for capsid 
formation, while VP1 is required for viral infection (Hermonat and Muzyczka, 1984; 
Tratschin et al., 1984; Smuda and Carter, 1991). Figure 1.7 shows a schematic 
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Fig. 1.7. Map of the wild type adeno-associated virus (AAV) genome. The AAV genome, flanked by two 
inverted terminal repeats (ITRs), contains 4680 nucleotides and is divided into 100 map units. Position p5, 
p19, and p40 represent promoters’ localisation, and position 96 corresponds to the polyadenylation signal 
(polyA). Transcripts of replication-associated protein (Rep) genes driven by p5 and p19 promoters give rise 
to four different Rep proteins (shown in violet). Rep68 and Rep78 are transcribed from the p5 promoter, 
while Rep40 and Rep52 are transcribed from the p19 promoter. Three capsid (Cap) proteins, termed VP1, 
VP2, and VP3 (shown in blue) are transcribed from the p40 promoter. ITR elements are important for 
replication, packaging and integration of AAV (Dent and Philpot, 1954). Rep proteins are essential for 
targeted integration (McManaman et al., 2002), while Cap proteins are important for viral packaging 
(Gargah et al., 2010). Scheme modified from Merten et al. (2005). 
 
The infection of AAV is a multistep process. First, the AAV attaches to the cell surface 
using its putative primary receptor, heparin sulphate proteoglycan (HSPG) (Summerford 
and Samulski, 1998). In addition, αvβ5 integrin and fibroblast growth factor receptor 1 
(FGFR1) were suggested as co-receptors (Qing et al., 1999; Summerford et al., 1999). 
FGFR1 is believed to enhance the attachment process, while αvβ5 integrin is probably 
involved in endocytosis via clathrin-coated pits. VP-receptor interaction initiates the 
internalisation process. So far several genes were characterised to regulate this process, 
including cytosolic GTP-ase, dynamin, whose oligomerisation into a ring structure is 
necessary for the formation of clathrin-coated vesicles and further pinching them from 
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the cell membrane (Baba et al., 1995; Hinshaw and Schmid, 1995; Sever et al., 2000). In 
addition, integrin clustering facilitates the internalisation via the GTP-binding protein 
Rac1, whose activation leads in turn to activation of the phosphatidylinositol-3 kinase 
(PI3K) signalling pathway that transports the virus encapsulated in the endosomal vesicles 
along microfilaments and microtubules (Sanlioglu et al., 2000). Furthermore, the AAV 
particles are delivered to the late endosomes and are released into the cytoplasm (Douar 
et al., 2001). Little is known about the process how the virus enters the nucleus, as well as 
the exact place of viral uncoating. The transport occurs presumably through the nuclear 
pore complex (NPC), while the uncoating seems to take place in the nucleus (Sonntag et 
al., 2006; Nonnenmacher and Weber, 2012). Figure 1.8 shows a schematic representation 
of the AAV infection mechanism. 
 
 
Fig. 1.8. Schematic representation of the AAV infection pathway. After the AAV binds to its primary 
attachment receptor (HSPG) and co-receptors (FGFR1 and αvβ5 integrin) the virus is rapidly internalised via 
clathrin-coated pits through a process involving αvβ5 integrin and in a dynamin-dependent manner. The 
internalisation is facilitated by the action of Rac1 which subsequently stimulates the PI3K pathway. These in 
turn control endosome trafficking along the cytoskeleton. The AAV particles are delivered to the late 
endosome where a progressive drop of pH changes the conformation of the viral capsid, leading to the 
disruption of the endosomal membrane. This leads to a release of viral particles to the cytoplasm and 
further transport to the nucleus most probably through the nuclear pore complex (NPC). Uncoating and 
subsequent releasing of the vector genome takes place in the nucleus. The DNA of the wild type AAV 
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integrates in a site-specific manner in a region on the long arm of human chromosome 19 (19q13-qter), 
termed the AAVS1 site. Scheme modified from Huttner (2003). 
 
1.6.2 Recombinant adeno-associated virus (AAV)-based gene therapy 
In order to produce a recombinant adeno-associated virus (rAAV), which will be suitable 
for gene therapy applications, most of the AAV genome has to be removed. Three 
different plasmids are required: [1] the therapeutic plasmid, which contains the 
therapeutic expression cassette flanked by inverted terminal repeats (ITRs), which are the 
only viral cis elements required for DNA replication and packaging (McLaughlin et al., 
1988). [2] The AAV Rep and Cap genes are provided in trans by a helper plasmid (Grimm 
et al., 1998). These two plasmids are co-transfected together with a third plasmid [3], 
providing the capsid information necessary for AAV replication. After transcription and 
translation of Rep and Cap proteins, the ITR flanked transgene cassette is replicated, and 
single-stranded DNA molecules are capsulated to form viral particles. Furthermore, the 
particles have to be harvested, purified and titred (Wright, 2009). The usefulness of AAV 
in gene therapy approaches can be attributed to its lack of pathogenicity due to its 
replication failure. It can mediate long-term expression in a variety of tissues. However, 
the genetic modifications in the AAV genome affect the ability for site-specific integration 
(Lai et al., 2002). During infection the rAAV genome enters the cell nucleus and persists 
there predominantly as an episome. However, the integration of the rAAV genome to the 
host chromosome is possible (Clark et al., 1999; Nakai et al., 2001; Inagaki et al., 2007). 
Since it was shown that neonatal mice injected with rAAV developed hepatocellular 
carcinoma (HCC) (Donsante et al., 2007; Chandler et al., 2015), the investigation of 
potential tumour induction after rAAV-based gene therapy should be elucidated. Another 
very important determinant of the outcome of gene transfer is the immune response 
against the vector capsid and transgene product (Mingozzi and High, 2013). Due to this 
fact there are many factors which have to be taken into consideration during rAAV-based 
gene therapy designing, e.g. serotype of the virus, promoter under which the therapeutic 
gene is expressed, amount of the virus as well as route and time-point of injection. rAAVs 
have been already used in preclinical applications with animal models such as those for 
haemophilia (Niemeyer et al., 2009), lysosomal storage diseases (Hu et al., 2012) and 
vision deficiency (Acland et al., 2005), all of these approaches have shown therapeutic 
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benefits through the viral treatment. Clinical trials using rAAV2 for the treatment of 
haemophilia B, cystic fibrosis, alpha-1-antitrypsin deficiency or Canavan disease have 
started already, and reports from phase I trials support the results of preclinical trials 
(Grieger and Samulski, 2005). Although a substitution therapy for molybdenum cofactor 
(MoCo) deficiency type A has already been established, a lifelong treatment with cPMP is 
required to rescue the phenotype. Therefore, a rAAV-based therapy could be an 
attractive alternative for an expensive and oppressive substitution therapy. A preliminary 
study has shown that an early treatment with rAAV carrying the expression cassette for 
the human MOCS1 gene can completely suppress the phenotype in the Mocs1 knockout 
mouse model of MoCo-deficiency type A (Kugler et al., 2007). 
 
1.7 AIMS 
The main aim of the present thesis was the generation and characterisation of a mouse 
model for molybdenum cofactor (MoCo) deficiency supplementation group B, as well as 
investigating the efficiency and drawbacks of a rAAV-based gene therapy. 
 
The main aims were as follows: 
• Generation of a mouse model for MoCo deficiency type B (Mocs2-/-) 
o Confirmation of the homologous recombination 
o Design of a genotyping strategy 
 
• Characterisation of Mocs2-/- animals 
o Analysis of Mocs2 isoforms expression on the RNA and protein level by 
qRT-PCR, LacZ staining and Western blot, respectively 
o Survival rate and body weight analyses of Mocs2-/- mice 
o Biochemical analysis of the urine parameters 
o Immunohistochemical analysis of the brain 
o Histochemical analysis of the kidneys 
 
• Generation and characterisation of MOCS2A and MOCS2B transgenic mice 
o Generation of MOCS2A and MOCS2B constructs 
o Pro-nucleus injection of MOCS2A or MOCS2B transgene constructs 
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o Evaluation of transgene copy numbers in founder animals 
o Verification of the integration site(s) 
o Development of a genotyping strategy 
o Generation of MOCS2A and MOCS2B transgenic lines 
o Characterisation of the phenotype 
 
• Development of rAAV therapy for MoCo deficiency type B 
o Generation of recombinant adeno-associated virus (rAAV) 
o Investigation of efficiency of rAAV transduction 
o Investigation of specificity of rAAV transduction 
o Investigation of the therapeutic potential of designed rAAV 
o Investigation of expression persistence of the MOCS2B therapeutic gene 
after rAAV injections 
o Investigation of the potential risk of mutagenesis after rAAV injections 
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2 MATERIALS AND METHODS 
2.1 MATERIALS 
2.1.1 Chemicals and reagents 
CHEMICALS MANUFACTURER 
1 kb plus DNA Ladder Life Technologies, Karlsruhe, Germany 
100 bp DNA Ladder Life Technologies, Karlsruhe, Germany 
2-Mercaptoethanol Life Technologies, New York, USA 
3,3'-Diaminobenzidine (DAB) Sigma-Aldrich GmbH, Steinheim, Germany 
5-Bromo-4-chloro-3-indolyl phosphate (BCIP) Sigma-Aldrich GmbH, Steinheim, Germany 
5-Brom-4-chlor-3-indoxyl-β-D-
galactopyranosid (X-Gal) 
Biomol, Hamburg, Germany 
Agar  Carl Roth GmbH, Karlsruhe, Germany 
Agarose Carl Roth GmbH, Karlsruhe, Germany 
Ammonium chloride (NH4Cl) Sigma-Aldrich, Deisenhofen, Germany 
Ampicillin Sigma-Aldrich, Deisenhofen, Germany 
Ampuwa (dH2O) Fresenius, Bad Homburg, Germany 
Boric acid (H3BO3) Scharlau Chemie S.A., Barcelona, Spain 
Bradford Reagent Sigma-Aldrich GmbH, Steinheim, Germany 
Chloroform (CHCl3) Sigma-Aldrich, Steinheim, Germany 
Cryo-Embedding Compound Medite, Winter garden, USA 
DePeX Mounting medium Serva, Heidelberg, Germany 
Dimethyl pyrocarbonate (DEPC) Sigma-Aldrich, Deisenhofen, Germany 
Dimethyl sulfoxid (DMSO) Merck, Darmstadt, Germany 
dNTPs Life Technologies, Karlsruhe, Germany 
Dulbecco's Modified Eagle Medium (DMEM) PAN Biotech GmbH, Aidenbach, Germany 
Ethanol (C2H5OH) Baker, Deventer, Netherlands 
Ethidium bromide (EtBr) Sigma-Aldrich, Deisenhofen, Germany 
Ethylendiamine-tetraacetic acid (EDTA) ICN, Aurora, USA 
Eukitt quick-hardening mounting medium Sigma-Aldrich, Deisenhofen, Germany 
Fetal bovine serum (FBS) PAN Biotech GmbH, Aidenbach, Germany 
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Ficoll 400 Amersham Pharmalia, Freiburg, Germany 
Formaldehyde solution 4% Otto-Fischar GmbH, Saarbrucken, 
Germany 
Gelatin Sigma-Aldrich, Deisenhofen, Germany 
Glacial acetic acid (CH3COOH) Life Technologies, Karlsruhe, Germany 
Glucose (C6H12O6) Carl Roth GmbH, Karlsruhe, Germany 
Glycerol (C3H8O3) Life Technologies, Karlsruhe, Germany 
Glycin (C2H5NO2) Carl Roth GmbH, Karlsruhe, Germany 
Glycerin (C3H8O3) Carl Roth GmbH, Karlsruhe, Germany 
Hydrochloric acid (HCl) Merck, Darmstadt, Germany 
Igepal Sigma-Aldrich, Deisenhofen, Germany 
Igepal-CA-360 (Np-40) Sigma-Aldrich, Deisenhofen, Germany 
Isopropanol (C3H8O) Baker, Deventer, Netherlands 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) Biomol, Hamburg, Germany 
Kanamycin Sigma-Aldrich, Deisenhofen, Germany 
Ketamin Medistar Aschenberg, Germany 
Leukemia Inhibitor factor (LIF) Millipore, Billerica, USA 
L-Glutamine PAN Biotech GmbH, Aidenbach, Germany 
Lipofectamine 2000 Life Technologies, Karlsruhe, Germany 
Magnesium chloride (MgCl2) Merck, Darmstadt, Germany 
Mayer's Hämalaun Merck, Darmstadt, Germany 
Medetomidin (Domitor) Janssen Animal Health, Germany 
Methanol (CH4O) Baker, Deventer, Netherlands 
Milk powder Carl Roth GmbH, Karlsruhe, Germany 
Mitomycin C Sigma-Aldrich GmbH, Steinheim, Germany 
Natriumchloride (NaCl) Merck, Darmstadt, Germany 
Natrium deoxycholat (C24H39NaO4) Sigma-Aldrich GmbH, Steinheim, Germany 
N, N-Dimethylfloramide (C3H7NO) Sigma-Aldrich GmbH, Steinheim, Germany 
Nitro Blue Tetrazolium (NBT) Sigma-Aldrich GmbH, Steinheim, Germany 
Non-essential aminoacid (NEAA) Life Technologies, Karlsruhe, Germany 
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Nuclear Fast Red Sigma-Aldrich GmbH, Steinheim, Germany 
NuPAGE MES SDS running buffer Life Technologies, Darmstadt, Germany 
NuPAGE LDS sample buffer (4×) Life Technologies, Karlsruhe, Germany 
Orange G  Merck, Darmstadt, Germany 
Opti-MEM Life Technologies, Karlsruhe, Germany 
Paraffin pellets Carl Roth GmbH, Karlsruhe, Germany 
Paraformaldehyde Merck, Darmstadt, Germany 
PBS  PAN-Systems, Nürnberg, Germany 
Penicillin/Streptomycin PAN-Systems, Nürnberg, Germany 
Phenol Biomol, Hamburg, Germany 
Potasium acetate (C2H3KO2) Sigma-Aldrich GmbH, Steinheim, Germany 
Potassium hexacyanoferrate (II) trihydrate 
K4[Fe(CN)6]·3H2O 
Sigma-Aldrich GmbH, Steinheim, Germany 
Potassium hexacyanoferrate (III) K3[Fe(CN)6] Sigma-Aldrich GmbH, Steinheim, Germany 
RNase A Qiagen, Hilden, Germany 
RNase away Biomol, Hamburg, Germany 
Roti-Mount FluoroCare DAPI Carl Roth GmbH, Karlsruhe, Germany 
Roti Safe Carl Roth GmbH, Karlsruhe, Germany 
SeeBlue Plus2 Pre-Stained Standard Life Technologies, Karlsruhe, Germany 
S.O.C Medium Life Technologies, Karlsruhe, Germany 
Sodium acetate (NaAc) Merck, Darmstadt, Germany 
Sodium citrate (Na3C6H5O7) Merck, Darmstadt, Germany 
Sodium Deoxycholate (C24H39NaO4) Sigma-Aldrich GmbH, Steinheim, Germany 
Sodium dodecyl sulphate (SDS) Sigma-Aldrich GmbH, Steinheim, Germany 
Sodium hydroxide (NaOH) Merck, Darmstadt, Germany 
Sodium pyruvate Life Technologies, Karlsruhe, Germany 
Streptavidin Sigma-Aldrich GmbH, Steinheim, Germany 
SuperSignal™ West Pico Chemiluminescent 
Substrate 
Life Technologies, Karlsruhe, Germany 
Tri Fast PeqLab, Erlangen, Germany 
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Tris (hydroxymethyl) aminomethane AppliChem GmbH, Darmstadt, Germany 
Tris Sigma, Deisenhofen, Germany 
Triton X-100 Serva, Heidelberg, Germany 
Tryptone/Peptone Roth, Karlsruhe, Germany 
Tween-20 Sigma, Steinheim, Germany 
Xylene Baker, Deventer, Germany 
Yeast Extract Carl Roth GmbH, Karlsruhe, Germany 
 
2.1.2 Biochemical enzymes 
ENZYMES MANUFACTURER 
Antarctic Phosphatase New England Biolabs, Ibswich, USA 
BigDye Life technologies, Darmstadt, Germany 
Complete Mini Protease Inhibitor Cocktail 
Tablets 
Roche, Manheim, Germany 
Direct PCR Lysis Reagent Peqlab, Erlangen, Germany 
DNAse  Sigma-Aldrich, Deisenhofen, Germany 
Proteinase K Carl Roth GmbH, Karlsruhe, Germany 
Restriction Enzymes (with supplied buffers) New England Biolabs, Ibswich, USA 
Reverse Transcriptase SuperScript II Life Technologies, Darmstadt, Germany 
RNAse A AppliChem GmbH, Darmstadt, Germany 
Platinum Taq polymerase Life Technologies, Karlsruhe, Germany 
T4 DNA Ligase  Life Technologies, Darmstadt, Germany 
TrypLE Express Life Technologies, Darmstadt, Germany 
 
2.1.3 Ready-to-use reaction systems 
REACTION SYSTEM MANUFACTURER 
DNasy Blood and Tissue Kit  Qiagen, Hilden, Germany 
DNA Walking Speed Up Kit Seegene, USA 
Direct PCR Tail Reagent Peqlab, Erlangen, Germany 
Endo Free Plasmid Maxi Kit Qiagen, Hilden, Germany 
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Genome Walker Universal Kit Clontech, Mountain View, CA, USA 
Platinum SYBR-Green qPCR Super Mix-
UDG 
Life Technologies, Darmstadt, Germany 
QIAquick Gel Extraction Kit Qiagen, Hilden, Germany 
RNAeasy Kit Qiagen, Hilden, Germany 
 
2.1.4 Plasmids  
PLASMID PROVIDED BY 
pAAV2.1TBGeGFP3 Telethon Institute of Genetics and Medicine 
(TIGEM), Napoli, Italy 
pCAAG-FLPe Prof. I. Adham, Institute of Human Genetics 
Goettingen 
pGEMTeasy Promega, Wisconsin, USA 
pWajaII Waja Wegner 
pWajaIII Waja Wegner 
 
2.1.5 Usage ware 
USAGE WARE MANUFACTURER 
12 well cell culture plates Cellstar, USA 
6-, 24-well cell culture plates Sarstedt, Numbrecht, Germany 
Corning Inc., New York, USA 
384 wells-plates, white AB-gene, Hamburg, Germany 
13, 15, 50 ml tubes Greiner-bio-one, Kremsmunster, Austria 
Blotting Paper GB 002, 003, 004 Schleicher & Schuell, Dassel, Germany 
Butterfly needle Terumo, Leuven, Belgium 
Cell culture flasks Sarstedt, Nurnbrecht, Germany 
Cover Glass 24x60mm Menzel Glaser, Braunschweig, Germany 
e-cup homogenisers Sartorius, Goettingen, Germany 
Electroporation cuvettes Peqlab, Erlangen, Germany 
Flat-bottomed NuclonTM surface 96 well Nunc A/S, Denmark 
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cell culture plates 
Hybond C Amersham, Braunschweig, Germany 
Hybond N Amersham, Braunschweig, Germany 
Membrane filter Millipore, Billerica, USA 
Microcentrifuge Tubes Sarstedt, Nurnbrecht, Germany 
NuPAGETM 4-12%, 10% Bis-Tris Gel Life Technologies, Darmstedt 
Para-film M Pechiney, Chicago, USA 
Petri dishes Greiner Nunc., Nurntingen, Germany 
Pipet tips Sarstedt, Nurnbrecht, Germany 
PVDF-Membrane GE Healthcare, Munich, Germany 
QIAfilter Cartrige Qiagen, Hilden, Germany 
Qiagen-tip 100 Qiagen, Hilden, Germany 
QIA quick column Qiagen, Hilden, Germany 
Single-use needle B. Broun Sterican, Melsungen, Germany 
Single-use syringe Norm-Ject, Tuttingen, Germany 
Sterile-single use filter Minisart Sartorius, Goettingen, Germany 
Sterile Corning Filter System Sarstedt, Newton, USA 
Superfrost slides Thermo Scientific, Braunschweig, Germany 
Syringe filters Minisart NML Sartorius, Goettingen, Germany 
Transfections tubes Lab-Tek/Nalge, Nunc, USA 
Whatman blotting paper Schleicher and Schüll, Dassel, Germany 
X-ray films Amersham, Braunschweig, Germany 
 
2.1.6 Technical equipment 
TECHNICAL EQUIPMENT MANUFACTURER 
Autoclave Systec DX-150 Systec GmbH Wettenberg, Germany  
BioRad gene pulser TM apparatus 
Electroporation 
BioRad laboratories, München, Germany 
Centrifuge 5415R Eppendorf AG, Hamburg, Germany 
Centrifuge, Megafuge 16R Thermo Scientific, Osterode, Germany 
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Centrifufe, Multifuge X3R Thermo Scientific, Osterode, Germany 
Cryostat  Leica Microsystems, Nussloch, Germany 
FluorChem Q Alpha Innotech, Logan, Utah, USA 
Freezer-152oC GFL mbH, Burgwedel, Germany 
Histocentre 2 embedding machine Shandon, Pittsburg, USA 
HT7900 Fast Real-Time PCR System Applied Biosystems GmbH, Darmstadt, 
Germany 
Incubator Incubat Melag OHG, Berlin, Germany 
Incubator MWG-Biotech mini 10, Ebersberg,Germany 
Incubator CO2, MOCO-20AIC  Sanyo, Japan 
Incubator Innova shaker-Series New Brunschwick Scientific 
Microtome Jung RM2035 Leica Instruments GmbH, Nussloch, Germany 
Laminar Heraeus Instruments HeraSafe, Hanau, Germany 
Microscope BX60 Olympus, München, Germany 
Microscope PrimoVert Zeiss Microimaging GmbH, Goettingen, Germany 
Monochrome Printer Mitsubishi P95 Biometra, Malaysia 
NanoDrop 2000C Spectrophotometer PeqLab Thermo Scientific, Erlangen, Germany 
Roller RM5 Assistant, M.Zipperer GmbH, Etzenbach, 
Germany 
Semi dry transfer machine (blotter) Biometra An Analitik Jena, Germany 
Sequencer 3500XL Applied Biosystems, Darmstadt, Germany 
Sonifier 250 Ultrasonic Cell Homogeniser Branson, Danburg, USA 
Spectrophotometer Ultraspec 3000 Amersham, Freiburg, Germany 
Thermal Cycler 2720 Applied Biosystems, Singapore 
Thermomixer 5436 Eppendorf-Netheler-Hinz GmbH, Hamburg, 
Germany 
Thermomixer comfort Eppendorf AG, Hamburg, Germany 
UV Kontaktlampe Chroma42 Vetter GmbH, Wiesloch, Germany 
UV Solo TS Imaging System (gel imaging) Biometra Analytic Jena, Germany 
Vortex Bibby Stuart Bibby Sterilin LTD, Stone, Staffordshiere, 
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England 
Water bath Kottermann, Hanigsen, Germany 





AE Buffer 10 mM Tris-HCl 
0.5 mM EDTA, pH 9 
Animal anesthesia solution  0.25 ml Medetomidin (Domitor) 
1 ml Ketamin 
8.75 ml Sodium Chloride 0.9% 
AP Buffer 100 mM NaCl 
50 mM MgCl2 
100 mM Tris/HCl, pH 9.5 
AP Staining Solution 45 µl NBT (75 mg/ml in DMF) 
35 µl BCIP (50 mg/ml in DMF) 
in 10 ml AP Buffer 
Blocking Buffer ( Western Blot) 1x TBS-Tween 
5% low-fat dry milk 
Detergent rinse (LacZ staining) 
 
0.02% Igepal 
0.01% Sodium Deoxycholate 
2mM MgCl2 in 0.1M phosphate buffer, pH 7.5 
Lysis Buffer I 50 mM Tris/HCl, pH 8.0 
100 mM EDTA 
0.5% SDS 
Lysis Buffer II 100 mM Tris/HCl, pH 8.0 
5 mM EDTA 
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100 μg/ml Proteinase K 
P1 Buffer (Plasmid Preparation) 50 mM Tris-HCl, pH 8.0 
10 mM EDTA 
100 µg/ml RNAse A 
P2 Buffer (Plasmid Preparation) 200 mM NaOH 
1% SDS 
P3 Buffer (Plasmid Preparation) 3 mM Potassium acetate, pH 5.5 
PE Buffer 20 ml NaCl 
2 mM Tris-HCl, pH 7.5 
80% EtOH 
Protein Lysis Buffer 150 mM NaCl 
1 mM EDTA 
50 mM Tris-HCl, pH 7.4 
1% IGEPAL-CA-360 (NP-40) 
0.25% Natriumdeoxycholat 
1 Tablet/ 10 ml Complete Mini protease 
inhibitor 
10 µl/10 ml Phosphatase-Inhibitor-Mix II  
QBT Buffer 750 mM Sodium chloride 
50 mM MOPS, pH 7.0 
15 % Ethanol 
0.5 % Triton X-100 
QC Buffer 1 mM Sodium chloride 
50 mM MOPS, pH 7.0 
15 % Ethanol 
QF Buffer 1.25 M Sodium chloride 
50 mM Tris/HCl, pH 8.5 
Stop Mix 15% Ficoll 400 
200 mM EDTA 
0.1 % Orange G 
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5 × TBE 450 mM Tris base 
450 mM Boric acid 
20 mM EDTA, pH 8 
10 × TBS 1.37 M NaCl 
100 mM Tris 
Adjusted to pH 7.6 with HCl 
TE Buffer 10 mM Tris/HCl, pH 8.0 
1 mM EDTA 
Transfer Buffer (Western Blot) 25 mM Tris, pH 8.3 
150 mM Glycin 
20% Methanol 
Washing Buffer (Western blot) 1 × TBS-Tween 
2% low-fat dry milk 
X-Gal staining solution (LacZ staining) 0.02% Igepal 
0.01% Sodium Deoxycholate 
5mM Potassium hexacyanoferrate (II) 
trihydrate 
5mM Potassium hexacyanoferrate (III) 
2mM MgCl2 in 0.1M phosphate buffer, pH 7.5 
1mg/ml X-Gal in N,N-dimethyl-formamide 
(prior to use) 
X-Gal Stock Solution 20 mg X-Gal/ml N.N.-Dimethyl-formamide 
 
2.1.8 Culture media antibiotics and agar plates 
2.1.8.1 Culture media for bacteria 
Luria-Bertani medium (LB medium) 10g/l Trypton/Pepton 
5g/l Yeast Extract 
10g/l NaCl 
pH 7.0 
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2.1.8.2 Culture media for eukaryotic cells 
Embryonic stem (ES) cell medium DMEM 
1 mM Non-essential amino acids 
1 mM Sodium pyruvate 
10 μM ß-Mercaptoethanol 
2 mM L-Glutamine 
 20% FBS 
 1000 U/ml Recombinant leukaemia inhibitory 
factor (LIF) 
Fibroblast cells medium (MEFs) DMEM 
2 mM L-Glutamine 
10% FCS 
1% penicillin/streptomycin 
Freezing medium  50% FCS 
20% DMSO 
 30% culture medium 
 
2.1.8.3 Antibiotics 
For the antibiotics stock solutions were prepared. They were filtered through sterile 
disposable filters and stored at -20°C. 
 
ANTIBIOTIC STOCK SOLUTION WORKING SOLUTION 
Ampicillin 50 mg/ml 50 μg/ml 
Kanamycin 50 mg/ml 50 μg/ml 
Puromycin 50 mg/ml 50 μg/ml 
 
2.1.8.4 IPTG/X-Gal plates 
IPTG/X-Gal plates 
 
LB-agar (1.5% Agar in the LB medium) 
50 μg/ml ampicillin 
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The medium was autoclaved. After it had cooled down to a temperature lower than 55°C, 
the antibiotic, IPTG and X-Gal was added. Finally, the medium was poured into Petri 
dishes and stored at 4°C. 
 
2.1.9 Biological material 
2.1.9.1 Bacterial strains 
Plasmids were transformed into the Escherichia coli strain DH5α, provided by Life 
Technologies, Karlsruhe, Germany. 
 
2.1.9.2 Eukaryotic cell lines 
NIH3T3 Mouse embryonic fibroblast cell line, ATCC, Rockville, USA 
HepG2 Human hepatocellular liver carcinoma cell line, ATCC, Rockville, USA 
HeLa Human cervix adenocarcinoma cell line, ATCC, Rockville, USA 
R1 ES Mouse embryonic stem cell line, ATCC, Rockville, USA 
 
2.1.9.3 Mouse strains 
C57Bl/6N as well as 129sv mice were obtained from a colony of our own department. The 
animals were kept in sterile conditions, at a 12 hours light/dark cycle at 22o C and 55 ± 5% 
relative humidity. All experiments were performed according to the European and 
German protection of animals act. The number of sacrificed animals, the stress and pain 
they were suffering was reduced to a minimum. Euthanasia was performed either by 
cranial dislocation or CO2 asphyxiation. 
 
2.1.10 Synthetic DNA oligonucleotides 
The synthetic oligonucleotide primers used in this study were obtained from Eurofins 
MWG Operon (Ebersberg, Germany), and dissolved in dH2O (Ampuwa) to a final 
concentration of 100 pmol/μl. Sequences are listed below, starting from 5’- to 3’- end. 
 
2.1.10.1 Vector-specific primer 
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2.1.10.2 Human-specific primers 













2.1.10.3 Mouse-specific primers 


























2.1.10.4 Genotyping primers 
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2.1.10.5 cDNA synthesis primers 
PRIMER NAME SEQUENCE 
oligo (dT)12-18 primer (T)12 and (T)18 
 
2.1.11 Antibodies 
2.1.11.1 Primary antibodies 
The MOCS2A and MOCS2B antibodies were produced by Eurogentec (Seraing, Belgium), 
based on protein sequences provided by us. The peptide sequences used for 
immunisations were specific either for mice or for human. 
 
PRIMARY ANTIBODY MANUFACTURER 
Anti-Mocs2a (EP130014) polyclonal antibody, 
rabbit 
Eurogentec, Seraing, Belgium 
Anti-Mocs2b (EP113633) polyclonal antibody, 
rabbit 
Eurogentec, Seraing, Belgium 
Anti-MOCS2B (EP113635) polyclonal antibody, 
rabbit 
Eurogentec, Seraing, Belgium 
Anti-α-tubulin, monoclonal antibody, mouse Sigma-Aldrich, Deisenhofen, 
Germany 




Anti-IBA1, polyclonal antibody, rabbit Wako, Neuss, Germany 
Anti-Caspase3, rabbit BD Pharmingen, Germany  
Anti-GFAP, monoclonal, mouse Sigma-Aldrich, USA 
 
2.1.11.2 Secondary antibodies 
SECONDARY ANTIBODY MANUFACTURER 
Alexa Fluor 546 goat anti-rabbit IgG Life Technologies, USA 
Alexa Fluor 555 goat anti-mouse IgG Life Technologies, USA 
Anti-Rabbit IgG, Cy3 Sigma-Aldrich, USA 
Anti-Mouse IgG-Peroxidase antibody produced in Sigma-Aldrich, USA 
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rabbit 
Anti-Rabbit IgG-Peroxidase antibody produced in 
goat 
Sigma-Aldrich, USA 
Anti-Rabbit IgG (whole molecule)-Alkaline 
Phosphatase antibody produced in goat 
Sigma-Aldrich, USA 
Anti-Mouse IgG (whole molecule)-Alkaline 
Phosphatase antibody produced in goat 
Sigma-Aldrich, USA 
Anti-Mouse IgG-Peroxidase antibody produced in 
sheep 
Amersham, Freiburg, Germany 
Anti-Rabbit IgG-Peroxidase antibody produced in 
goat 




Bioinformatics Ensembl (http://www.ensembl.org/index.html) 
Nation Center for Biotechnology Information (NCBI) 
(http://www.ncbi.nlm.nih.gov/) 
ExPASy (http://www.expasy.org/) 
Online Mendelian Inheritance in Man (OMIM) 
(http://www.omim.org/) 




Cell counting Image Processing and Analysis in JAVA (ImageJ) 
(http://imagej.nih.gov/ij/) 
Primer design Primer 3 (http://primer3.ut.ee/) 
Protein sequence 
analysis 








NEB Cutter 2.0 (http://nc2.neb.com/NEBcutter2/) 
WEB Cutter 2.0 (http://bio.lundberg.gu.se/cutter2/) 
 
2.1.13 Statistical methods 
STATISTICAL METHOD APLICATION 
Student’s t-test Calculation of differences between WT and KO animals 
Chi-square test Calculation of differences between F1 genotype frequencies 
and the Mendelian frequencies that would be expected after 
breading of heterozygous Mocs2+/- animals 
 
2.1.14 Sterilisation of solutions and equipment 
Heat-sensitive solutions were filtered using disposable sterile filter units (0.2 to 0.45 μm 
pore size). All solutions which were not heat-sensitive and the plastic equipment were 
sterilised at 121°C, 105 Pa for 60 min in an autoclave. Glass wares were sterilised 
overnight in an oven at 180°C. 
 
2.2 METHODS 
2.2.1 Isolation and purification of nucleic acids 
2.2.1.1 Minipreparation of plasmid DNA 
A single bacterial colony was inoculated into 5 ml LB medium, containing an antibiotic 
(ampicillin or kanamycin) (50 μg/ml), and incubated at 37°C overnight in the shaker with a 
shaking speed of 160 rpm. 0.6 ml of the overnight-culture was used for glycerol stock 
preparation. The rest was centrifuged at 13000 rpm for 5 min at RT. The bacteria pellet 
was resuspended in 100 μl of resuspension buffer P1 (Qiagen). The bacterial cells were 
lysed with 200 μl of P2 lysis solution (Qiagen), incubated at RT for 5 min, and then 
neutralised with 150 μl of buffer P3 (Qiagen). The precipitated solution was centrifuged at 
13000 rpm at RT for 20 min. The supernatant was transferred into a fresh tube and 
centrifuged again under the same condition for 10 min. Finally, the supernatant (~450 μl) 
was transferred to fresh tube and mixed with an equal volume of ice-cold isopropanol to 
precipitate the DNA. After 30 min of incubation on ice, it was centrifuged at 13000 rpm at 
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4oC for 30 min. The DNA pellet was washed with 1ml of 70% ethanol, and after air-drying, 
dissolved in 30 μl of dH2O (Ampuwa). 
 
2.2.1.1.1 Preparation of bacterial glycerol stocks 
200 μl of 80% sterile glycerol was added to 600 μl of a bacterial suspension, well mixed 
and stored at -80oC. 
 
2.2.1.2 Large-scale preparation of Endotoxin-free plasmid DNA using the Qiagen 
Maxi Kit 
A single colony was inoculated into 5 ml LB medium, containing an appropriate antibiotic 
(50 μg/ml). The pre-culture was incubated overnight at 37°C with shaking (160 rpm). 
Further, the pre-culture was diluted 500-fold in 100 ml of the LB medium and incubated 
12 hours at 37°C with shaking (160 rpm). On the next day the overnight culture was 
centrifuged at 4000 rpm for 15 min at 4°C. The bacterial pellet was resuspended in 4 ml of 
P1 solution. Further, the cells were lysed with 4 ml of P2 buffer, neutralised with 4 ml of 
buffer P3 and immediately poured into the barrel of the QIAfilter Cartridge, provided by 
the company. After 10 min of incubation, the lysate was filtered to a 50 ml tube. Further, 
1 ml of buffer ER was added to the filtered lysate and mixed. It was incubated on ice for 
30 min. Before the lysate was applied to the supplied QIAGEN-tip 100, the column was 
equilibrated with buffer QBT. After the lysate passed through the resin by gravity flow, 
the QIAGEN-tip was washed twice with 10 ml of buffer QC, and the DNA was eluted using 
5 ml of QN solution. To precipitate the DNA, 3.5 ml of isopropanol was added, mixed 
thoroughly and then centrifuged at 13000 rpm for 30 min at 4°C. The obtained DNA pellet 
was washed with 70% endotoxin-free ethanol, air-dried and dissolved in 100 μl of TE 
buffer. 
 
2.2.1.3 Isolation of genomic DNA 
2.2.1.3.1 Isolation of genomic DNA from tissue samples  
Mouse tissue was homogenised and incubated in 700 μl of lysis buffer I, containing 35 μl 
proteinase K (100 μg/ml), overnight at 55°C in a thermomixer. The tissue lysate was 
centrifuged at 13000 rpm for 15 min and the supernatant was transferred into a fresh 
reaction tube. Further, genomic DNA was precipitated by adding an equal volume of 
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isopropanol, mixed by inverting and centrifuged at 13000 rpm at RT for 15 min. The DNA 
pellet was washed with 1 ml of 70% ethanol, dissolved in 50-100 μl of dH2O (Ampuwa) 
and incubated at 60°C for 10 min. 
 
2.2.1.3.2 Isolation of genomic DNA from cells  
Cells were washed with DPBS, trypsinised and collected by centrifugation. The 
supernatant was removed by aspiration; the cell pellet was resuspended in DPBS and 
subsequently transferred into a reaction tube. After centrifugation at 1000 rpm for 5 min, 
the supernatant was removed, and cells were incubated overnight in 105 μl of lysis buffer 
II at 55oC. After inactivation of proteinase K, an equal volume of isopropanol was added, 
mixed by inverting several times, and incubated for 10 min at RT. After centrifugation for 
15 min at 13000 rpm, the DNA pellet was washed with 70% ethanol. The genomic DNA 
was dissolved in 50-100 μl of dH2O (Ampuwa) and incubated at 55oC for 10 min.  
 
2.2.1.3.3 Isolation of genomic DNA from sperm 
To collect the sperm, the chimeric male was bred with a wild type female. Once the 
vaginal plug was confirmed, the female was sacrificed and spermatozoa were flushed out 
from the uterus into DPBS and pelleted by centrifugation at 13000 rpm. The DNA from 
spermatozoa was isolated using the DNeasy Blood and Tissue Kit (Qiagen). The sperm was 
incubated for 1 hour at 56°C in the 100 μl of buffer X2. Further, 200 μl of buffer AL was 
added and mixed. After the 200 μl of 100% ethanol was added and mixed, the mixture 
was loaded into DNeasy Mini spin column, placed in a 2 ml collection tube and 
centrifuged at 6000 rcf for 1 min. The flow through was discarded. The column was 
washed with 500 μl of buffer AW1, and centrifuged at 6000 rcf for 1 min. Again, the flow 
through was discarded, while the column was placed in a new 2 ml tube, and washed with 
500 μl of buffer AW2 and subsequently centrifuged 3 min at 14000 rpm to dry the 
membrane. Next, the column was placed in a 1.5 ml tube, and the DNA was eluted with 
50 μl of buffer AE. After 1 min of incubation, the tube was centrifuged for 1 min at 8000 
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2.2.1.3.4 Isolation of genomic DNA from recombinant adeno-associated virus 
(rAAV) 
To extract DNA from rAAV, 10 μl of the viral sample was boiled at 90°C for 10 min in 90 μl 
DPBS, and subsequently centrifuged for 15 min at 13000 rpm at RT. 150 μl of lysis buffer 
containing proteinase K was added and the solution was incubated for 30 min at RT. After 
5 min of centrifugation at 13000 rpm, 200 μl of isopropanol was added, and the solution 
was incubated 15 min at -20°C. After incubation, the sample was centrifuged for 5 min at 
13000 rpm. The DNA pellet was washed with 70% ethanol, air-dried, and resuspended in 
10-20 μl of dH2O (Ampuwa). The DNA was stored at -20°C. 
 
2.2.1.4 Isolation of total RNA from tissue samples  
100-200 mg of tissue sample was homogenised in 0.5 ml of Tri Fast Reagent using an e-
cup homogeniser. After 5 min incubation at RT, 100 μl of chloroform was added, mixed 
vigorously, and incubated 10 min at RT. After centrifugation at 12000 rpm for 15 min at 
4°C, the upper aqueous phase was transferred into a new tube. The RNA was precipitated 
by adding 250 μl of isopropanol, incubated for 10 min at RT, and at centrifuged 12000 
rpm at 4°C for 10 min. Finally, the RNA pellet was washed with 75% RNAse-free ethanol, 
dissolved in 20-50 μl of RNase-free water (DEPC H2O), and stored at -80°C. 
 
2.2.1.5 Determination of nucleic acid concentration 
The concentration of nucleic acids was determined spectrophotometrically using a Nano 
Drop spectrophotometer. Prior to measurement, the instrument was calibrated with 
buffer used for the sample dilution. To evaluate the concentration, 1 μl of the solution 
was loaded on the pedestal arm. The concentration was determined automatically. The 
quality of nucleic acids, i.e. contamination with proteins, was estimated by the ratio of 
absorbance 260 nm/280 nm. The correct value of the ratio is between 1.8 and 2.0.  
 
2.2.1.6 Cloning techniques 
2.2.1.6.1 Cleavage of DNA with restriction endonucleases 
Restriction enzyme digestions were performed by incubating double-stranded DNA with a 
restriction enzyme in a total volume of 10 μl. Per 1 μg DNA 7.5 U of restriction enzyme 
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was used, together with a buffer recommended by the supplier. The reaction was 
incubated at 37°C for 90 min. 
 
2.2.1.6.2 Isolation of DNA fragments from agarose gels using the QIAquick Gel 
Extraction Kit (Qiagen) 
The kit was used to extract and purify DNA of 70 bp to 10 kb in length from agarose gels. 
Up to 400 mg agarose could be processed during a single isolation. Three gel volumes (gel 
volume corresponds to the slice weight, 100 mg = 100 µl) of QG buffer were added to the 
agarose gel piece and incubated at 50°C for 10 min. After the gel slice was dissolved, one 
gel volume of isopropanol was added. The solution was applied to a QIAquick column, 
provided by the company, and centrifuged for 1 min at 13000 rpm. The flow through was 
discarded, and the column was washed with 0.75 ml of PE buffer. After 5 min of 
incubation, the column was centrifuged, and the flow through was discarded. The column 
was placed into a fresh microcentrifuge tube. DNA was eluted by application of 50 μl of 
EB buffer to the centre of the QIAquick membrane, and a subsequent centrifugation for 1 
min. 
 
2.2.1.6.3 Dephosphorylation of plasmid DNA 
Dephosphorylation was performed to avoid self-religation of linearised plasmid DNA. To 
remove the terminal 5’-phosphate group of the vector, the DNA was incubated with 2 U 
of Antarctic phosphatase for 1 hour at 37°C. 
 
2.2.1.6.4 Ligation of DNA fragments 
The cloning of an insert DNA into a vector (digested with appropriate restriction 
enzyme(s)) was carried out in the following ligation reaction mix in a total volume of 10 μl 
for 3 hours at RT. 
 
Ligation reaction Ligase Buffer × 10 1 μl 
Vector DNA (digested) 25-50 ng 
Insert DNA 30-120 ng 
T4 DNA ligase (5 U/μl) 1 μl 
H2O up to 10 μl 
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2.2.1.6.5 TA-Cloning  
Taq polymerase and other DNA polymerases have a terminal transferase activity that 
results in the non-template addition of a single nucleotide to the 3' ends of PCR products. 
In the presence of all four dNTPs, dATP is preferentially added. This terminal transferase 
activity is the basis of the TA-cloning strategy. For cloning of PCR products, a pGEMT-easy 
vector system that has 5‘-dT overhangs was used. The reaction was incubated in a total 
volume of 10 μl for 3 hours at RT, or overnight at 16°C.  
 
Cloning of PCR products 
using pGEMT-easy vector 
system 
pGEMT-easy vector 50 ng  
PCR product 150 ng 
T4 DNA Ligase buffer (×10) 1 μl 
T4 DNA Ligase 1 μl 
H2O up to 10 μl  
 
2.2.1.6.6 Transformation of competent bacteria (Hanahan, 1983) 
Transformation of bacteria was done by gently mixing a 50 μl aliquot of DH5α competent 
bacteria with 10 μl of ligation reaction. After incubation for 30 min on ice, bacteria were 
heat-shocked for 45 sec at 42°C, and cooled down for 5 min on ice. After adding 950 μl of 
S.O.C. medium, the mixture was incubated at 37°C, at 600 rpm, for 1 hour. Finally, 150 μl 
of the transformed bacteria were plated out on LB-agar plates containing an appropriate 
antibiotic (50 μg/ml), and incubated overnight at 37°C.  
 
2.2.1.7 Gel electrophoresis 
Gel electrophoresis is the technique which enables the separation of nucleic acids and 
proteins in an electrical field according to their size, which is directly related to the 
number of nucleotides or amino acids in the molecule, charge and shape. 
 
2.2.1.7.1 Agarose gel electrophoresis of DNA 
Agarose gels were used to run nucleic acid molecules from 50 bases to more than 20 kb, 
depending on the concentration of the agarose. Usually, 1.2 g agarose was added to 100 
ml of 0.5 × TBE buffer, and boiled in the microwave to dissolve the agarose. After cooling 
down the solution to approximately 60°C, 3 μl of ethidium bromide (10 mg/ml) or 5 μl of 
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Roti Safe were added to stain the gel. The prepared agarose gel was poured into a 
horizontal gel chamber. Gel electrophoresis was performed 5 min at 95 V, and further at 
120 V for 40 min.  
 
2.2.1.7.2 Length standard 
For determination of DNA fragment length on agarose gels, length standards were loaded 
in parallel (100 bp, or 1Kb Plus DNA-ladder, Life Technologies) 
 
2.2.1.8 Polymerase Chain Reaction (PCR) 
2.2.1.8.1 Amplification of DNA fragment 
The PCR is an in vitro method to amplify specific DNA fragments. The method uses high 
temperatures to denature double-stranded DNA, and to allow bindings of primers 
(annealing). After primers bind to the single-stranded DNA, oligonucleotides are extended 
by the polymerase (elongation). Denaturation, annealing and elongation are steps which 
are repeated certain time to increase exponentially the number of DNA fragments. The 
amplified products can be loaded on an agarose gel. 
 
PCR reaction components DNA 10 ng 
forward primer (10 pmol) 1 μl 
reverse primer (10 pmol) 1 μl  
10 mM dNTPs 1 μl  
10 × PCR buffer 5 μl 
 50 mM MgCl2 1.5 μl 
 Taq DNA Polymerase (5 
U/μl) 
0.5 μl 
 dH2O Up to 50 μl 
 
The reaction mixture was performed in a 200 μl reaction tube and placed in a 
thermocycler. Thermal cycling was carried out for 25-35 cycles with denaturation at 94°C 
for 30 sec, annealing at 55-62°C for 30-45 sec and extension at 72°C for 30-90 sec. 
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2.2.1.8.2 cDNA synthesis 
cDNA synthesis generates cDNA fragments from RNA templates and helps to determine 
the expression of genes in specific tissues or in different development stages. After 
DNAse digestion, 1-5 μg of total RNA was mixed with 1 μl of oligo (dT) (10 pmol/μl) in a 
total volume of 13 μl. For RNA denaturation, the mixture was heated to 65°C for 10 min 
and then quickly chilled on ice. After a brief centrifugation, 4 μl of 5x first strand buffer 
and 2 μl of 0.1 M DTT were added, mixed and incubated at 42°C for 2 min. Further, 1 μl of 
reverse transcriptase enzyme (Superscript II RT) was added and the mixture was 
incubated at 42°C for 50 min for first strand cDNA synthesis. The reaction was inactivated 
by heating at 70°C for 15 min. The quality of synthesised cDNA was checked by PCR using 
primers specific for the housekeeping gene Hprt, before it was subjected to further 
analysis. 
 
2.2.1.8.3 Quantitative Real-Time PCR (qPCR or qRT-PCR) 
The quantitative real-time PCR is a method that relies on the basic PCR principle; 
however, due to the presence of fluorescent dye in the mastermix, which binds 
unspecifically to double stranded DNA, provides very accurate and reproducible 
quantitation of gene copies. In the study we used the PCR mastermix including Platinum 
SYBR Green qPCR. SYBR-Green which is bound to double stranded DNA can be excited 
with light with a wavelength of 480 nm. Its emission spectrum is comparable to that of 
fluorescein with a maximum at 520 nm. The fluorescent intensity was measured after 
every PCR cycle using the HT7900 Fast Real-Time PCR System (Applied Biosystems), and a 
graph was generated. During the exponential phase the threshold value was determined. 
It defines the PCR cycle where the optimal conditions, with enough reaction materials and 
the maximal polymerase activity, are obtained. This value is used for further calculations 
(Ct value). The data were evaluated with the Sequence-detection system software (SDS 
Version 2.4, PE Applied Biosystems). The reaction was comprised of the following 
components: 
 
Real-time PCR reaction 
components 
SYBR-Green 5 μl 
Primer F (100 pmol/μl) 1 μl 
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 Primer R (100 pmol/ μl) 1 μl 
 H20 1 µl 
 cDNA (1:20) 2 μl 
 
The following program was used on the HT7900 Fast Real-Time PCR System: 
50°C 2 min  
95°C 15 min Taq activation 
94°C 15 sec Denaturation 
60°C 30 sec Annealing 
72°C 30 sec Elongation 
95°C 15 sec  
60°C 15 sec  
60°C- 95°C 2°C/min melting curve 
 
After measurement the data was transferred to MS Excel (Microsoft) for further 
calculations. Relative expression was determined by the ΔΔCt method based on the 
following formula:  
 
 
ΔCt = Ct (gene of interest) - Ct (reference gene) 
ΔΔCt = ΔCt (control) - ΔCt (sample of interest) 
Relative expression = 2ΔΔCt 
 
 
For detection of the housekeeping gene Gapdh-specific primers were used. 
 
2.2.1.8.4 Sequence analysis, Sanger DNA-sequencing 
The non-radioactive sequencing is based on the principle of chain termination developed 
by Sanger and Coulson (Sanger and Coulson, 1975). The method uses four 
dideoxynucleotides that are labelled with different fluorescent dyes. These 
dideoxynucleotides lack a 3’-hydroxyl group required for the formation of 
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a phosphodiester bond between two nucleotides. Incorporation of such a 
dideoxynucleotide leads to a termination of the DNA extension. 
 
The sequencing PCR reaction was performed using following components: 
Sequencing PCR reaction 
components 
DNA 1 μl 
Sequence-specific primer (10 pmol/ μl) 1 μl 
 BigDye 1 μl 
 5 × Buffer 2 μl 
 ddH2O 5 μl 
 
Sequencing program: 
95°C                   5 min Polymerase activation 




53°C 30 sec Annealing 
60°C 2 min Elongation 
72°C                    5 min Final elongation 
8°C                      ∞  
 
After PCR completion, 10 μl of dH2O (Ampuwa) were added to the reaction and gel 
electrophoresis was performed in the automatic sequencer 3500XL (Applied Biosystems, 
Life Technologies, Darmstadt, Germany). 
 
2.2.1.9 Protein analysis methods 
2.2.1.9.1 Isolation of total protein lysate from tissues 
Approximately 100 mg of tissue was homogenised in 300-500 μl protein lysis buffer and 
incubated 1 hour on ice. Then, the samples were treated with ultrasound on ice with 3 x 
15 impulses, centrifuged at 13000 rpm for 20 min at 4oC, and the supernatant was 
transferred to a fresh Eppendorf tube. To isolate the proteins from cells, 5×106 cells/ml 
were washed with cold DPBS, and resuspended in 50-200 μl of protein lysis buffer. The 
cells were incubated on ice for 30 min, treated with ultrasound on ice with 3×10 impulses, 
and centrifuged at 13000 rpm for 20 min at 4oC. The supernatant was transferred to a 
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fresh Eppendorf tube. The protein extracts were either used immediately or stored at -
80oC. 
 
2.2.1.9.2 Determination of protein concentration (Bradford, 1976) 
To determine the protein concentration, the Bradford assay was employed. The method 
uses the Brilliant Blue G dye which binds unspecifically to cationic and hydrophobic site 
chains of proteins. Upon binding the absorption maximum is shifted from 495 nm to 595 
nm. The absorption of light, measured at 595 nm in a spectrophotometer is proportional 
to the protein concentration. The exact concentration of the proteins was calculated 
based on the standard curve. 
 
Protein quantitation assay  Protein 2 μl 
PBS 798 μl 
 Bradford reagent 200 μl 
 
2.2.1.9.3 SDS-PAGE gel for separation of proteins  
The NuPage Precast Gel System was used for the separation of proteins. NuPage 4-12% 
Bis-Tris gel is a SDS-PAGE polyacrylamide gel with 4-12% percentage gradient, what 
allows more efficient separation of proteins. It consists of NuPage Bis-Tris pre-cast gels 
and specifically optimised buffers which have an operating pH of 7.0. This neutral pH 
increases the stability in both proteins and gels, providing increased confidence in 
electrophoresis results. 
 
2.2.1.9.4 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Usually, 30 μg of protein were diluted in DPBS (total volume of 30 μl) and mixed with 10 
μl of 4 × SDS loading dye, denatured at 70°C for 10 min, and chilled on ice. The protein 
samples and additionally 10 μl of protein marker (pre-stained protein standard) were 
loaded on the gel, placed in the chamber which was filled with 1 × MES Running Buffer. 
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2.2.1.9.5 Semi-dry blotting of proteins (Gershoni and Palade, 1982) 
After protein electrophoresis, the SDS PAGE gel, a PVDF membrane at the appropriate 
size, and six pieces of Whatman paper were moistured with transfer buffer. They were 
further placed on the lower plate of semi-dry blotter, 3 Whatman papers, membrane, gel 
and on the top 3 more Whatman papers, to form a sandwich model. The upper plate was 
placed over the sandwich and the transfer was carried out at 3.5 mA/cm2 for 1 hr. 
 
2.2.1.9.6 Incubation of protein-bound membranes with antibodies 
To block unspecific binding sites, the membrane was incubated in blocking buffer 
(Western Blot) for 1 hour at RT. Further, the membrane was incubated with the primary 
antibody at a recommended antibody dilution at 4°C overnight in washing buffer 
(Western Blot). On the next day, the membrane was washed three times for 20 min with 
washing buffer to wash out unbound antibodies, and incubated with the appropriate 
secondary antibody in washing buffer (Western Blot) at RT for 1 hour. After the 
incubation step, the membrane was washed three times for 20 min with washing buffer 
(Western Blot). Next, the membrane was washed 3 × 5 min in DPBS, and placed on a 
plastic film. For the detection of the chemiluminescent signals, the detection solution was 
pipetted on the membrane and incubated for 2 min, before the signals were captured 
using the Western Blot detection system (FlourChem Q Alpha Innotech, Logan, USA). For 
the detection of proteins using alkaline phosphatase (AP), the secondary antibodies were 
conjugated to alkaline phosphatase. After the membrane was incubated three times for 
20 min with washing buffer (Western Blot), the membrane was washed 3 x 10 min with 
AP Buffer at RT. Further, to visualise protein bands, the PVDF membrane was incubated in 
the darkness with the AP staining solution. The reaction was stopped by washing with 
DPBS, and the membrane was dried. 
 
2.2.1.10 Histological techniques 
2.2.1.10.1 Perfusion 
The animal was anesthetised by intraperitoneal injection with 0.1 ml of animal anesthesia 
solution per 10 g of body weight. Once the mouse was sedated, the abdomen and chest 
were opened to free the heart and liver. The butterfly needle providing DPBS was placed 
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in the left ventricle very carefully and gentle to avoid penetration of the cardiac septum. 
To enable the drain of blood, the hole in the right atrium had to be done immediately 
(using an additional needle). DPBS was infused until the out-flow solution turned clear 
and the liver colour became light brown. 
 
2.2.1.10.2 Tissue preparation for paraffin-embedding 
The freshly prepared mouse tissues were fixed in 4% paraformaldehyde solution. The 
dehydration process was accomplished by passing the tissue through a series of 
increasing alcohol concentrations: 70%, 80%, 90%, 100% ethanol, and overnight in 
isopropanol. Later, the alcohol was removed from the tissue by incubation in 75%: 25%, 
50%: 50%, 25%: 75% isopropanol-xylene solutions, and at the end in 100% xylene 
overnight. The next step was the incubation of the tissues in paraffin at 60°C. Before 
embedding, the paraffin was changed at least four times. Finally, the tissue was placed in 
the embedding mould and melted paraffin was poured into the mould to form a block. 
The paraffin block was incubated overnight at 4°C before sectioning. 
Dehydration protocol: 
overnight 4% Formaldehyde solution 
overnight 70% EtOH 
1 × 15 min 70% EtOH 
3 × 20 min 80% EtOH 
4 × 30 min 90% EtOH 
5 × 20 min 100% EtOH 
overnight Isopropanol 
30 min 75%: 25% isopropanol-xylene 
30 min 50%: 50% isopropanol-xylene 
30 min 25%: 75% isopropanol-xylene 
overnight Xylene 
5 × 4 hours Paraffin 
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2.2.1.10.3 Sections of the paraffin block 
Paraffin blocks were clamped into the microtome (Leica Instruments GmbH, Nussloch, 
Germany). The thickness of the tissue section was 5 μm. The sections were floated on 
pre-warmed to 40°C water which helped to spread the sections out. Afterwards, sections 
were transferred onto glass slides. After complete drying of the sections at 37°C, slides 
were stored at 4°C for further analysis. 
 
2.2.1.10.4 Immunofluorescence staining of paraffin sections 
Tissue sections were incubated 3 × 3 min in xylene to remove the paraffin. Then, they 
were re-hydrated in a decreasing ethanol series (100%, 96%, 70%, 50%, and 30%) for 2 
min each. For immunofluorescence staining, the sections were washed in DPBS, and fixed 
in 4% paraformaldehyde solution. After washing with DPBS, the slides were incubated 
with 50 mM NH4Cl for 10 min, and again washed with DPBS. Next step was 
permeabilization of the tissue section using 0.2% Triton in DPBS, and a 1 hour incubation 
step with the primary antibody in a humidified chamber at RT. After washing with 0.2% 
Triton-DPBS, the slides were incubated with the secondary antibody in the humidified 
chamber also for 1 hour. Further, they were washed with 0.2% Triton-DPBS and DPBS. 
The nuclei were counterstained with DAPI. Immunostaining of the sections was examined 
using a fluorescence equipped microscope (Olympus, München, Germany). 
Rehydration and staining protocol:  
3 × 3 min Xylene 
2 min 100% EtOH 
2 min 96% EtOH 
2 min 70% EtOH 
2 min 50% EtOH 
2 min 30% EtOH 
2 × 5 min DPBS 
15 min 4% Formaldehyde solution 
2 × 5 min DPBS 
10 min NH4Cl (pre-warmed to 37oC) 
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2 × 5 min DPBS 
3 × 4 min 0.2% Triton-DPBS 
1 hour Primary antibody in 0.2% Triton-DPBS 
3 × 4 min 0.2% Triton-PBS 
1 hour Secondary antibody in 0.2% Triton-DPBS 
3 × 4 min 0.2% Triton-DPBS 
2 × 5 min DPBS 
 DAPI 
 
2.2.1.10.5 Diaminobenzidine (DAB) immunohistochemistry 
Tissue slides were incubated for 1 hour at 60°C to melt the paraffin, further dewaxed in 
xylol, hydrated in isopropanol, and washed in dH2O. In the next step the slides were 
cooking for 30 min in a streamer: slides for NeuN and Iba-1 were boiled in citratbuffer 10 
mM pH 6, while slides for Caspase-3 in Tris/EDTA Buffer pH 9 (10 mM Tris, 1 mM EDTA). 
After washing in dH2O the slides were incubated for 30 min in the incubation box (with a 
wet milieu) with 100 μl FCS/PBS, and further incubated overnight at 4°C with primary 
antibody. On the next day, slides were washed in PBS, and incubated 1 hour with 
secondary antibody, and again washed with PBS. Further, each slide was incubated for 1 
hour with 100 μl of Streptavidin (Sigma), diluted 1:1000. After washing in PBS, the signal 
was developed with DAB, washed with dH2O, and the nuclei were stained with Mayer's 
Hämalaun (Merck). After dehydration in isopropanol, the slides were put in xylol and 
embedded in DePex. 
 
2.2.1.10.6 Hematoxylin-eosin (HE) staining of histological sections 
Tissue sections were first incubated three times for 5 min in xylene, followed by 
incubation in 100%, 95%, 90%, 80%, 70%, and 50% ethanol for 3 min each. Thereafter, 
slides were washed in ddH2O for 5 min, and stained for 5 min in hematoxylin. The staining 
was followed by rinsing with deionised water, and washing in tap water for 10 min. The 
treated slides were dipped fast in acid ethanol (1ml concentrated HCl in 400 ml 70% 
ethanol) for 8-12 times to destain the tissue sections, and in amonium water (0.25%). 
After rinsing in tap water for 2 min and further in deionised water for 2 min, the slides 
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were stained in eosin for 2 min, incubated in 70%, 80%, 90%, 95% and 100% ethanol for 2 
min each, and 15 min in xylene. Finally, the stained tissue sections were incubated in 
xylene for 15 min and mounted with Eukitt-quick hardening mounting medium. 
Rehydration and staining protocol:  
3 × 5 min Xylene 
3 min 100% EtOH 
3 min 95% EtOH 
3 min 90% EtOH 
3 min 80% EtOH 
3 min 70% EtOH 
3 min 50% EtOH 
5 min H2O 
5 min Hematoxilin Mayers 
wash ddH2O 
5 × 70% EtOH + HCl 
wash Ammonium ddH2O 
wash ddH2O 
2 min 30 sec Eosine 
wash ddH2O 
2 min 50% EtOH 
2 min 70% EtOH 
2 min 80% EtOH 
2 min 95% EtOH 
2 min 100% EtOH 
15 min Xelene 
 Close with Eukitt-quick hardening mounting medium 
 
2.2.1.10.7 Tissue preparation for cryomedium-embedding 
After perfusion, the liver was dissected and dehydrated first in 15% sucrose for 3 hours, 
and further overnight in 30% sucrose. The liver samples were embedded in Cryo-
Embedding Compound on dry ice, and stored overnight at -80oC.  
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2.2.1.10.8 Sections of the cryo-block  
Cryo-tissue blocks were clamped into the cryotome (Leica Microsystems, Nussloch, 
Germany). The thickness of the tissue section was 5 μm. Tissue sections were collected on 
glass slides, and kept at -20°C for further analysis.  
 
2.2.1.10.9 DAPI staining of cryo-sections 
Slides were fixed for 15 min in 4% paraformaldehyde and washed three times for 5 min in 
DPBS. The nuclei were counterstained with DAPI. Sections were examined using a 
fluorescence equipped microscope (Olympus, München, Germany). 
 
2.2.1.10.10 LacZ staining  
Tissue slides were fixed in 0.2% glutaraldehyde for 10 min on ice. After 10 min of washing 
in DPBS, tissue sections were permeabilised 10 min by rinsing in detergent (Igepal) and 
immersed in 1 mg/ml X-gal staining solution overnight at 37°C in the dark. On the next 
day, the tissue sections were post-fixed for 10 min in 4% paraformaldehyde (PFA), rinsed 
in PBS for 10 min and washed 2 × 5 min in ddH2O. Nuclei were counterstained with 
Nuclear Fast Red, subsequently; sections were rinsed in ddH2O and washed for 2 min. The 
tissue sections were dehydrated, mounted with Eukitt-quick hardening mounting 
medium, and enclosed with coverslips. 
 
2.2.1.11 Eukaryotic cell biological methods 
The cells were cultured at 37°C in a humidified incubator (Sanyo, Japan) with 5% CO2. All 
media and components (see paragraph 2.1.8.2) were always pre-warmed in the water 
bath. 
 
2.2.1.11.1 Preparation of MEFs feeder layers 
A frozen aliquot of MEFs was quickly thawed in the water bath at 37°C and transferred to 
10 ml MEF medium. After centrifugation at 1000 rpm for 5 min, the cell pellet was gently 
resuspended in 10 ml MEFs medium and plated in 3 × T75 culture flasks. Cells were 
incubated at 37°C in 5% CO2. When the cells formed a confluent monolayer, they were 
trypsinised (using TrypLE-Express), transferred to 24 × T75 flasks and grown until they 
reached confluency. Inactivation of mitotic activity was performed by treatment with 
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mitomycin C (1 mg/ml) for 3 hours. Afterwards, the cells were washed twice with 10 ml of 
DPBS, trypsinised, pelleted and stored at -80°C. 
 
2.2.1.11.2 Trypsinisation of eukaryotic cells 
Cells were washed twice with sterile DPBS and incubated in minimal amount of TrypLE-
Express at 37°C until the cells detached from the bottom of the culture flask. Trypsin was 
inhibited by addition of culture medium, in which the cells were subsequently 
resuspended. The enzyme was removed by centrifugation at 1000 rpm for 5 min. Cells 
were resuspended in an appropriate volume of fresh cell culture medium, and transferred 
into a new flask/plate. 
 
2.2.1.11.3 Cryopreservation and thawing of eukaryotic cells 
Cells were grown to a confluency of > 80%, washed with DPBS, and trypsinised. They were 
spun down (1000 rpm for 5 min) in growth medium. The supernatant was aspirated, and 
the cells were resuspended in freezing medium. Aliquots of the cells were kept at -80°C. 
For revitalisation, frozen cells were quickly thawed in the water bath, inoculated in a 
suitable amount of growth medium, centrifuged and plated. 
 
2.2.1.11.4 Growth of ES cells on feeder layer 
An aliquot of frozen ES cells was quickly thawed at 37°C in the water bath. The cells were 
transferred to a 15 ml tube containing 6 ml of ES cell medium. After 5 min of 
centrifugation at 1000 rpm, the cell pellet was resuspended in 5 ml of ES cell medium and 
plated on 6 cm gelatine-coated dishes containing feeder layer. One day later, the medium 
was changed to a fresh one. On the next day, cells were washed with DPBS, trypsinised 
and pelleted. The cell pellet was resuspended in 10 ml ES cell medium and distributed 
either to 5-6 dishes (6 cm) or to 2 dishes (10 cm) covered with feeder layers. The cells 
were passaged every second day as described above. 
 
2.2.1.11.5 Transfection of plasmids into eukaryotic cells 
Eukaryotic cells were transfected with plasmids in order to induce an overexpression of 
gene of interest. The transfection was performed using the lipofectamine reagent. The 
day before transfection, cells were trypsinised and counted. The appropriate number of 
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cells was plated into a 6-well plate. On the day of transfection the confluency of cells 
should be around 85-90%. In two separate tubes two transfection cocktails were 
prepared. In the first tube plasmid DNA was placed in Opti-MEM, and in the second tube 
lipofectamine was put in Opti-MEM. After 5 min of incubation at RT, both mixtures were 
combined gently, and incubated for 20 min at RT. Subsequently, the medium from 
prepared cells was replaced with the transfection cocktail for 4 hours at 37°C and 5% CO2. 
Afterwards, the medium was changed to the normal culture medium. Cells were either 
analysed under a fluorescent microscope, or cells were trypsinised after 1-2 days of 
growing and subjected for DNA, RNA or protein isolation. 
 
2.2.1.12 Production of targeted embryonic stem (ES) cell clones 
2.2.1.12.1 Electroporation of ES cells 
ES cells, which have grown for two days in 10 cm dishes, were trypsinised. The cell pellet 
was washed in 20 ml DPBS, centrifuged and resuspended in 1 ml DPBS. Subsequently, 0.8 
ml of cell suspension was mixed with 40 μg of a linearised DNA construct and transferred 
into an electroporation cuvette. The electroporation was performed at 240V, 500μF with 
the Bio-Rad gene pulserTM apparatus. After electroporation, the cuvette was placed on 
ice for 20 min. The cell suspension was transferred from the cuvette into 20 ml of ES cell 
medium and plated onto two 10 cm dishes containing feeder layers. The medium was 
changed every day. Two days after the electroporation, the puromycin for selection was 
added (2 μg/ml). Again, medium was changed every day. After approximately eight days 
of selection, drug resistant colonies had appeared and were genotyped. 
 
2.2.1.13 Production of chimeras by injection of ES cells into blastocysts 
The injection of the Mocs2 knockout ES cells was performed in cooperation with Dr. 
Ursula Fünfschilling (Max Planck Institute of Experimental Medicine, Göttingen, 
Germany). The ES cells were injected into blastocysts, which were further transplanted 
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2.2.1.14 Detection of chimerism and mice breeding 
Chimerism of obtained animals was assessed based on the coat colour. Further, chimeric 
mice were bred with wild type animals to ascertain contribution of the ES cells to the 
germline. Additionally, the genotyping of spermatozoa was performed.  
 
2.2.1.15 DNA preparation for microinjection 
A large-scale preparation of the plasmids was performed using Endotoxin-free Qiagen 
Maxi Kit. Plasmids were linearised overnight in 37°C with the restriction enzyme XmaI. 
The samples were loaded on an EtBr-free 0.7% agarose gel as follows: 1 kb plus DNA 
ladder, undigested plasmid, 0.5 μg of digested plasmid, empty well, and 4.5 μg digested 
plasmid. The agarose gel electrophoresis was running for 15 min at 95 V, and further 1 
hour at 120 V. In the next step, the gel was cut in the place of the empty well which 
separated small and large amount of the digested plasmid. The part of the agarose gel 
which contained the marker, undigested and 10 μl of digested plasmid was incubated for 
20 min in 0.5 × TBE with EtBr. Both parts were recombined and the isolation of the 
unstained digested plasmid band was possible, since the corresponding 10 μl digested 
plasmid band was stained with EtBr. After gel extraction one volume DNA was 
precipitated with 10% volume of 2 M NaAc. Further, 2.2 × volume of ice-cold absolute 
100% EtOH was added, mixed and centrifuged at 13000 rpm for 5 min at 4°C. The 
supernatant was discarded; the DNA pellet was washed with 0.5 ml of 70% EtOH, and 
centrifuged at 13000 rpm at 4°C for 5 min. Again, the supernatant was discarded, and to 
remove the ethanol completely, DNA samples were incubated for 5 min at 45°C. The DNA 
pellet was resuspended in TE buffer. The DNA concentration was estimated using a Nano 
Drop spectrophotometer. The final concentration should be 30 μg/ml. The microinjection 
was performed by Dr. Ursula Fünfschilling (Max Planck Institute of Experimental 
Medicine, Göttingen, Germany). 
 
2.2.1.16 Determination of transgene integration with the DNA Walking Speed Up 
Kit 
The DNA Walking Speed Up Kit is a method using a unique DNA Walking ACP (DW-ACP) 
primer designed to capture unknown target sites with high specificity. The optimised PCR 
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conditions allow obtaining unknown flanking regions of up to 3 kb in length. The 
subsequent nested PCR reactions using one primer provided by the company, and one 
transgene-specific primer, as well as the special composed PCR Master Mix allowed to 
obtained different PCR products, which indicated the integration site(s) of the transgene 
after sequencing. The procedure was performed according to manufacturer’s protocol 
(DNA Walking SpeedUp Premix Kit, Seegene, USA).  
 
2.2.1.17 Tattooing neonate animals 
To identify the animals in the litter, foot tattoos were done using the MPI code. Tattoos 
are permanent and do not alter the physiology of animals. For the pigment injection a 
sterile syringe and needle were used.  
 
2.2.1.18 rAAV production 
The rAAV particles used in the study were produced by Vector Core from the Telethon 
Institute of Genetics and Medicine, Naples, Italy, by triple transfection of HEK293 cells. 
The viral particles were further purified by CsCl2 ultracentrifugation. Physical titres 
(genome copies (GC)/mL) were determined using a real-time PCR-based assay and a dot 
blot analysis. 
 
2.2.1.19 rAAV preparation and injection 
The rAAV particles were stored at -80°C, and were always thawed on ice prior to injection. 
The appropriate amount of the viral particles was diluted in DPBS. The injection of 
neonatal mice was performed using a sterile 1 ml syringe, and a sterile, single-use 0.5 × 16 
mm needle. The injections were performed directly into the liver (intrahepatic injection), 
or into the peritoneal cavity (intraperitoneal injection). Viral titres were calculated in 
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3 RESULTS 
3.1 Generation of Mocs2 knockout (KO) mice 
3.1.1 Generation of an isolated Mocs2b KO mouse 
One of the main aims of this study was to develop a therapy for patients suffering from 
molybdenum cofactor deficiency type B (or molybdenum cofactor deficiency, 
complementation group B (MOCODB); OMIM #252160), caused by mutations in the 
subunit B of the MOCS2 gene (OMIM #603708). To achieve this goal, we decided to 
generate a KO mouse model of the disease. Taking the advantage of commercially 
available knockout embryonic stem cells (ESCs), we have purchased JM8A3 ESCs with a 
targeted mutation in the murine Mocs2b gene. Originally, JM8A3 cells are derived from 
the C57BL/6N mouse strain. These ES cells have been modified to correct the black 
mutation on the Agouti allele, therefore, mice derived from these ES cells have an agouti 
coat colour. In these ES cells one copy of the murine Mocs2b gene was targeted by a 
knockout first construct. A targeting vector was designed to insert a flippase recognition 
target (FRT) site followed by an En2-IRES-LacZ-pA trapping cassette. In the trapping 
cassette En2 (engrailed 2) the splice acceptor site is followed by an IRES (internal 
ribosome entry site), the beta-galactosidase (LacZ) gene and a pA (polyadenylation) 
signal. Additionally, a floxed β-actin-driven neomycin cassette, an FRT site and a loxP site 
(FRT-LacZ-loxP-Neo-FRT-loxP) are located upstream of the 4th exon of the murine Mocs2b 
gene, and a single loxP site is placed downstream of the 6th exon of the Mocs2 gene. A 
knockout first allele is initially a non-expressed form, but can be converted to a 
conditional allele via flippase (Flp) recombination. Figure 3.1 demonstrates a schematic 
representation of knock first and conditional alleles together with corresponding 
transcripts and proteins. Although the trapping cassette affects both, Mocs2a and 
Mocs2b transcripts, it has no effect on Mocs2a protein expression and disrupts only 
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Fig. 3.1. Schematic representation of the Mocs2b knockout first and conditional constructs together with 
encoded transcripts and corresponding proteins. The knockout first construct incorporates the engrailed 2 
(En2) splice acceptor; internal ribosomal entry sites (IRES), the LacZ reporter gene with a polyadenylation 
signal (LacZ-pA), and the neomycin resistance gene (Neo-pA) under the control of the human β-actin 
promoter (hβ-Actin). The LacZ-Neo cassette is flanked by flippase recognition target (FRT) sites, and loxP 
sites are flanking the neomycin resistance gene and Mocs2b critical exons 4, 5 and 6. During the 
transcription process, exon 3 is spliced into the splice acceptor site of the En2-LacZ reporter gene truncating 
thereby both, Mocs2a and Mocs2b transcripts. Although trapping cassette affects both transcripts, open 
reading frame (ORF) of Mocs2a is intact allowing to normal translation. In contrast, truncated Mocs2b 
transcript leads to formation of short polypeptide, corresponding to part of exon 3. In parallel, the IRES 
sequence present in KO transcripts initiates translation of the LacZ protein (left panel). In presence of the 
flippase (Flp) recombinase the LacZ-Neo cassette can be deleted, thus restoring Mocs2b expression and 
converting the knockout first to a conditional allele (right panel). 
 
The KO ESCs were propagated in our institute, and sent for the blastocyst injection to the 
Max Planck Institute (MPI) of Experimental Medicine, Göttingen (this experiment was 
performed in collaboration with Dr. Ursula Fünfschilling). Mocs2b KO JM8A3 ESCs were 
injected into C57BL/6N blastocysts, which were then transferred to pseudopregnant 
females. Chimerism of the obtained pups was assessed based on the coat colour. 
Unfortunately, the Mocs2b KO JM8A3 cells failed to contribute to chimera formation, as 
all pups obtained after the first injection were wild type (WT). To exclude that the 
presence of the LacZ-Neo cassette impaired chimera formation, it was removed from KO 
ESCs by expression of the Flp recombinase (see Fig 3.1). For this reason, KO ESCs were 
transiently transfected with a pCAAG-FLPe vector to express FLP-recombinase, and to 
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remove the FRT-flanked reporter/selector (LacZ-Neo) cassette. The Flp transfection was 
performed in collaboration with Prof. Dr. Ibrahim Adham (Institute of Human Genetics, 
University Medical Center Göttingen (UMG)). Following the Flp transfection, KO JM8A3 
ESCs were plated on Nanog-GFP feeder layer, and exposed to puromycin selection. The 
survived ESC colonies were picked manually from the selection dish, and transferred into 
24-well plates where they were cultured to 70-80% confluency. Subsequently, one part of 
the cells was frozen, whereas the rest was used for DNA analysis. The efficiency of Flp 
recombination was tested by PCR using MOCS2-5’arm, LAR3 and MOCS2-3’arm primers, 
thus, allowing to distinguish between the knockout first (293 bp), conditional (621 bp) 
and WT allele (470 bp) (Fig. 3.2a-c). Specificity of the designed strategy was verified by 
genotyping PCR of Mocs2b KO ESCs and WT cells (Fig. 3.3a). The PCR analysis with KO 
DNA gave rise to two bands corresponding to knockout first and WT bands, while PCR 
with WT DNA resulted only in one band corresponding to the WT product. Next, we 
analysed genotypes of ES cell lines obtained after puromycin selection. In 3 out of 48 
clones (No. 13, 16 and A) the knockout first allele was converted to a conditional one via 
Flp recombination (Fig. 3.3b). The positive clones were then injected into the C57Bl/6N 
blastocyst to obtain chimeras. Blastocyst injection was performed in collaboration with 
Dr. Ursula Fünfschilling (MPI of Experimental Medicine, Göttingen). 
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Fig. 3.2. Genotyping strategy used for the evaluation of Flp-recombination in Mocs2b KO ESCs. Schematic 
representation of the (a) knockout first, (b) conditional and (c) WT alleles, together with the corresponding 
PCR products amplified with Mocs2-5’arm (F), Lar3 (R) and Mocs2-3’arm (R) primers. The arrows depict the 
localisation and the direction of primers used for genotyping PCR (F = forward; R = reverse). 
 
 
Fig. 3.3. Genotyping PCR of Mocs2b knockout first, conditional and WT allele. (a) Electrophoresis pattern 
of PCR products from Mocs2b KO ESCs, and wild type mouse tail (WT tail tip) DNA determined by 
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genotyping PCR. (b) Results of genotyping PCR performed with DNA extracted from Mocs2b KO ESCs 
transfected with the pCAAG-FLPe vector. In clone 13, 16 and A (marked with green arrows) Flp 
recombination has occurred successfully, thereby the knockout allele (corresponding to 293 bp) was 
converted to the conditional allele (621 bp). (100bp = 100 bp DNA ladder; Blank = negative control w/o 
DNA). 
 
Blastocyst injections with conditional Mocs2b ESCs, derived from clones 13 and 16, gave 
rise to chimeras successfully, while the ESCs derived from clone A failed to contribute to 
chimera formation. Chimerism of obtained pups was next estimated based on the coat 
colour, and is presented in Table 1. At the age of 8 weeks, chimeric males were bred with 
C57Bl/6N females (n=10), nonetheless, the conditional allele was not transmitted to the 
F1 generation. Genotyping of spermatozoa of a 15% chimeric male confirmed impaired 
germline contribution (Fig. 3.4). To collect the sperm, the chimeric male was bred with a 
WT female and vaginal plug was monitored to indicate insemination time. Following 
insemination, the female was sacrificed by cervical dislocation and sperm was flashed out 
from the uterus for genotyping PCR. To test the quality of the sperm DNA and to test for 
the gender, PCR analyses for two other genes, namely Zfyve27 (chromosome 19-specific) 
and Sry (Y-chromosome-specific), were performed. 
 
Tab. 1. Chimerism of the pups obtained after blastocyst injection with Mocs2b ESCs derived from clones 
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Fig. 3.4. Genotyping of sperm extracted from a 15% chimeric male. (a) Results of Zfyve27 PCR showed 
good quality of DNA extracted from sperm, and DNA from male and female tail tips (♂ and ♀). (b) Results of 
Sry-specific PCR determined the male DNA. (c) Genotyping PCR could not detect the conditional allele in the 
examined sperm. Wild type male and female (♂ and ♀) DNA served as a control. (1kb = 1kb DNA plus 
ladder; Blank = negative control w/o DNA). 
 
3.1.2 Generation of a knockout mouse of the complete Mocs2 gene 
To overcome the problem with the generation of the Mocs2b knockout mouse, we 
decided to purchase a commercially available knockout mouse model of the total Mocs2 
gene. The 95% male chimera was provided by the Knockout Mouse Project (KOMP) 
Repository at the University of California, Davis. The Mocs2tm1(KOMP)Vlcg targeting vector 
was designed to insert a β-galactosidase (lacZ) gene and a neomycin (Neo) resistance 
cassette downstream of the start codon of the Mocs2 gene, abolishing gene function (Fig. 
3.5). Homologous recombination led to targeted deletion of 10.049 bp (NCBI Chr13: 
114.818.308-114.828.357) encompassing almost the whole genomic sequence of the 
murine Mocs2 gene. As a result, the LacZ reporter gene is under the control of the 
endogenous Mocs2 promoter, and LacZ staining is observed where the deleted Mocs2 
gene is normally expressed. 
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Fig. 3.5. Scheme of the strategy used for targeting of the complete Mocs2 allele. (a) The targeting 
construct includes 5’ and 3’ homologous arms, a LacZ reporter gene (LacZ-pA) and neomycin cassette driven 
by a human Ubiquitin C promoter (hUbC-Neo-pA) flanked by two loxP sites. (b) Schematic representation of 
the homologous recombination product. Homologous recombination led to the deletion of almost the 
complete Mocs2 gene. The gene trap cassette (LacZ-Neo) replaced the sequence downstream of the start 
codon (ATG) of Mocs2a up to stop codon (Stop) of Mocs2b isoform. 
 
To establish a heterozygous Mocs2 KO line (Mocs2+/-), the 95% chimeric male was bred 
with a C57Bl/6N WT female, and transmission of the KO allele was confirmed in the F1 
generation by PCR for 5’ and 3’ arms (Fig. 3.6.). Next, Mocs2+/- mice were bred with each 
other to obtain homozygous Mocs2 knockout mice (Mocs2 KO or Mocs2-/-), where both 
alleles of the complete Mocs2 gene were deleted. The strategy for genotyping the Mocs2-
/- and WT alleles to distinguish homo-and heterozygous animals was established using 
three primers: Mocs2KOGeno_F1, Neo_F and GeneSpec_R1. Predicted products 
correspond to 694 bp for the KO allele and 945 bp for the WT allele (Fig. 3.7). After 
crossing of heterozygous mice, homozygous Mocs2 deficient mice were obtained in 
accordance with Mendelian distribution (Fig. 3.8). 
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Fig. 3.6. The 95% male chimera transmitted the Mocs2 KO allele to the F1 generation. PCR with 
Mocs2_5’F, Mocs2KO_R and Mocs2KO_F, Mocs2_3’R primers confirmed homologous recombination on the 
(a) 5’ and (b) 3’ site, respectively. The arrows indicate the localisation and the direction of primers used for 
genotyping PCR. (100bp = 100 bp DNA ladder; F = forward; R = reverse; Blank = negative control w/o DNA). 
 
 
Fig. 3.7. Strategy of genotyping PCR to distinguish between homozygous and heterozygous Mocs2 
knockout mice. (a) Schematic representation of the Mocs2 wild type (WT) and knockout (KO) alleles 
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together with primer arrangements. (b) Results of the genotyping PCR show that 7 out of 12 pups from the 
F1 generation were heterozygous (Mocs2+/-). The arrows indicate the localisation and the direction of 
primers used for genotyping PCR. (100bp = 100 bp DNA ladder; F = forward; R = reverse; Blank = negative 
control w/o DNA) 
 
 
Fig. 3.8. Schematic diagram of the Mocs2 KO allele inheritance. Breeding of heterozygous (Mocs2+/-) mice 
resulted in 27% WT (Mocs2+/+)-, 46% heterozygous (Mocs2+/-)- and 27% homozygous Mocs2 knockout 
(Mocs2-/-)  pups (n=413). Chi-square test did not show any statistically significant deviations from a 1:2:1 
segregation ratio (Mendelian ratio). 
 
3.1.3 Endogenous expression of murine Mocs2 gene 
In human the MOCS2 gene is localised on the long arm of chromosome 5 (5q11.2). It is a 
unique example of a bicistronic gene, as it encodes two overlapping transcripts for 
MOCS2A and MOCS2B, respectively. Beside the function in molybdenum cofactor (MoCo) 
biosynthesis, there are not many informations regarding the genomic structure and tissue 
distribution of the MOCS2 gene. For a better understanding of the clinical and 
pathomorphological aspects of MoCo deficiency we started with expression analysis of 
mouse Mocs2 transcripts. For this reason, we extracted total RNA from different tissues 
of 12-day-old and adult WT mice, respectively. Subsequently, cDNA was synthesised and 
used as a template for quantitative RT-PCR (qRT-PCR) analysis. In contrast to human 
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MOCS2A and MOCS2B isoforms, mouse Mocs2a and Mocs2b transcripts cannot be 
distinguished via RT-PCR (see Fig. 1.2), therefore, it was only possible to prove the global 
expression of Mocs2 transcripts using Mocs2a/b-specific primers qF_Mocs2Ex4 and 
qR_Mocs2Ex5. The qRT-PCR analyses demonstrated ubiquitous expression of the 
Mocs2a/b transcripts in 12-day-old wild type mice, with the highest expression observed 
in the liver, kidney and skin. In tissues derived from adult wild type mice expression of 
Mocs2a/b decreased, but the tissue distribution patterns seemed to remain identical (Fig. 
3.9). Subsequently, these qRT-PCR results were confirmed by Western blot analysis using 
proteins extracted from tissues of 12-day-old wild type mice. Here, Mocs2b protein 
expression could be detected in the liver and brain using the Mocs2b-specific antibody 
EP113633 (Fig. 3.10). 
 
 
Fig. 3.9. Mocs2a/b expression in different tissues obtained from 12-day-old or adult wild type mice by 
qRT-PCR analyses. Real-time PCR results representing the expression of the endogenous Mocs2a/b gene in 
12-day-old (blue bars) and adult wild type mice (red bars). In the majority of tissues analysed, 12-day-old 
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(12d) wild type mice showed significantly higher levels of Mocs2a/b gene expression than adult mice. The 
results were normalised to Glyceraldehyde-3-phosphate dehydrogenase (Gapdh) expression, and are 
presented as a relative value to the Mocs2a/b expression level in the brain derived from adult wild type 
mice. Values and associated error bars represent mean ± s.d. (n=3). 
 
 
Fig. 3.10. Mocs2b protein expression in different tissues derived from a 12-day-old wild type mouse. 
Western blot analysis demonstrating robust expression of the Mocs2b protein in the liver and moderate 
expression in the brain of a 12-day-old wild type mouse. The α-tubulin antibody was used as a control for 
protein loading. M = SeeBlue Plus2 Pre-stained Protein Standard. 
 
In order to visualise the cellular distribution of the murine Mocs2a/b gene in different 
tissues, we took advantage of the LacZ reporter gene included in the Mocs2 knockout 
cassette (see Fig. 3.5). Here, LacZ expression is driven by the endogenous murine Mocs2 
gene promoter, thereby an indirect expression of both Mocs2 isoforms (Mocs2a and 
Mocs2b) can be followed by expression of β-galactosidase. Due to the problem that 
homozygous Mocs2 knockout (Mocs2-/-) mice die early after birth, LacZ staining was 
performed on tissue sections derived from heterozygous Mocs2 knockout (Mocs2+/-) 
mice. For this reason different tissues from 12-day-old Mocs2+/-mice and adult Mocs2+/-
mice were extracted, respectively, and subjected to LacZ staining. In Figure 3.11 and 3.13 
results of LacZ staining performed on corresponding tissue sections from Mocs2+/-mice 
are presented. LacZ positive cells were detected in each tissue analysed except spleen 
and adult muscle, and in contrast to the results obtained by qRT-PCR analysis, expression 
of β-galactosidase driven by the endogenous Mocs2 gene promoter seemed to be age-
independent. The most prominent LacZ signals were detected in the brain, with the 
highest intensity in the grey matter of the cortex, hippocampus and brainstem (Fig. 3.11). 
Double staining with the neuron-specific nuclear protein NeuN confirmed the neuronal 
origin of LacZ positive cells (Fig. 3.12). In the kidney, LacZ staining was restricted to the 
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elements of the collecting system including collecting ducts, calyx and renal pelvis (Fig. 
3.13a). Moderate LacZ signal intensity was detected in the liver (Fig. 3.13b). In the skin 
clear LacZ signals were detected in hair follicles (Fig. 3.13c). Finally, intensive LacZ signals 
were detected in the gonads (Fig. 3.13d, e). In the testis LacZ staining was restricted to 
germ cells, in particular to undifferentiated spermatogonia, as positive cells were 
detected as a single cell, paired cells or aligned cells inside the seminiferous tubules. A 
representative image from a 600× magnification revealed also the presence of a mitotic 
spindle, supporting our data. In contrast, in the ovary a week signal was detected in the 
stroma, however, the strongest LacZ staining was observed in oocytes. 
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Fig. 3.11. LacZ images for Mocs2a/b expression in the brain of adult and 12-day-old Mocs2+/- mice. LacZ 
staining of 10-μm brain sections from adult and 12-day-old Mocs2+/- mice showing reporter gene activity in 
the hippocampus (CA1 and DG), cortex and brainstem. Nuclei were visualised by counterstaining with 
Nuclear Fast Red. Scale bars correspond to 1 mm for stereomacroscopic images, as well as 20 μm for 
images with ×200 magnification. CA1 = Cornu Ammonis 1, DG = Dentate gyrus. 
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Fig. 3.12. Co-localisation of NeuN and LacZ signals in neurons from hippocampal, cortical and brainstem 
areas of adult Mocs2+/- #620 mouse. (Left column) Sections derived from an adult Mocs2+/- mouse brain 
were stained with a NeuN-specific antibody showing neuronal cell bodies stained in brown. (Right column) 
LacZ staining of the following brain sections showing Mocs2 expressing cells in blue. Nuclei for LacZ staining 
were visualised by counterstaining with Nuclear Fast Red. Scale bars correspond to 1 mm for 
stereomacroscopic images, as well as 20 μm for images with ×200 magnification. CA1 = Cornu Ammonis 1, 
DG = Dentate gyrus. 
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Fig. 3.13. LacZ images for Mocs2a/b expression. LacZ staining of 10-μm tissue sections from adult and 12 
day-old Mocs2+/- mice shows reporter gene activity in (a) kidney’s collecting duct system, (b) hepatocytes, 
(c) hair follicles of the skin and (d, e) germ cells, including undifferentiated spermatogonia (arrows) and 
oocytes (arrowheads). Nuclei were visualised by counterstaining with Nuclear Fast Red. Scale bars 
correspond to 1 mm for stereomacroscopic images, as well as 20 μm and 5 μm for images with ×200 and 
×600 magnifications, respectively. 
 
3.1.4 Characterisation of Mocs2 knockout mice 
To begin with, we wanted to confirm on the genomic DNA level that the Mocs2 gene was 
deleted in all examined tissues of Mocs2 knockout (Mocs2-/-) mice, and that it is present 
in corresponding tissues obtained from WT (Mocs2+/+) mice. The PCR analyses were 
performed using primers Mocs2aF_In2-3 and Mocs2aR_In2-3 specific for the Mocs2a 
isoform, and primers Mocs2bF_Ex5 and Mocs2bR_In5-6 specific for the Mocs2b isoform. 
Primers specific for Zfyve27 (Zfyve27_F and Zfyve27_R) were used to test the quality of 
extracted DNA samples (Fig. 3.14).  
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Fig. 3.14. Characterisation of Mocs2-/- mice on the genomic DNA level. (a) Schematic representation of the 
Mocs2 wild type (WT) allele together with primer arrangements. (b, c) PCR results showing the bands 
corresponding to Mocs2a and Mocs2b gene products (183 bp and 250 bp, respectively) in WT tissues, which 
are absent in Mocs2-/- samples. (d) PCR analyses with primers specific for the Zfyve27 sequence (526 bp) 
confirmed a good quality of isolated DNA. The arrows illustrate the localisation and the direction of primers 
used for genotyping PCR. (100bp = 100 bp DNA ladder; F = forward; R = reverse; Blank = negative control 
w/o DNA). 
 
To confirm the successful deletion of the Mocs2a/b gene on the RNA level, we performed 
RT-PCR analyses. For this reason, we extracted total RNA from different tissues of Mocs2-
/- and Mocs2+/+ mice, respectively. Subsequently, cDNA was synthesised and used as a 
template for RT-PCR analysis. In contrast to human MOCS2A and MOCS2B isoforms, 
mouse transcripts cannot be distinguish via RT-PCR (Fig. 3.15a), therefore, we were able 
to prove only global depletion of both, Mocs2 transcripts. For this reason we designed 
two primer pairs, including Mocs2aF_Ex1, Mocs2aR_Ex3 and Mocs2bF_Ex5, Mocs2bR_Ex6 
(Fig. 3.15b). In agreement with results from the DNA study, we were unable to detect 
Mocs2a/b mRNA in any of Mocs2-/- mouse tissues analysed, but it was detectable in 
corresponding tissues obtained from WT mice (Fig. 3.15c, d). Primers specific for the 
housekeeping gene Hprt (HPRT_F, HPRT_R) were used to test the quality of synthesised 
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Fig. 3.15. Characterisation of Mocs2-/- mice on the RNA level. (a) Schematic representation of the Mocs2 
wild type (WT) allele and (b) transcripts encoding Mocs2a and Mocs2b subunits. (c, d) RT-PCR results 
showing the bands corresponding to Mocs2a/b transcripts (188 bp and 328 bp) in WT tissues, while they are 
not present in the knockout samples. (e) RT-PCR analyses with primers specific for the Hprt gene (300 bp) 
confirmed a good quality of synthesised cDNA. The arrows illustrate the localisation and the direction of 
primers used for RT-PCR. (100bp = 100 bp DNA ladder; F = forward; R = reverse; Blank = negative control 
w/o DNA). 
 
Furthermore, a qRT-PCR approach was employed to quantify Mocs2a/b expression in 
different tissues obtained from WT (Mocs2+/+), heterozygous (Mocs2+/-) and homozygous 
(Mocs2-/-) mice. As expected, Mocs2-/- mice did not express Mocs2a/b mRNA, and 
heterozygous mice showed reduced expression of both products compared to WT mice. 
Interestingly, in some tissues (e.g. lung or liver) no significant differences in Mocs2a/b 
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Fig. 3.16. Expression of Mocs2a/b gene in different tissues from Mocs2+/+ (wild type), heterozygous 
Mocs2+/- and homozygous Mocs2-/- mice. Quantitative RT-PCR data showing the expression of Mocs2a/b 
mRNA in different tissues from wild type (+/+ = green bars), heterozygous (+/- = red bars) and homozygous 
Mocs2 knockout mice (-/- = blue bars). The results were normalised to Gapdh expression and are presented 
as a relative value to Mocs2a/b level in the WT liver. Values and associated error bars represent mean ± s.d. 
(n=3). 
 
Finally, expression of Mocs2a and Mocs2b on the protein level should be analysed in WT 
and Mocs2-/- animals. For this purpose, whole protein lysate was extracted from different 
tissues of Mocs2+/+ and Mocs2-/- mice, respectively. From one part of each tissue, proteins 
were isolated for Western blot (WB), whereas the rest of the tissue specimens was 
prepared for immunohistochemical (IHC) analysis. Both experiments were performed by a 
Bachelor student, Ann-Christin Franke (Franke, 2014). For these purposes, specific 
antibodies for either Mocs2a (EP130014) or Mocs2b (EP113633) were used. Based on the 
molecular weight the Mocs2a protein should correspond to a 10 kDa band, while the 
Mocs2b protein to a 21 kDa band in WB analysis. Unfortunately, only the Mocs2b 
antibody was specific for WB analysis, and a strong expression of Mocs2b protein was 
detected exclusively in the WT liver and was not present in the Mocs2-/- liver (Fig. 3.17a). 
Immunohistochemical analyses using either a Mocs2a or Mocs2b-specific antibody 
showed a cytoplasmic localisation of both proteins in WT liver sections, while staining for 
Mocs2a and Mocs2b was undetectable in the Mocs2-/- liver (Fig. 3.17b, c). 
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Fig. 3.17. Mocs2a/b protein expression in different tissues of adult wild type mice. (a) Western blot 
analysis revealed expression of Mocs2b in the liver derived from wild type (WT) mice, whereas expression 
of Mocs2b in other tissues could not be detected. In the liver of Mocs2-/- mice Mocs2b expression was 
depleted. α-tubulin served as a loading control. Immunofluorescence staining with specific antibodies 
against Mocs2a and Mocs2b revealed Mocs2a and Mocs2b expression (red) (b) in liver cells of WT mice, but 
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not (c) in liver sections obtained from Mocs2-/- (KO) mice. Nuclei were counterstained with DAPI. Scale bars 
correspond to 10 μm. 
 
3.1.5 Phenotypical analyses of Mocs2-/- mice 
Mocs2 homozygous knockout (Mocs2-/-) pups are much smaller in comparison to WT 
(Mocs2+/+) and heterozygous (Mocs2+/-) littermates (Fig. 3.18 left). Additionally, Mocs2-/- 
mice present curly whiskers and a defect in the overall hair growth. They have flaky and 
wrinkled skin and are generally in a weaker health condition compared to Mocs2+/+ and 
Mocs2+/- animals (Fig. 3.18). Mocs2-/- mice appear normal at birth. During their first days 
of life Mocs2-/- mice increase their body weight, although at a significantly slower rate 
than their WT and heterozygous littermates (Fig. 3.19). The mean life span of Mocs2-/- 
mice is 4.7 days, although most of them die at postnatal day 1, or between postnatal day 
6 and 7 (Fig. 3.20). 
 
 
Fig. 3.18. Mocs2-/- mice show growth retardation, abnormal shape of whiskers, a defect in the overall hair 
growth, as well as flaky and wrinkled skin compared to heterozygous and WT littermates. (Left image) 
Exemplary picture of a 7-day-old Mocs2-/- mouse, in comparison to control animals from the same litter. 
(Middle and right images) Exemplary picture of a 7-day-old WT (Mocs2+/+) and a knockout (Mocs2-/-) mouse 
from the same litter. The WT mouse presented straight whiskers, while the Mocs2-/- animal whiskers 
appeared curly and flopped (shown by arrows). 
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Fig. 3.19. Reduced postnatal body weight gain of Mocs2-/- mice. Line graphs showing body weights of WT 
(+/+, green), heterozygous (+/-, red) and homozygous KO pups (-/-, blue). Body weight gain after birth of 
Mocs2-/- mice was significantly slower as compared to WT (Mocs2+/+) or heterozygous (Mocs2+/-) littermates. 
Body weight and associated error bars representing mean ± s.d. from n = 35 for WT, n = 60 for heterozygous 
and n = 34 for homozygous KO pups. * p<0.05, ** p<0.01, *** p<0.001. 
 
 
Fig. 3.20. Life span of Mocs2-/- mice. The majority of homozygous Mocs2-/- pups died shortly after birth. Bar 



























Day after birth 
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died within 11 days after birth, however, two important periods could be observed. The first critical time 
point was directly after birth (47% of animals died during this time), and a second time point between 
postnatal day 5 and 10 (52%), (n=107). 
 
As presented above, Mocs2-/- mice showed a reduced gain of their body weights 
compared to control animals, thereby Mocs2-/- mice were significantly smaller. However, 
impaired growth did not completely explain the mortality of KO animals. Interestingly, 
shortly before death, all Mocs2-/- mice presented a urinary retention. The post-mortem 
examination showed an accumulation of yellow deposits in the bladder (Fig. 3.21a). These 
structures were most probably the underlying cause of the urinary track obstruction 
observed in Mocs2-/- animals, however, biochemical analyses failed to identify the 
composition of these structures (Fig. 3.21b). 
 
 
Fig. 3.21. Mocs2-/- mice present a urinary retention and insoluble crystals in the bladder. (a) Exemplary 
picture of a 6-day-old Mocs2-/- mouse. Arrow points to the presence of yellow deposits in the bladder. (b) 
Stereomicroscope images showing aggregates collected from the bladders of Mocs2-/- animals. Scale bars 
correspond to 100 μm. (n = 50). 
 
A reverse flow of the urine, i.e. from the bladder back into the kidneys, can result in 
hydronephrosis and cause permanent and severe damage to the kidneys, resulting in 
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kidney failure (Iravani et al., 2014). In order to proof a possible renal involvement in the 
Mocs2-/- phenotype, histopathological analyses of kidney sections was performed. The 
histological analysis of kidneys derived from Mocs2-/- mice demonstrated the presence of 
crystals in the collecting duct system (Fig. 3.22). This experiment was performed in 
cooperation with Dr. Samy Hakroush, Institute of Pathology, UMG. Consistent with these 
results, elevated level of proteins (proteinuria) and extremely high concentrations of 
haemoglobin and/or damaged erythrocytes (haemoglobinuria) in the Mocs2-/- urine were 
identified (Fig. 3.23). Both parameters are well-known indicators of kidney and urinary 
track diseases (House and Cattran, 2002). 
 
 
Fig. 3.22. Mocs2-/- mice present kidney stones in the collecting duct system. (a) Exemplary images of HE-
stained kidney sections from Mocs2-/- mice show the localisation of stones. Black box in the kidney section 
indicates the region of renal pelvis seen in the higher magnification (b and c). Arrows point to the presence 
of crystals in renal pelvis. To visualise stones, picture (c) was performed with reduced light intensity, which 
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Fig. 3.23. Mocs2-/- mice show elevated level of proteins and erythrocytes in the urine. Exemplary image 
demonstrating the results of colorimetric tests estimating the level of specific parameters, including 
glucose, leukocytes, nitrite, proteins and erythrocytes. In contrast to WT (Mocs2+/+) animals, Mocs2-/- mice 
present elevated level of proteins (green colour in the test patch), and extremely elevated numbers of 
erythrocytes (dark-blue colour in the test patch) in the urine. (n = 3). 
 
Furthermore, sulphite concentration, the substrate of sulphite oxidase, another 
molybdenum cofactor (MoCo)-dependent enzyme, was investigated. Using another 
colorimetric test, it was shown that Mocs2-/- mice presented an elevated concentration of 
urinary sulphite compared to WT control mice (Fig. 3.24). 
 
 
Fig. 3.24. Mocs2-/- mice present a higher concentration of urinary sulphite than WT littermates. Exemplary 
picture showing the results of a colorimetric test estimating the sulphite concentration. The level of urinary 
sulphite was higher in Mocs2-/- than in WT (Mocs2+/+) control animals. (n = 10). 
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In rodents, an elevated level of sulphite leads to neuron loss in the hippocampus 
(Kocamaz et al., 2012). To check the potential toxic effect of an increased sulphite level in 
the brain of Mocs2-/- mice, immunohistological analyses were performed. Brain sections 
from WT, Mocs2+/- and Mocs2-/- animals were either subjected to hematoxylin-eosin (HE) 
staining or stained with GFAP, NeuN, Casp3 and IBA1-specific antibodies. GFAP (glial 
fibrillary acidic protein) is an intermediate filament protein that is expressed in astrocytes 
(Reeves et al., 1989). NeuN (RNA binding protein, fox-1 homolog (C. elegans) 3) is a 
neuronal nuclear antigen that is commonly used as a biomarker for neurons. Casp3 
(Caspase 3 or apoptosis-related cysteine peptidase) plays a central role in the execution-
phase of cellular apoptosis (Jeruc et al., 2006) and is the predominant caspase involved in 
the cleavage of amyloid-beta 4A precursor protein, which is associated with neuronal 
death in Alzheimer's disease (Eimer and Vassar, 2013). IBA1 (ionising calcium-binding 
adaptor molecule) is specifically expressed in macrophages/microglia, and is up-regulated 
during the activation of these cells. IBA1 expression is up-regulated in microglia following 
nerve injury, central nervous system (CNS) ischemia and several other brain diseases (Ito 
et al., 2001). Although the GFAP and NeuN stainings did not show any significant 
differences in astrocyte and neuron number (data not shown), HE staining revealed 
apoptosis in the hippocampus, cortex and brainstem (midbrain and pons) of Mocs2-/- and 
Mocs2+/- mice compared to brain sections from WT (Mocs2+/+) mice (Fig. 3.25). Typical 
apoptotic neurons show central aggregation and fragmentation of chromatin. To evaluate 
these results, Mocs2-/-, Mocs2+/- and WT brain sections were stained with Casp3 (Fig. 
3.26a). Mocs2-/- and Mocs2+/- mice revealed elevated numbers of cells expressing Caspase 
3 protein (Fig. 3.26b). Surprisingly, increased number of Caspase 3 positive cells did not 
correlate with the number of IBA-1 positive cells (Fig. 3.27). These results indicate that 
apoptosis which occurs in the brain of Mocs2-/- mice may be one of the main factors 
responsible for severe somatic symptoms observed in these mice. These experiments 
were performed in collaboration with Dr. Imke Metz (Institute of Neuropathology, UMG). 
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Fig. 3.25. Mocs2-/- animals presented apoptotic neurons in hippocampus, cortex and brainstem. 
Exemplary images of hematoxylin-eosin (HE) staining of brain sections derived from Mocs2+/+, Mocs2+/- and 
Mocs2-/- animals. Arrows point to the presence of apoptotic neurons. Scale bars correspond to 200 μm for 
hippocampus and 20 μm for CA1 (Cornu Ammonis 1), CA3 (Cornu Ammonis 3), DG (Dentate gyrus), cortex 
and brainstem (n = 2). 
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Fig. 3.26. Mocs2-/- animals presented massive apoptosis in hippocampus, cortex and brainstem. (a) 
Exemplary images of Caspase 3 (Casp3) immunostaining of brain sections derived from Mocs2+/+, Mocs2+/- 
and Mocs2-/- animals. Arrows point to the presence of Casp3 positive neurons. Nuclei were counterstained 
with hematoxylin. Scale bars correspond to 200 μm for hippocampus and 20 μm for CA1 (Cornu Ammonis 
1), CA3 (Cornu Ammonis 3), DG (Dentate gyrus), cortex and brainstem (n = 2). (b) Bar graphs showing the 
number of apoptotic neurons in Mocs2+/+, Mocs2+/- and Mocs2-/- brains. Values and associated error bars 
represent mean ± s.d. from 10 sections for each genotype (n = 2, * p<0.001, ** p<0.0001).  
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Fig. 3.27. Expression of IBA1 protein in hippocampus, cortex and brainstem of Mocs2+/+, Mocs2+/- and 
Mocs2-/- animals. Exemplary images of ionising calcium-binding adaptor molecule (IBA1) immunostaining of 
brain sections derived from Mocs2+/+, Mocs2+/- and Mocs2-/- animals. Arrows point to the presence of IBA1 
positive neurons. Nuclei were counterstained with hematoxylin. Scale bars correspond to 200 μm for 
hippocampus and 20 μm for CA1 (Cornu Ammonis 1), CA3 (Cornu Ammonis 3), DG (Dentate gyrus), cortex 
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3.1.6 Generation of isolated Mocs2a and Mocs2b knockout mice 
To generate the respective isolated forms of Mocs2 knockout animals (either the 
knockout of the Mocs2a isoform or the knockout of the Mocs2b isoform) based on the 
knockout model of the complete Mocs2 gene, we decided to breed these mice with 
MOCS2A or MOCS2B transgenic animals, respectively. Figure 3.28 presents the strategy 
used for the generation of isolated Mocs2a and Mocs2b knockout mice. 
 
 
Fig. 3.28. Schematic representation of the strategy used for the generation of a pure Mocs2a knockout or 
a Mocs2b knockout mouse model. (a) To obtain an isolated Mocs2a knockout mouse model, Mocs2+/- mice 
were crossed with transgenic Mocs2B animals expressing ubiquitously human MOCS2B protein (Mocs2BTb/-
). Further, double heterozygous mice (Mocs2+/-;Tb/-) were bred to each other to establish the Mocs2a 
knockout line with supplementation of the MOCS2B subunit (Mocs2-/-;Tb/Tb). (b) The Mocs2b knockout line 
was generated by crossing Mocs2+/- mice with transgenic Mocs2A animals expressing ubiquitously human 
MOCS2A protein (Mocs2ATa/-). Next, double heterozygous mice (Mocs2+/-;Ta/-) were bred to each other to 
give rise to the isolated form of Mocs2b knockout mice (Mocs2-/-;Ta/Ta).  
 
3.1.7 Generation of a MOCS2A transgenic mouse line 
To generate a MOCS2A transgenic mouse model, the pronuclear injection with the 
construct pWajaIII was performed. The pWajaIII construct was generated by Dr. Waja 
Wegner (Wegner, 2007). The vector contains the complete human MOCS2A open reading 
frame driven by an enhanced β-actin promoter (Fig. 3.29a). Before pronuclear injection, 
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Fig. 3.29. Preparation of the MOCS2A transgene construct. (a) Schematic representation of the pWajaIII 
vector showing the human MOCS2A ORF under the control of the Cytomegalovirus (CMV) enhancer and β-
actin promoter followed by a bovine growth hormone polyadenylation signal (bGH polyA), the kanamycin 
(Kan) resistance gene and the origin of replication (Ori). (b) Agarose gel electrophoresis revealed bands 
specific for the undigested and digested pWajaIII plasmid. Band 1 and 2 correspond to the undigested 
plasmid either in nicked circles (1) or supercoiled (2) conformation. Band 3 (3.3 kb) corresponds to the 
linearized plasmid after XmaI digestion.  
 
Microinjections into the male pronuclei of fertilised oocytes, as well as the transfer of 
injected embryos to C57Bl/6N pseudopregnant foster mothers were performed in 
collaboration with Dr. Ursula Fünfschilling (MPI of Experimental Medicine, Göttingen). 
The first injection resulted in 37 pups. To identify potential founder animals, genotyping 
PCR experiments were performed using human MOCS2A transgene-specific primers 
qMOCS2AEx1a_F and qMOCS2AEx2_R (Fig. 3.30a). In 6 out of 37 animals the MOCS2A 
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Fig. 3.30. Detection of the MOCS2A transgene in putative founder animals. (a) Scheme of the strategy 
used for the identification of founder animals. (b) Results of the genotyping PCR (102 bp) revealed six 
animals presenting the MOCS2A transgene. Results of the genotyping PCR for negative pups are not shown. 
The arrows indicate the localisation and the direction of primers used for genotyping PCR. (100bp = 100 bp 
DNA ladder; F = forward; R = reverse; Blank = negative control w/o DNA). 
 
The number of transgene copies integrated in founder animals genome was estimated by 
real-time PCR experiments using MOCS2A-specific primers qMOCS2AEx1a_F and 
qMOCS2AEx2_R. Normalised results presented in figure 3.31 revealed that all animals 
carried 2 copies of the MOCS2A transgene. 
 
 
Fig. 3.31. Copy number evaluation of the MOCS2A transgene in founder animals. Bar graphs showing the 
results of qPCR analysis indicated that all investigated animals carried 2 copies of the MOCS2A transgene. 
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The results obtained from the MOCS2A transgene were normalised against a murine single copy gene, 
namely acrosin (Acr), and are presented as a relative value to another single copy gene, named pelota 
(Pelo). Values and associated error bars represent mean ± s.d. (n = 3). 
 
To establish a MOCS2A transgenic line we bred founder animals with C57Bl/6N wild type 
mice. Due to several problems with MOCS2A founder animals (one animal died, one 
presented no germline contribution, and two other animals were infertile), we were able 
to establish only two transgenic lines, namely MOCS2A #44 (A6) and MOCS2A #56 (A5). To 
exclude that random transgene integration disturbed the function of other genes, the 
position of the transgene integration in the genome of the MOCS2A founder animal #56 
was investigated. In agreement with previous findings, founder animal #56 had two 
integration sites on chromosome 2. The first transgene (Ta1) was integrated into the third 
intron of the DnaJ (Hsp40) Homolog, Subfamily C, Member 24 (Dnajc24) gene (NCBI 
chr2:107210791-107210601). The integration site of the second transgene (Ta2) was 
localised in the second intron of the Aven gene (NCBI chr2: 112538459-112537983). In 
Figure 3.32a the strategy designed for genotyping of the WT and transgenic alleles is 
shown. For the identification of the first MOCS2A transgene Ta1 we used the following 
primers: Mouse#56_T1F, TransgeneA_F and Mouse#56_T1R, whereas, for the detection 
of the second MOCS2A transgene Ta2 primers Mouse#56_T2F, TransgeneA_F and 
Mouse#56_T2R were used (Fig. 3.32b). Genotyping PCR revealed that only the first 
MOCS2A transgene Ta1 was transmitted to the offspring, giving rise to a MOCS2A5 
transgenic mouse line with a single copy of the MOCS2A transgene (Fig. 3.32c). Both, 
integration and expression of the MOCS2A transgene, were confirmed in each tissue of 
heterozygous MOCS2A mouse (MOCS2ATa/-) by PCR analyses (Fig. 3.33a-c). To check if the 
first MOCS2A transgene Ta1 integration has any influence on the murine Dnajc24 host 
gene, Dnajc24 expression was analysed in transgenic tissues in the F1 generation. Primers 
used for the detection of Dnajc24 transcripts were localised in the 3rd and 4th exon of the 
Dnajc24 gene, respectively, flanking the third intron containing the MOCS2A Ta1 
transgene. Using qRT-PCR analyses a significant reduction in Dnajc24 expression was 
observed in MOCS2ATa/- mice compared to WT animals (Fig. 3.34). Although heterozygous 
MOCS2ATa/- animals were healthy and fertile, homozygous MOCS2ATa/Ta mice were 
embryonically lethal. Therefore, heterozygous MOCS2ATa/- mice were bred with 
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heterozygous Mocs2+/- knockout mice to obtain Mocs2+/-, Ta/- mice. Furthermore, double 
heterozygous Mocs2+/-, Ta/- mice were bred either to each other or with Mocs2+/- mice to 
obtain Mocs2-/-, Ta/Ta or Mocs2-/-, Ta/- (knockout mouse model corresponding to the Mocs2b 
isoform). Although ten breeding pairs were established, they have never given rise to 
living offspring. In most cases pregnancy finished with spontaneous abortion for unknown 
reason. In few cases, females had to be sacrificed due to delivery complications. For these 




Fig. 3.32. The MOCS2A transgene Ta1 presented in the MOCS2A5 line is transmitted to the F1 generation. 
(a) Schematic representation of the strategy used for the identification of transgenic alleles MOCS2A Ta1 
and Ta2. (b) PCR results showing the integration of both transgenes (Ta1 and Ta2) in the genome of the 
founder mouse #56, and (c) segregation of the transgenes in the F1 generation. The arrows depict the 
localisation and the direction of primers used for genotyping PCR. (100bp = 100 bp DNA ladder; F1 = 
Mouse#56_T1F; R1 = Mouse#56_T1R; F2 = Mouse#56_T2F; R2 = Mouse#56_T2R; Ft= TransgeneA_F; Blank = 
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Fig. 3.33. The MOCS2A transgene Ta1 is present and expressed in each tissue of mice from the MOCS2A5 
line. (a) Genotyping PCR results demonstrate the presence of the MOCS2A transgene Ta1 in all tissues 
investigated in mice from the F1 generation. A DNA sample derived from the tail of the MOCS2A founder 
mouse #56 was used as a positive control. (b) RT-PCR analyses demonstrated the expression of the human 
MOCS2A transcript in different tissues derived from a mouse of the F1 generation. A cDNA sample derived 
from the tail of the MOCS2A founder mouse #56 was used as a positive control. (c) PCR analysis of the 
housekeeping gene Hprt was performed as a control for cDNA quality. (100bp = 100 bp DNA ladder). 
 
 
Fig. 3.34. Integration of the MOCS2A transgene impaired the expression of the Dnajc24 host gene in 
several tissues. qRT-PCR experiments revealed reduced expression of the Dnajc24 gene in several tissues of 
MOCS2A transgenic mice (MOCS2ATa/-) compared to WT tissues. The results were normalised to Gapdh 
expression, and are presented as a relative value to the Dnajc24 expression level in the liver of a WT mouse. 
Values and associated error bars represent mean ± s.d. (n = 3).  
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In the second MOCS2A transgenic line (A6) the integration site of MOCS2A transgene was 
localised by employing a genome walker assay. By using this approach a single integration 
site of the MOCS2A transgene could be identified on murine chromosome 6 (NCBI chr6: 
44712888) and no other gene is localised in this chromosomal region. Figure 3.35a 
represents the strategy used for the identification of MOCS2A transgene integration by 
genotyping PCR. For this reason the following primers were used: Mouse#44_F, 
TransgeneA_R and Mouse#44_R. Subsequently, the MOCS2A transgene integration could 
be shown in all tissues of founder animal #44. Moreover, the MOCS2A transgene was 
transmitted to the offspring, as PCR products with the right size were also detected in 
pups of the F1 generation (Fig. 3.35b). Heterozygous transgenic MOCS2ATa/- mice were 
bred with heterozygous knockout Mocs2+/- mice to generate Mocs2+/-, Ta/- mice, which 
were further bred to each other. Using this breeding strategy, mice with the following 
genotypes were obtained: Mocs2+/-, Ta/Ta, Mocs2+/-, Ta/-, Mocs2-/-, Ta/Ta, and Mocs2+/+, -/- (Fig. 
3.36). All animals were healthy and appeared normally developed, but in comparison to 
the transgenic MOCS2A5 mouse line these mice did not express the MOCS2A transgene 
(Fig. 3.37). RT-PCR analyses with primers qMOCS2AEx1a_F and qMOCS2AEx2_R showed 
strong RT-PCR bands corresponding to the MOCS2A product only in tissues of founder 
animal #56, whereas MOCS2A expression could not be detected in tissues derived from 
founder animal #44 as well as in its progeny. Following the RT-PCR experiments, these 
results were confirmed by qRT-PCR analyses with the following primers: qMOCS2AEx1a_F 
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Fig. 3.35. The MOCS2A6 mouse line contained only one copy of the MOCS2A transgene. (a) Schematic 
representation of the strategy used for the identification of the MOCS2A transgene in mice from the 
MOCS2A6 mouse line. (b) Results of genotyping PCR with primers F1, R1 and Rt showed the presence of the 
MOCS2A transgene (Ta) in different tissues of founder animal #44 as well as its germline transmission to the 
progeny. Genomic DNA from tail tips of wild type (WT) mice was used as a negative control. The arrows 
illustrate the localisation and the direction of primers used for genotyping PCR. (100bp = 100 bp DNA 
ladder; F1 = Mouse#44_F; R1 = Mouse#44_R; Rt = TransgeneA_R; Blank = negative control w/o DNA). 
 
 
Fig. 3.36. The MOCS2A transgene Ta presented in the MOCS2A6 line is transmitted to the F1-generation. 
(a) Genotyping PCR results from different tissues demonstrating the presence of MOCS2A transgene or the 
wild type allele (WT) in pups derived from the breeding of Mocs2+/-, Ta/- mice. (b) PCR analyses specific for 
the murine Zfyve27 gene was used as a quality control of extracted DNA samples. Genomic DNA samples 
from founder #44 and #56 were used as an internal control. (100bp = 100 bp DNA ladder; Blank = negative 
control w/o DNA). 
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Fig. 3.37. Expression analyses of the MOCS2A transgene in different tissues of the MOCS2A5 mouse line. 
(a) RT-PCR analyses demonstrating that the MOCS2A transgene was not expressed in tissues derived from 
founder animal #44 and its progeny compared to MOCS2A transgene expression observed in founder 
animal #56. (b) RT-PCR analyses for the murine housekeeping gene Hprt served as a quality control of 
synthesised cDNA. (100bp = 100 bp DNA ladder; Blank = negative control w/o DNA). (c) The results of qRT-
PCR experiments confirmed the lack of MOCS2A transgene expression in tissues obtained from founder 
animal #44 and its progeny. The results were normalised to the expression of the murine housekeeping 
gene Gapdh, and are presented as a relative value to the MOCS2A transgene expression level in the liver 
from founder animal #56. Values and associated error bars represent mean ± s.d. (n = 3). 
 
3.1.8 Generation of the MOCS2B transgenic mouse line 
To generate MOCS2B transgenic mice, a pronuclear injection with the linearised pWajaII 
(Wegner, 2007) construct encoding the human MOCS2B gene was performed. The 
pWajaII construct carries the human MOCS2B gene under the control of the β-actin 
promoter (Fig. 3.38a). Prior to injection, the pWajaII construct was linearised by XmaI 
digestion and purified (Fig. 3.38b). Pronuclear injection of the pWajaII construct into 
mouse fertilised oocytes was performed in collaboration with Dr. Ursula Fünfschilling 
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Fig. 3.38. Preparation of the MOCS2B transgene construct. (a) Schematic representation of the pWajaII 
vector showing the human MOCS2B ORF under the control of the Cytomegalovirus (CMV) enhancer and β-
actin promoter followed by a bovine growth hormone polyadenylation signal (bGH polyA), the kanamycin 
(Kan) resistance gene and the origin of replication (Ori). (b) Agarose gel electrophoresis revealed bands 
specific for the undigested and digested pWajaII plasmid. Band 4.5 kb corresponds to the linearised plasmid 
after XmaI digestion.  
 
To identify potential founder animals carrying the MOCS2B transgene genotyping PCR 
analyse with MOCS2B-specific primers qMOCS2BEx5_F and qMOCS2BEx6_R was 
performed (Fig. 3.39a). In 5 out of 25 animals the MOCS2B transgene was observed (Fig. 
3.39b). In order to estimate the number of MOCS2B transgene copies in the respective 
founder animals, qPCR experiments were done with MOCS2B transgene-specific primers 
qMOCS2BEx5_F and qMOCS2BEx6_R. The qPCR results indicated that two copies of the 
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Fig. 3.39. Detection of the MOCS2B transgene in putative founder animals. (a) Schematic representation 
of the strategy used for the identification of founder animals. (b) Results of the genotyping PCR (94 bp) 
revealed five animals presenting the MOCS2A transgene. Results of the genotyping PCR for negative pups 
are not shown. The arrows indicate the localisation and the direction of primers used for genotyping PCR. 
(100bp = 100 bp DNA ladder; F = forward; R = reverse; Blank = negative control w/o DNA). 
 
 
Fig. 3.40. Copy number evaluation of the MOCS2B transgene in founder animals. Bar graphs showing the 
results of qPCR analysis indicated that all investigated animals carried 2 copies of the MOCS2B transgene. 
The results obtained from the MOCS2B transgene were normalised against a murine single copy gene, 
namely acrosin (Acr) and are presented as a relative value to another single copy gene, named pelota (Pelo). 
Values and associated error bars represent mean ± s.d. (n = 3). 
 
To exclude that the integration of the human MOCS2B transgene into the murine genome 
did not influence the expression of a murine gene in the vicinity of the integration site, 
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the MOCS2B transgene integration site was localised in founder animal #84 using the 
genome walker assay. In contradiction to the obtained qPCR results, only one integration 
site on mouse chromosome 5 could be identified (NCBI ch5: 139888374-139888100) and 
to date no other mouse gene was described in this chromosomal region. To establish a 
transgenic MOCS2B mouse line, founder animal #84 was crossed with C57BL/6N wild type 
mice. Genotyping PCR experiments of mice from the F1 generation with Mouse#84_F, 
Mouse#84_R and TransgeneB_F (Fig. 3.41a) demonstrated germline transmission of the 
MOCS2B transgene (Fig. 3.41b). Heterozygous transgenic mice (MOCS2BTb/-) were 
healthy, fertile and gave rise to homozygous MOCS2BTb/Tb animals with the predicted 
Mendelian ratio after breeding with MOCS2BTb/- mice (data not shown). Thus, the 
transgenic MOCS2B4 mouse line could be established. Furthermore, expression of the 
human MOCS2B transgene was confirmed by RT-PCR experiments using human MOCS2B-
specific primers Nest.hum.F1Ex3 and Nest.hum.R1Ex6 (Fig. 3.42), or by Western blot 
analysis with the human MOCS2B-specific antibody EP113635 (Fig. 3.43). 
 
 
Fig. 3.41. The MOCS2B4 mouse line contained only one copy of the MOCS2B transgene. (a) Schematic 
representation of the strategy used for the identification of the MOCS2B transgene in mice from the 
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MOCS2B4 mouse line. (b) Results of genotyping PCR with primers F1, R1 and Rt showed the presence of the 
MOCS2B transgene (Tb) in different tissues of founder animal #84 as well as its germline transmission to the 
progeny (#1-3). Genomic DNA from tail tips of wild type (WT) and founder #73 mice was used as a negative 
control. The arrows illustrate the localisation and the direction of primers used for genotyping PCR. (100bp 




Fig. 3.42. The MOCS2B transgene (Tb) is expressed in each tissue of mice from the MOCS2B4 line. (a) RT-
PCR analyses demonstrated the expression of the human MOCS2B transcript in different tissues derived 
from a mouse of the F1 generation. A pWajaII construct and cDNA sample derived from human testis was 
used as a positive control. A cDNA sample derived from mouse muscle served as a negative control. (b) PCR 
analysis of the murine housekeeping gene Hprt was performed as a control for cDNA quality. (100bp = 100 
bp DNA ladder). 
 
 
Fig. 3.43. Expression of the human MOCS2B transgene in tissues of the transgenic MOCS2B4 mouse. To 
analyse MOCS2B protein expression in different tissues of the transgenic MOCS2B4 mouse, whole proteins 
were isolated from liver and muscle, and subjected to Western blot analyses using a specific antibody 
against human MOCS2B. In the liver and muscle derived from MOCS2B4 #2 mouse a MOCS2B-specific signal 
of 21 kDa could be observed. Proteins extracted from livers of wild type (WT) or Mocs2-/- mice were loaded 
as a negative control. The anti α-tubulin antibody was used as a protein loading control. 
 
In order to generate an isolated Mocs2a knockout mouse model, heterozygous transgenic 
MOCS2BTb/- mice were bred with heterozygous Mocs2+/- mice to obtain Mocs2+/-, Tb/- mice 
which were further bred with each other to obtain Mocs2-/-, Tb/- (corresponding to a 
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knockout mouse model for the Mocs2a isoform). Similar to Mocs2-/- offspring, Mocs2-/-, 
Tb/- (= Mocs2a knockout) pups died within the first 8 days after birth manifesting a related 
phenotype, i.e. Mocs2-/-, Tb/- mice exhibited a general poor health condition, curly whiskers 
and bladder obstructions (data not shown). In contrast to Mocs2-/- mice, Mocs2-/-, Tb/- mice 
showed a significantly improved increase in body weight postnatally (Fig. 3.44), however, 
it was still significantly lower than weight gain of WT animals. Additionally, Mocs2-/-, Tb/- 
mice extended their mean life span to 5.9 days, as most of them died between day 5 and 
8 after birth (Fig. 3.45). 
 
 
Fig. 3.44. Gain of weight of Mocs2-/-, Tb/- mice after birth. Mocs2-/-, Tb/- expressing the human MOCS2B 
transgene presented a significantly improved gain in weight postnatally as compared to Mocs2-/- mice. Line 
graphs showing the body weight of WT (green, +/+), Mocs2+/- (red, +/-), Mocs2-/-, Tb/- (orange, -/- Tb/-) and 
Mocs2-/- (blue, -/-). Body weight and associated error bars representing mean ± s.d. (n = 35 for WT, n = 60 
for Mocs2+/-, n = 34 for Mocs2-/- and n = 12 for Mocs2-/-, Tb/- pups). * p<0.05, ** p<0.01, *** p<0.001. Black 
stars indicate significant differences between WT and Mocs2-/- mice, green stars showed the significance 
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Fig. 3.45. Life span of Mocs2-/-, Tb/- mice. Bar graphs represents the life span of Mocs2-/-, Tb/- mice. In total, 12 
Mocs2-/-, Tb/- mice were investigated. All of them died within 8 days after birth with a critical time point 
between postnatal day 5 and 8 (83%), (n = 12). 
 
3.1.9 Rescue of the Mocs2 knockout phenotype by supplementation with the 
transgenes encoding MOCS2A and MOCS2B proteins 
In order to rescue the Mocs2-/- phenotype, both Mocs2 subunits (human MOCS2A and 
MOCS2B) were supplemented by crossing Mocs2+/- animals with both transgenic 
MOCS2A5 and MOCS2B4 mice (Fig. 3.46). Although the MOCS2A transgene was known to 
impair the expression of murine Dnajc24 gene, heterozygous MOCS2ATa/- animals were 
viable and expressed the MOCS2A transgene (see Fig. 3.33). For this reason MOCS2+/-, Ta/- 

















Day after birth 
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Fig. 3.46. Gene therapy approach designed for Mocs2 knockout mice. Schematic representation of the 
mating strategy to rescue the phenotype of Mocs2-/- mice by complementation of the Mocs2 gene with 
both Mocs2 subunits expressed by the transgenic animals MOCS2ATa/- and MOCS2BTb/-. 
 
3.2 Gene therapy approach for molybdenum cofactor deficiency, 
supplementation group B 
3.2.1 Generation of MOCS2B recombinant adeno-associated viruses (rAAVs) 
Recombinant adeno-associated viruses (rAAVs) are currently among the most frequently 
used viral vectors for gene therapy approaches (Daya and Berns, 2008). The generation of 
rAAV serotype 2/8 was performed in collaboration with Prof. A. Auricchio (Telethon 
Institute of Genetics and Medicine, TIGEM, Italy). Briefly, the open reading frame (ORF) of 
the human MOCS2B gene was cloned into the pAAV2.1TBGeGFP3 plasmid (kindly 
provided by TIGEM, Italy). The pAAV2.1TBGeGFP3 plasmid contains the liver-specific 
Thyroxine binding globulin (TBG) promoter followed by a multiple cloning site, an eGFP 
reporter gene, and a polyA signal flanked by inverted terminal repeats (ITRs) (Fig. 3.47). 
The ORF of the human MOCS2B gene was amplified from a human cDNA library with two 
different pairs of MOCS2B gene-specific primers: F_NotIEx3, R_NotIEx7, or F_NotIEx3, R_ 
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NotISTOPEx7 (Fig. 3.48a). The first primer pair amplified the MOCS2B ORF, deprived of 
the stop codon in exon 7, while the second pair of primers amplified the complete 
MOCS2B transcript including the stop codon. MOCS2B and MOCS2B-STOP PCR products 
were cloned into the pGEMT-easy vector, transformed into DH5α competent E.coli and 
checked for the correct sequence, respectively. Furthermore, both inserts and the 
pAAV2.1TBGeGFP3 backbone plasmid were digested with the restriction enzyme NotI and 
ligated together (Fig. 3.48b). The correct orientation of the inserts for MOCS2B and 
MOCS2B-STOP was confirmed by digestion with the restriction enzymes NdeI and BamHI, 
respectively (Fig. 3.48c). Finally, both pAAV2.1TBG-MOCS2B-eGFP3 and pAAV2.1TBG-
MOCS2B-STOP-eGFP3 constructs were purified and sent to TIGEM where they were used 
for the production of viral particles. In Figure 3.48d the structure of the final vectors 
pAAV2.1TBG-MOCS2B-eGFP3 and pAAV2.1TBG-MOCS2B-STOP-eGFP3 is represented. This 
cloning strategy let us to produce two types of viruses, encoding either the MOCS2B-eGFP 
fusion protein or only the MOCS2B protein. 
 
 
Fig. 3.47. Map of pAAV2.1TBGeGFP3 backbone vector. The pAAV2.1TBGeGFP3 vector contains Inverted 
Terminal Repeats (ITRs) flanking the Thyroxine binding globulin (TBG) promoter, followed by chimeric 
intron, eGFP and bovine growth hormone polyadenylation (bGH polyA) signal. The NotI restriction site is 
localised between the chimeric intron and eGFP sequence. (ori = origin of replication). 
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Fig. 3.48. Cloning of MOCS2B and MOCS2B-STOP into the pAAV2.1TBGeGFP3 backbone vector. (a) 
Agarose gel electrophoresis image showing PCR products of both human MOCS2B transcripts. Left panel 
presenting the 580 bp PCR product of MOCS2B transcript without the STOP codon (MOCS2B Ø), the right 
panel showing the 583 bp PCR product of the MOCS2B transcript with the STOP codon (MOCS2B-STOP). (b) 
Agarose gel electrophoresis image of cloned MOCS2B Ø and MOCS2B-STOP inserts and the 
pAAV2.1TBGeGFP3 backbone vector after NotI digestion. Restriction analyses revealed correct sizes of the 
MOCS2B (580 bp) and MOCS2B-STOP (583 bp) inserts, respectively, and the linearised backbone vector 
(5612 bp). (c) Agarose gel electrophoresis image of MOCS2B and MOCS2B-STOP inserts after cloning into 
the pAAV2.1TBGeGFP3 vector and NdeI, BamHI double digestion. To verify the correct orientation of cloned 
MOCS2B and MOCS2B-STOP sequences, inserts were cut out from the pAAV2.1TBGeGFP3 vector with NdeI, 
BamHI double digestion. Expected bands were: 5612 bp for the pAAV2.1TBGeGFP3 vector; 820 bp for the 
correctly orientated MOCS2B insert and 823 bp for the correctly orientated MOCS2B-STOP insert. Three 
positive clones for pAAV2.1TBG-MOCS2B-eGFP3 and one positive clone for pAAV2.1TBG-MOCS2B-STOP-
eGFP3 were obtained (arrows indicate positive clones). (d) Schematic representation of the pAAV2.1TBG-
MOCS2B-eGFP3 and pAAV2.1TBG-MOCS2B-STOP-eGFP3 plasmids encoding the MOCS2B-eGFP fusion 
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To check the functionality of generated constructs, human hepatocellular carcinoma cells 
(HepG2) were transfected with the pAAV2.1TBG-MOCS2B-eGFP3. Although the efficiency 
of transfection was very poor, eGFP-positive HepG2 cells have been found (Fig. 3.49). 
 
 
Fig. 3.49. TBG promoter-driven expression of the MOCS2B-eGFP fusion protein in HepG2 cells. HepG2 
cells transfected with the pAAV2.1TBG-MOCS2B-eGFP3 vector presented an eGFP signal. Scale bars 
correspond to 10 μm. (BF = Bright field). 
 
The production of recombinant adeno-associated virus required three different plasmids. 
Besides the plasmid encoding the therapeutic protein, a plasmid carrying the AAV2 Rep-
Cap genes and a helper plasmid are involved. All three plasmids had to be co-transfected. 
After expression of Rep and Cap proteins, the ITR flanked transgene cassette was 
replicated, and the single-stranded DNA molecules were encapsulated. Thereafter, viral 
particles were harvested, purified and titred (AAV 1461 rAAV2/8TBG-MOCS2B-eGFP3 = 
2,5×1012 genome copies (GC)/ml, and AAV1460 rAAV2/8TBG-MOCS2B-STOP-eGFP3 = 
4,6×1012 GC/ml). To confirm that the rAAV was able to infect hepatocytes in vivo, 
intrahepatic (n = 2) or intraperitoneal injections (n = 2) with either 1×1010 GC of AAV1460 
rAAV2/8TBG-MOCS2B-STOP-eGFP3 or with PBS as a control (n = 2) were performed in 
wild type mice. Nested PCR analysis using MOCS2B-specific primers nest.humF1_Ex3 and 
nest.hum.R1_Ex6 followed by a PCR with humF2_Ex3 and nest.hum.R2_Ex3 revealed the 
presence of AAV-delivered MOCS2B DNA into the liver, independent on the injection 
technique (Fig. 3.50). However, at the RNA level, RT-PCR analyses showed MOCS2B 
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Fig. 3.50. Infection ability of rAAV 1460 (rAAV2/8TBG-MOCS2B-STOP-eGFP). (Upper panel) Agarose gel 
electrophoresis image of nested PCR experiments showing the presence of the MOCS2B transgene in the 
livers of wild type mice after intrahepatic or intraperitoneal injection with rAAV2/8TBG-MOCS2B-STOP-
eGFP regardless of the type of injection. (Lower panel) PCR analyses specific for the murine Zfyve27 gene 
was used as a quality control of extracted DNA samples from livers after intrahepatic or intraperitoneal 
injection with AAV or PBS, respectively. (100bp = 100 bp DNA ladder; Blank = negative control w/o DNA). 
 
 
Fig. 3.51. Efficiency of MOCS2B expression after different routes of rAAV2/8TBG-MOCS2B-STOP-eGFP 
infections. RT-PCR analysis showed that MOCS2B is transcribed in the liver only after intrahepatic injection. 
PCR products amplified from cDNA synthesised without reverse transcriptase (Ø RT) served as a negative 
control. (100bp = 100 bp DNA ladder; Blank = negative control w/o cDNA). 
 
To visualise the expression of the MOCS2B protein after viral infection in vivo, 
immunohistochemical analyses were performed. For this reason, wild type newborn pups 
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were injected intrahepatically with rAAV2/8TBG-MOCS2B-eGFP3 as well as with 
rAAV2/8TBG-MOCS2B-STOP-eGFP3 viruses, and 11 days after injection staining of liver 
sections were performed with a EP113635 MOCS2B-specific antibody. The results showed 
that hepatocytes transduced with the rAAV2/8TBG-MOCS2B-STOP-eGFP3 virus presented 
a cytoplasmic expression of the MOCS2B protein, while hepatocytes transduced with 
rAAV2/8TBG-MOCS2B-eGFP3 demonstrated a co-localisation of both MOCS2B as well as 
the MOCS2B-EGFP signal (Fig. 3.52). 
 
Fig. 3.52. Immunohistochemical analysis of mouse hepatocytes transduced either with the rAAV2/8TBG-
MOCS2B-STOP-eGFP3 virus or with the rAAV2/8TBG-MOCS2B-EGFP virus. (a) After antibody staining the 
MOCS2B protein was shown to be expressed in the cytoplasm of hepatocytes after transduction with the 
rAAV2/8TBG-MOCS2B-STOP-eGFP. Non-injected livers from wild type mice served as a negative control. (b) 
MOCS2B expression co-localised with MOCS2B-EGFP fusion proteins after transduction with rAAV2/8TBG-
MOCS2B-eGFP3. Scale bars correspond to 20 μm for the negative control and the lower panel, and to 10μm 
for the upper panel. 
 
In order to study if intrahepatic injections could lead to infection of other tissues, wild 
type mice were injected with 1×1010 GC of AAV1460 rAAV2/8TBG-MOCS2B-STOP-eGFP3 
or with PBS as a control. One week after injection, genomic DNA from several tissue 
samples was extracted and analysed by PCR using MOCS2B-specific primers 
F2nest.hum.F2Ex3 and R2nest.hum.R2Ex3 primers. PCR products specific for the MOCS2B 
transgene were detected in all tissues investigated except in the brain, however, MOCS2B 
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Fig. 3.53. Characterisation of rAAV (1460AAV2/8TBGMOCS2B-STOP-eGFP3) tropism. (a) MOCS2B-specific 
PCR products were detected in almost all tissues of rAAV2/8TBG-MOCS2B-STOP-eGFP (rAAV) injected mice 
except in the brain. (b) In contrast, in tissues of mice injected with PBS MOCS2B-specific PCR products were 
not observed. DNA extracted from 1460AAV2/8TBGMOCS2B-STOP-eGFP3 virus (rAAV DNA) was used as a 
positive control. (Lower panels) PCR analyses specific for the murine Zfyve27 gene was used as a quality 
control of extracted DNA samples from different tissues of mice injected either with rAAV2/8TBG-MOCS2B-
STOP-eGFP (rAAV) or with PBS (negative control). (100bp = 100 bp DNA ladder; Blank = negative control w/o 
DNA). 
 
To examine the expression profile of human MOCS2B-EGFP fusion protein, wild type mice 
were injected with pAAV2/8TBG-MOCS2B-eGFP3 virus. To increase the efficiency of viral 
transduction animals received two intrahepatic injections with 1×1010 GC and 4×1010 GC, 
respectively. The first injection was applied at the day of birth, and the second injection at 
postnatal day 6. Mice were anesthetised 11 days or 6 months after the second injection 
and following perfusion, tissues from both animals were fixed and objected to 
cryosectioning. In both cases MOCS2B-EGFP signals were detected exclusively in liver 
sections (Fig 3.54). At this stage we were in the position to conclude that intrahepatic 
injection with pAAV2/8TBG-MOCS2B-eGFP3 causes co-infection of other tissues, 
however, MOCS2B-EGFP expression was restricted exclusively to the liver. 
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Fig. 3.54. Visualisation of MOCS2B-EGFP expression after injection with pAAV2/8TBG-MOCS2B-eGFP3. 
Fluorescence images showing the expression of TBG-driven MOCS2B-EGFP in different mouse tissues (a) 11 
days and (b) 6 months after the second intrahepatic injection, respectively. Nuclei were counterstained 
with DAPI. Scale bars correspond to 20 μm. 
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3.2.2 Therapeutic potential of rAAV-MOCS2B-based gene therapy 
In order to investigate the effect of a rAAV-MOCS2B gene therapy in homozygous Mocs2-/- 
mice, we performed double intrahepatic injection of Mocs2-/- animals with pAAV2/8TBG-
MOCS2B-STOP-eGFP3 (first injection shortly after birth with 1×1010 GC in 20 ul PBS, and 
second injection at postnatal day 6 with 4×1010 GC of rAAV in 40 ul PBS). As expected, it 
did not rescue the phenotype, and the Mocs2-/- animals died witin the first 8 days of life. 
However, in agreement with previous results (see Fig. 3.44), the body weight of treated 
animals was higher as compared to untreated Mocs2-/- pups (Fig. 3.55). Because only 
three animals were treated with pAAV2/8TBG-MOCS2B-STOP-eGFP3 statistical analysis 
was not performed. 
 
 
Fig. 3.55. Mocs2-/- animals treated with rAAV-MOCS2B have higher body weight in comparison to non-
treated Mocs2-/- mice. Line graphs showing the body weight of WT (green), Mocs2+/- (red), Mocs2-/- (blue), 
Mocs2-/-, Tb/- (orange), and Mocs2-/- mice treated with rAAV-MOCS2B (yellow). Body weight and associated 
error bars representing mean ± s.d. (n = 35 for WT, n = 60 for Mocs2+/-, n = 34 for Mocs2-/-, n = 12 for Mocs2-
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3.2.3 Long-term study designed to determine MOCS2B overtime expression 
after injection with rAAV 
In the next step, we investigated expression efficiency of the transgene, delivered via 
rAAV infection. We injected animals at different time points using different amounts of 
rAAV. To visualise MOCS2B protein expression we used AAV2/8TBG-MOCS2B-eGFP3 
which encodes for the fusion MOCS2B-eGFP protein. We divided animals into three 
groups. The first group (I) obtained single intrahepatic injection at the day of birth with 
1×1010 GC of rAAV in 20 ul PBS. The second group (II) obtained a single injection at 
postnatal day 6 with 4×1010 GC of rAAV in 40 ul of PBS, and the last group (III) obtained a 
double injection, i.e. a first injection shortly after birth with 1×1010 GC in 20 ul PBS, and a 
second injection at postnatal day 6 with 4×1010 GC of rAAV in 40 ul of PBS. Animals 
treated in the same way with PBS were used as a negative control. Table 2 shows an 
overview of the injection scheme for the long term study experiment. 
 
Tab. 2. Strategy of rAAV injections used for investigation of rAAV gene therapy duration. 
 
 
Expression of the fusion protein MOCS2B-eGFP was analysed at different time points: 1 
week-, 1 month-, 3 months-, 6 months-, 12 months- and 24 months after injection(s). The 
animals were anesthetised and perfused. Afterwards, the livers were isolated and fixed 
before cryosections were established. After nuclei staining, slides were analysed under a 
fluorescent microscope. The results showed that in all groups the expression of the 
therapeutic gene persists at least 12 months. Moreover, in the groups which obtained a 
single injection (at the day of birth or at postnatal day 6) we were able to detect MOCS2B-
eGFP expression even 24 months after injections (Fig. 3.56a, 3.57a and 3.58a). 
Quantitative analysis, evaluating the percentage of MOCS2B-eGFP positive cells, showed 
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the highest number of infected hepatocytes one week after the 1st injection. There were 
approximately 6.5% of all liver cells infected, however, one month after injection the 
number of eGFP-positive cells decreased to 2% (Fig. 3.56b). In the two other groups, the 






R E S U L T S  
 
 
Fig 3.56. eGFP expression analysis at different time points after injection at the day of birth with 1×1010 
GC of rAAV MOCS2B-eGFP in 20 ul PBS. (a) Fluorescent images showing eGFP expression after single 
injection at the day of birth. Liver sections from animals treated with PBS serve as a negative control. (b) 
Bar graphs showing the number of eGFP positive cells were normalised to the total number of liver cells. 
Values and associated error bars represent mean ± s.d. (n = 1). 
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Fig. 3.57. eGFP expression analysis at different time points after injection at day 6 after birth with 4×1010 
GC of rAAV MOCS2B-eGFP in 40 ul PBS. (a) Fluorescent images showing eGFP expression after single 
injection at postnatal day 6. Liver sections from animals treated with PBS served as a negative control. (b) 
Bar graphs showing the number of eGFP positive cells were normalised to the total number of liver cells. 
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Fig. 3.58. eGFP expression analysis at different time points after injections at the day of birth with 1×1010 
GC of rAAV MOCS2B-GFP in 20 ul PBS, and at postnatal day 6 with 4×1010 GC of rAAV MOCS2B-GFP in 40 
ul PBS. (a) Fluorescent images showing eGFP expression after double injection. Liver sections from animals 
treated with PBS served as a negative control. (b) Bar graphs showing the number of eGFP positive cells 
were normalised to the total number of liver cells. Values and associated error bars represent mean ± s.d. 
(n = 1). 
 
3.2.4 Long-term study of the tumorigenic potential of rAAV-based gene 
therapy 
Although rAAV remains one of the most promising vector for gene therapy, its site 
specific integration is lost due to genetic modifications. It has been shown to either 
persist as episomes or integrate randomly into the host genome. Aim of this study was to 
check the tumorigenic potential of rAAV in different mouse genetic backgrounds, 
including C57Bl/6N and 129sv. A cohort of 50 animals from each strain received two 
intrahepatic injections with rAAV (1460 AAV2/8TBGMOCS2B-STOP-eGFP3). The first 
injection at the day of birth (1×1010 GC in 20 ul of PBS), and the second one at postnatal 
day 6 (4×1010 GC in 40 ul of PBS). At the same time, 50 animals from each background 
were injected in the same way with PBS and served as a control. Animals were kept in 
sterile conditions, and the underlying cause of each death was investigated in 
collaboration with pathologists, Dr. Ursula Kohlhofer, Dr. Klaudia Kloss, and PD Dr. Leticia 
Quintanilla-Martinez de Fend (Institute of Pathology, University of Tübingen,). 
Animals treated with rAAV analysed from the C57Bl/6N strain were in average at an age 
of 11 to 30 months. In that cohort, 21 animals developed hepatic tumours, one animal a 
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primary intestine tumour with metastases, one mouse a malignant hematopoietic tumour 
(unclassifiable lymphoma), and one adenocarcinoma of the lung. Additionally to 
hepatocellular carcinoma (HCC), five animals presented also with hematopoietic tumours 
(one animal a histiocytic sarcoma, and four animals diffuse large B-cell lymphomas, 
DLBCL). One animal developed additionally a hemangiosarcoma (Tab. 3). The first onset 
of HCCs was manifested quite late, as it was observed between 17-21 months. In younger 
mice no hepatic tumour was detected. Mice which developed a malignant hepatic tumour 
together with a hematopoietic tumour, were older than 22.5 months. From the group 
treated with PBS, analysed animals were in average at an age of 8 to 30 months. 22 
animals with an age range of 9 to 28 months developed tumours. Four animals developed 
hemangiosarcoma, one together with leukaemia; one animal a sarcoma of the skin; three 
animals histiocytic sarcomas; five animals diffuse large B-cell lymphomas including two 
with plasmatic differentiation; one mouse a B-cell lymphoma of follicular centre cell type; 
one B-cells lymphoblastic lymphoma; one animal a plasma cell neoplasm; five animals 
hepatocellular carcinoma; and one animal both: i.e. a plasma cell neoplasm and a HCC. 
Mice that developed hemangiosarcomas were 14, 17, 18 and 22.5 months old, whereas 
mice that developed a hematopoietic neoplasia were 18 to 28 months old (Tab. 3). Non-
malignant causes of death are listed in the table (Tab. 4). 
 
Tab. 3 Summary of malignant reason of death of C57Bl/6N mice treated either with rAAV or with PBS (n = 
50) 




Primary intestine tumour with metastases to other organs 1 (2%) - 
Lymphoma unclassifiable 1(2%) - 
Hepatocellular carcinoma (HCC) 10 (20%) 5 (10%) 
HCC with lung metastases 3 (6%) - 
HCC with lung metastases and diffuse large B-cell lymphoma 
(DLBCL) 
1 (2%) - 
HCC, histiocytic sarcoma with questionable acute leukaemia 
with maturation 
1 (2%) - 
HCC and DLBCL  1 (2%) - 
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HCC, hemangiosarcoma of the spleen and ovary 1 (2%) - 
HCC, DLBCL, hemangiosarcoma 1 (2%) - 
HCC and DLBCL with plasmatic differentiation 1 (2%) - 
Hepatocellular adenoma (HCA) 1 (2%) - 
HCC vs (HCA) 1 (2%) - 
Adenocarcinoma of the lung with tubulopapillary growth 
formation 
1 (2%) - 
Hemangiosarcoma of the spleen - 2 (4%) 
Hemangiosarcoma of the spleen and leukaemia with 
maturation 
- 1 (2%) 
Hemangiosarcoma of the liver - 1 (2%) 
Sarcoma of the skin - 1 (2%) 
Histiocytic sarcoma  - 1 (2%) 
Histiocytic sarcoma, solid type - 1 (2%) 
Histiocytic sarcoma with liver metastases - 1 (2%) 
Diffuse large B-cell lymphoma - 3 (6%) 
Diffuse large B-cell lymphoma with plasmatic differentiation - 2 (4%) 
B-cells lymphoma of follicular centre cell type - 1 (2%) 
B-cells lymphoblastic lymphoma - 1 (2%) 
Plasma cells neoplasm and HCC - 1 (2%) 
Plasma cell neoplasm - 1 (2%) 
Σ 24 (48%) 22 (44%) 
 
Tab. 4. Overview of non-malignant reason of death of C57Bl/6N mice treated either with rAAV or with 
PBS (n = 50) 




Skin injuries 2 (4%) 3 (6%) 
Ulcerative dermatitis   9 (18%)   9(18%) 
Gastrointestinal obstruction 1 (2%) 2 (4%) 
Cardiac diseases 1 (2%) 1 (2%) 
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Kidney and cardiac diseases 1 (2%) 1 (2%) 
Hydronephrosis or urinary track obstruction 3 (6%)    5 (10%) 
Penis inflammation 1 (2%)  1 (2%) 
Enlargement of seminal vesicles 1 (2%) - 
Dehydration 1 (2%) - 
Eye abnormalities -   1 (2%) 
Seminal vesicles abnormalities -   3 (6%) 
Hepatomegaly and splenomegaly -   1 (2%) 
Age 5(14%)   1 (2%) 
Unknown 1 (2%) - 
Σ 26 (52%) 28 (56%) 
 
In the 129sv strain the analysed animals after rAAV injections were 11 to 22.5 months old. 
Only seven animals developed tumours. HCC was found in three animals, one of these 
additionally developed a hemangiosarcoma of the uterus. In this group the youngest 
mouse that developed a hepatic lesion was 15 months, the oldest one 25 months. Four 
mice developed other malignant neoplasms (diffuse large B-cell lymphoma, marginal cell 
lymphoma and hemangiosarcoma of the uterus, uterine endometrial adenocarcinoma, 
and bronchoalveolar adenocarcinoma). The animals were 21-, 20-, 24- and 25.5 months 
old, respectively (Tab. 5.). The youngest analysed animal injected with PBS from the 
129sv line was 3 months old, the oldest one 26 months old. In contrast to the rAAV-
injected mice, in that group only three mice developed tumours. One animal developed a 
HCC, and two other animals showed malignant neoplasms (urothelial carcinoma with 
squamous cell differentiation, and hemangiosarcoma of the uterus). The animal that 
developed a hepatocellular carcinoma was 19 months old; the mice with malignant 
neoplasms were 22.5 and 23 months, respectively (Tab. 5). Non-malignant causes of 
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Tab. 5. Summary of malignant reason of death of 129sv mice treated either with rAAV or with PBS (n = 
50) 
MALIGNANT DIAGNOSIS 129sv rAAV 129sv PBS 
Hepatocellular carcinoma (HCC) 2(4%) 1(2%) 
HCC and uterus hemangiosarcoma 1(2%) - 
Diffuse large B-cell lymphoma 1(2%) - 
Uterine endometrial adenocarcinoma 1(2%) - 
Uterus hemangiosarcoma and marginal cell lymphoma 1(2%) - 
Bronchoalveolar adenocarcinoma 1(2%) - 
Hemangiosarcoma of the uterus and uterine endometrial 
adenocarcinoma 
- 1(2%) 
Urothelial carcinoma with squamous cell differentiation - 1(2%) 
Σ 7(14%) 3(6%) 
 
Tab. 6. Overview of non-malignant reason of death of 129sv mice treated either with rAAV or with PBS (n 
= 50) 
NON-MALIGNANT DIAGNOSIS 129sv rAAV 129sv PBS 
Epilepsy 1 (2%) - 
Retrobulbar abscesses with periocular swelling 10 (20%) 4 (8%) 
Gastrointestinal obstruction 3 (6%) 1 (2%) 
Hydronephrosis, urinary track obstruction with stones in the 
bladder 
3 (6%)   7 (14%) 
Stones in the bladder 10 (20%)   8 (16%) 
Penis inflammation 2 (4%) 1 (2%) 
Uterus and uterine horn abnormalities   6 (12%)   5 (10%) 
Hematometra 1 (2%) - 
Common bad condition 2 (4%) - 
Cardiac disease - 1 (2%) 
Lung infection - 1 (2%) 
Seminal vesicles abnormalities - 2 (4%) 
Obesity - 2 (4%) 
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Age   5 (10%) 15 (30%) 
Σ 43 (86%) 47 (94%) 
 
There was no coincidence between results obtained from both strains, and they showed 
extremely different patterns. In the C57Bl/6N strain almost half of the animals from both 
groups, injected with rAAV or PBS, developed tumours (48% and 44%, respectively). 
However, animals from the 129sv strain died mostly because of other diseases, only 14% 
of animals injected with rAAV developed tumours and only 6% from the group which 
obtained injections with PBS. The results indicate, that there is a different potential of 
rAAV-based malignancy in different mouse strains. Additionally, 18% from each group of 
C57Bl/6N mice suffered from Ulcerative dermatitis. They were mostly females (16 
females and 2 males, data not shown). In the 129sv strain were three non-malignant 
frequent causes of death: kidney obstruction, cystine stones formation, and retrobulbar 
abscess with periocular swelling. Except one animal, all mice which suffered from the first 
two diseases were males (data not shown) regardless of injection which they obtained. 
The retrobulbar abscess with periocular swelling was not gender-specific but it occurred 
more frequently in the rAAV than PBS treated mice (20% vs 8%). 
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4 DISCUSSION 
4.1 Summary of results 
Molybdenum cofactor (MoCo) deficiency type A is thus far only one curable type of MoCo 
deficiency. In the present study, a mouse model for MoCo deficiency type B (Mocs2-/-) 
was generated, characterised and used for preclinical trials. To create pure knockouts of 
each Mocs2 isoform (Mocs2a-/- and Mocs2b-/-), Mocs2-/- animals were crossed with 
generated transgenic mice expressing either the human MOCS2A or human MOCS2B 
isoform. In turn, the Mocs2a-/- animals were established. Due to several problems with 
MOCS2A transgenic mice, we could not establish a Mocs2b-/- line. 
The type of therapy relevant for MoCo deficiency is strictly dependent upon the type of 
the disease. The substitution therapy sufficient for rescuing MoCo deficiency type A is not 
effective in type B or C. In contrast to cyclic pyranopterin monophosphate (cPMP), other 
intermediate products of MoCo biosynthesis such as molybdopterin (MPT) and active 
MoCo, are unstable due to incorporated sulphur atoms. For this reason, we designed and 
developed a gene therapy approach using recombinant adeno-associated virus (rAAV). A 
single injection using relatively low doses of rAAV was able to drive expression of the 
MOCS2B therapeutic protein for at least two years. Additionally, a potential tumour 
formation risk caused by random integration of rAAV DNA into the host genome was 
analysed. Although the rAAV treatment increased the risk of tumour formation, it was 
highly dependent upon the genetic background of treated animals. Moreover, rAAV 
induced tumours did not occur earlier in treated animals compared with the onset of 
spontaneous tumours presented in untreated control animals. Finally, the rAAV encoding 
human MOCS2B protein was generated and its infection ability was evaluated in mice. 
Thus far, we have been unable to test therapeutic values of generated rAAV. 
 
4.2 Expression pattern of Mocs2a/b isoforms 
To date, the expression of MOCS genes has not been studied in detail. Besides northern 
blot analyses of MOCS1 (Reiss et al., 1998) and MOCS2 (Stallmeyer et al., 1999) 
transcripts, very little is known about the tissue distribution of MOCS genes. In the 
present study, the expression of Mocs2 isoforms was investigated in mouse tissues using 
the quantitative real time PCR (qPCR) method. Mocs2 isoforms were present in all 
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investigated tissues, with the highest expression in the skin, kidney, liver, lung, brain, and 
the lowest expression in the heart and spleen. Our data correlate with the previously 
described expression of Mocs1 transcripts (Lee, 2003). In the study by Lee and co-
workers, the highest expression of Mocs1 transcripts was detected in the liver, brain and 
kidney, while a weak expression was found in muscles. To visualise the cellular 
distribution of Mocs2 transcripts, we took advantage of the β-Galactosidase (LacZ) 
reporter cassette presented in the Mocs2 knockout allele. In agreement with our qPCR 
results, LacZ signals (equivalent of Mocs2a/b expression) were detected in all investigated 
tissues, with the highest incidence in kidney, brain, skin and germ cells. In the present 
study, LacZ-positive cells were detected in the collecting system of the kidney, in the 
cortex, the hippocampus and the brainstem, as well as in the hair follicles of the skin. An 
interesting pattern was observed in the testes, with strong LacZ staining detected in 
undifferentiated spermatogonia. LacZ-positive cells resembled the morphology of the 
undifferentiated spermatogonia inside seminiferous tubules. They existed either as a 
single cell or as chains of two, three or four cells. Counterstaining of the chromatin 
revealed the presence of mitotic spindle in each LacZ positive spermatogonia-like cell. 
Moreover, these cells were identified in testes of 12-day-old Mocs2+/- mice, which do not 
contain later stages of germ cells (e.g. spermatocytes, spermatids), but rather only 
spermatogonia (Meikar et al., 2011). In contrast to the qRT-PCR results, it was difficult to 
obtain reproducible LacZ-staining results in tissue sections of the liver, given that LacZ 
signals were either very week (as in 12-day-old pups) or uneven (as in liver sections of 
adult animals). It has been shown in rats that hepatocytes are responsible for the uptake 
and degradation of β-Galactosidase (Blomhoff et al., 1985). Indeed, this finding could 
explain the discrepancy between qRT-PCR and LacZ staining results, as the β-
Galactosidase protein is rapidly digested in the liver tissue and thus reproducible LacZ 
staining could not be detected. Table 7 summarises the expression of Mocs1 and Mocs2 
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Tab. 7. Expression of Mocs1 and Mocs2 genes in murine tissues 
Tissue Mocs1 Mocs2 (qPCR) Mocs2 (LacZ) 
Brain ++ +++ +++ 
Heart n.a. + + 
Lung n.a +++ +++ 
Liver +++ +++ +
* 
Stomach n.a ++ ++ 
Spleen n.a + - 
Kidney +++ +++ +++ 
Testis n.a ++ + 
Ovary n.a + + 
Skin n.a +++ +++ 
Muscle + ++ - 
- = no expression, + = low expression, ++ = moderate expression, +++ = high expression, n.a. = not analysed. 
* β-galactosidase is metabolised in the liver, thus LacZ staining does not correlate with Mocs2 gene 
expression in the liver. 
 
Here, the immunohistochemical analysis of WT mouse hepatocytes using a Mocs2b-
specific antibody revealed a cytoplasmic localisation of Mocs2b protein with a punctuate 
expression pattern. One could expect that the expression of MOCS proteins correlates 
with the activity of molybdenum cofactor-dependent enzymes. In rat liver cells, aldehyde 
oxidase and sulphite oxidase are expressed in mitochondria (Williams, 1952; Cohen et al., 
1972), while xanthine oxidoreductase was shown to be localised in peroxisomes 
(Angermuller et al., 1987; Frederiks and Vreeling-Sindelarova, 2002) and the amidoxime 
reducing component is expressed in both cellular compartments (Wahl et al., 2010; Klein 
et al., 2012). Additionally, it was shown in Arabidopsis thaliana that the MOT2 protein- 
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the putative homologue of human molybdate transporter - exhibits a vacuolar localisation 
(Wiese et al., 2007; Gasber et al., 2011). All such findings together support our results 
concerning a cytosolic, vesicle-like expression pattern of Mocs2 proteins in mouse 
hepatocytes.  
 
4.3 Characterisation of Mocs2 knockout mice 
To date, 80 MoCo deficient patients have been diagnosed worldwide. The majority (50%) 
of the mutations leading to MoCo deficiency have been identified in the MOCS1 gene 
(MoCo deficiency type A), while 32.5% of mutations have been described in the MOCS2 
gene (type B), and only 14 mutations (17.5%) have been reported in the Gephyrin (GPHN) 
gene (type C) (HGMD Professional 2015.1). Mouse models for type A and type C diseases 
have already been established (Feng et al., 1998; Lee et al., 2002). Although protein 
products of both Mocs1 and Gphn genes are involved in the biosynthesis pathway of 
molybdenum cofactor, the Gphn knockout mice do not resemble the phenotype of Mocs1 
knockout mice. Besides its role in the MoCo biosynthesis pathway, Gphn protein has an 
additional function in glycin- and GABAA -receptors’ localisation and anchoring. Gephyrin-
deficient mice display a failure in inhibitory neurotransmission, which consequently 
prevents suckling. Accordingly, Gphn-/- animals die within the first day of their life. Since 
MoCo deficient mice show first symptoms at day 3-4 after birth, premature death of 
Gphn-/- mice is a result of impaired neurotransmission rather than MoCo deficiency (Reiss 
et al., 2005). 
In the present study, the mouse model for MoCo deficiency type B has been developed. 
Similar to Mocs1+/- (Lee et al., 2002) and Gphn+/- (Feng et al., 1998) mice, heterozygous 
Mocs2+/- animals are phenotypically normal and fertile. In all three KO mouse models, 
heterozygous matings lead to the birth of homozygous mutants in expected numbers 
(~25%). In contrast to Gphn-/- animals, Mocs1-/- and Mocs2-/- pups appear normal at birth 
and suckle; however, they failed to thrive and died between day of birth and day 12 after 
birth, with a mean life span of 6.3 ±3.7 and 4.7 ± 3.1 days for Mocs1-/- (n=28) and Mocs2-/- 
(n=107) pups, respectively. Mocs2-/- pups presented two critical periods after birth: 
between day 0-4 when 47% of Mocs2-/- neonates died; and later between day 5-10 when 
51% of the animals died. Mocs1-/- animals present only one critical time point between 
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day 3-10 when 82% of the animals died (Lee et al., 2002). Figure 4.1 presents the survival 
rate of Mocs2-/- mice in comparison to Mocs1-/- mice. Discrepancies between the survival 
rates of Mocs1-/- and Mocs2-/- animals could result from different genetic backgrounds, 
given that Mocs1 knockout mice were derived from a hybrid (C57Bl/6J × 129sv) strain, 
while Mocs2 knockout mice were derived from a pure C57Bl/6N background. On the 
other hand, one can speculate that Mocs2 proteins can display additional function(s) 
shortly after birth. In turn, the depletion of Mocs2 proteins not only impaired the 




Fig. 4.1. Survival rate of Mocs1-/- and Mocs2-/- pups. Line graph showing the survival rate of Mocs2-/- pups 
(orange) in comparison to Mocs1-/- mice (blue). Arrows depict critical survival periods of knockout animals 
after birth. Mocs2-/- mice present two critical periods (shown with orange arrows): the first between day of 
birth (0) and postnatal day 4 (47% of Mocs2-/- pups died), and the second between postnatal day 5 and 10 
(51% of Mocs2-/- pups died). In contrast, Mocs1-/- mice present only one critical point between postnatal day 
3 and 10. During this time, 82% of Mocs1-/- pups died. The results showing the survival of Mocs1-/- mice 
were adopted from Lee et al.(2002). 
 
Similar to Mocs1-/-neonates, Mocs2-/- appeared externally normal but failed to grow due 
to an impaired gain of weight. The intense weight loss of Mocs1-/- and Mocs2-/- mice may 
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be due to either hindered access to the milk - as stronger heterozygous (Mocs2+/-) and 
wild type (Mocs2+/+) littermates eliminate homozygous mutant mice from the mother - or 
simply a very severe systemic phenotype. Apart from their smaller size in comparison to 
Mocs2+/+ and Mocs2+/- littermates, Mocs2-/- and Mocs1-/- mice present a poor skin 
condition, curly whiskers and an overall problem with hair growth (Fig. 4.2). One could 
ask why their whiskers can grow whereas growing other types of hair is impaired. This 
may be explained by differences between development of whiskers and other hairs 
(Wrenn and Wessells, 1984; Maklad et al., 2010). In rodents, whiskers develop prenatally 
and pups are born with an intact vibrissae, which is invisible to the naked eye (Landers et 
al., 2006). By contrast, the last step of anagen (active growth phase of hair follicles) - 
when hair fibres emerge through the epidermis - occurs at day 5 postpartum and can be 
affected by MoCo deficiency (Hedrich, 2004). Surprisingly, skin and hair phenotypes seem 
more severe in Mocs2-/- mice compared with Mocs1-/- pups. As previously mentioned, the 
different genetic backgrounds can explain these differences, although I speculate that the 
more severe externally phenotype of Mocs2-/- mice is rather a result of impaired functions 
of Mocs2 isoforms.  
 
 
Fig. 4.2. Mocs1-/- and Mocs2-/- mice show growth retardation, abnormal shape of whiskers, and defect in 
the overall hair growth as compared to healthy littermates. (Left) Exemplary picture of a 8-day-old Mocs1-
/- mouse, and (right) a 7-day-old Mocs2-/- mouse, in comparison to control animals from the same litters. 
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Owing to the loss of MoCo, all molybdenum-dependent enzymes should be inactive in 
Mocs1- and Mocs2-deficient mice. In the study by Lee and colleagues, the activities of 
sulphite oxidase and xanthine dehydrogenase in Mocs1-/- mice were measured directly 
from the liver extract (Lee et al., 2002). In our study, we performed the semi-quantitative 
test showing an elevated level of sulphite in the fresh urine of Mocs2-/- neonates 
compared to control littermates. 
Despite a description of the general phenotype (i.e. smaller size and curly whiskers) and 
biochemical analyses, a previous study by Lee did not analyse Mocs1-deficient mice in 
detail (Lee et al., 2002). The authors suggested that the phenotype presented in mice 
resembles the phenotype presented in patients. Since MoCo deficiency in patients leads 
to the loss of white matter (Endres et al., 1988; Graf et al., 1998; Johnson et al., 2001), 
Lee and colleagues performed a morphological analysis of Mocs1-/- brain sections. Nuclear 
staining of hippocampus, cortex and spinal cord derived from Mocs1-/- mice showed no 
abnormalities in cell number or changes in the cellular layers in the brain. In agreement 
with these results, we could not show any changes in the cell number and morphology of 
Mocs2-/- brains. In contrast to Lee’s study, we performed a deep pathological analysis of 
HE, NeuN and GFAP stained Mocs2-/- brain sections. Although NeuN and GFAP did not 
show any significant differences in the number of neurons and astrocytes, respectively, 
HE staining revealed the presence of apoptotic neurons in hippocampus, cortex and 
brainstem regions of Mocs2-/- brains. Subsequently, we confirmed these findings by 
Caspase 3 immunostaining, showing massive apoptosis of neurons in Mocs2-/- brains. 
Apoptotic neurons were also identified in Mocs2+/- brains, albeit with lower incidence (5-6 
fold lower than in Mocs2-/- brains). These results support the previous study by Reiss and 
colleagues, showing massive cell death programme in the brain of Mocs1-/- mice. 
Although the authors could not show any morphological changes in Mocs1-/- brain, 
expression analysis with microarrays indicated the activation of a cell death programme 
(Reiss et al., 2005). In light of these results, we showed for the first time that the mouse 
model for MoCo deficiency resembles not only biochemical but also pathological features 
observed in MoCo-deficient patients. In MoCo-deficient animals, the brain phenotype is 
milder than observed in patients, probably because the life span of MoCo-deficient 
animals (12 days) is too short to develop such severe abnormalities. Thus far, brain 
130 
 
D I S C U S S I O N  
 
dysmorphologies described in MoCo-deficient patients have been explained by sulphite 
toxicity to the central nervous system (CNS), whereby sulphite is endogenously generated 
during the metabolism of sulphur-containing amino acids and drugs (Fig. 4.3). Zhang and 
colleagues analysed the sulphite toxicity in rat brains, in hepatocellular carcinoma 
(HepG2) and human foetal liver cell lines, as well as different neuronal cell lines derived 
from rodents. In vivo, sulphite induced a significant and dose-dependent decrease in ATP 
synthesis in rat brain mitochondria. Additionally, an in vitro study revealed a sulphite-
mediated depletion of ATP in the investigated cell lines, although the accumulation of 
sulphite was more likely to occur in neuronal cells (Zhang et al., 2004). Furthermore, 
Grings and colleagues showed in detail that sulphite disrupts brain mitochondrial energy 
homeostasis and induces mitochondrial permeability transition pore opening via thiol 
group modification (Grings et al., 2014). Reiss and colleagues excluded sulphate 
deficiency as a potential trigger for neuronal death (Reiss et al., 2005). 
 
 
Fig. 4.3. Metabolism of sulphur-containing amino acids. Sulphite is generated during the metabolism of 
sulphur-containing amino acids, i.e. methionine. In the final step, sulphite is oxidised to sulphate by one of 
the MoCo-dependent enzymes, sulphite oxidase. Scheme adopted and modified from Tan et al. (2005). 
 
During our study, I observed that all Mocs2-/- pups manifested urinary obstruction 
associated with a presence of yellow deposits in the bladder. Subsequently, I also 
confirmed this phenotype in bladders of Mocs1-/- mice (data not shown). Yellow deposits 
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have already been described in rescued Mocs1-/- mice (Hahnewald, 2009). During this 
study, Hahnewald tested the therapeutic potential of different cPMP concentrations, 
whereby the higher doses of cPMP were able to completely rescue the phenotype of 
MoCo deficiency type A, while the lower doses led to the precipitation of yellow deposits 
in kidneys (Fig. 4.4). Hahnewald showed that the reconstitution of xanthine 
dehydrogenase activity in animals treated with lower cPMP doses was insufficient; thus, it 
was speculated that these deposits might have a xanthine composition. In agreement 
with this study, Ohtsubo and colleagues showed that the knockout of xanthine 
oxidoreductase (Xor) leads to premature death of Xor-/- mice due to the deposition of 
crystals and lipid-rich substances in renal tubes (Ohtsubo et al., 2009) (Fig. 4.4.). To check 
the ingredients of the deposits extracted from the Mocs2-/- bladder, I sent them for 
biochemical analysis, although their composition was not identified. Interestingly, crystal 
concretions were also present in the kidneys of Mocs2-/- neonates. 
 
 
Fig. 4.4 Concretions presented in kidneys derived from Mocs1-/- and Xor-/- mice. (Left) Xanthine stones 
identified by Hahnewald and colleagues in adult kidneys of Mocs1-/- mice treated with lower doses of cPMP. 
(right) Examplary image of xanthine crystals and lipid-rich substances in kidneys of 4-week old Xor-/- mice. 
Arrows depict yellow deposits in kidneys. Images were adopted from Hahnewald (2009) and Ohtsubo et al. 
(2009). 
 
To conclude, I characterised the phenotype of a mouse model for molybdenum cofactor 
deficiency type B and compared it with the mouse model for molybdenum cofactor 
deficiency type A (Tab. 8). Briefly, Mocs2-/- mice shared most of the external features 
previously described in Mocs1-/- mice, including curly whiskers, poor skin condition and 
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overall hair growth abnormalities. Mocs2-/- pups presented a shorter live span compared 
to Mocs1-/- mice, with two critical postnatal periods during which almost 98% of the pups 
died. In addition to external changes, we also identified severe phenotypes in the brain, 
kidneys and in the skin. However, I could not point out which of these phenotypes is the 
primary cause of death, given that defects in one of these organs could result in 
secondary effects in other tissues. I can speculate that malformed hair follicles can trigger 
a wound-like condition of the skin, resulting in wrinkle formation and flakiness in the skin. 
The animals may undergo dehydration, which can occur due to a defective barrier 
function in the skin (Cartlidge, 2000; Rutter, 2000). If water and electrolyte are 
continuously lost, blood pressure can fall dangerously low and result in shock and severe 
damage to many internal organs, such as the kidneys, liver and brain. As dehydration is 
associated with renal dysfunction (Roncal Jimenez et al., 2014), it can explain the 
phenotype observed in the kidney. We have shown that the Mocs2-/- animals present 
crystals in the collecting duct system of kidneys, as well as in the bladder. Since Mocs2 
isoforms are highly expressed in kidney collecting system, the knockout of the Mocs2 
gene can be a primary cause of crystal formation (nephrolithiasis). On the other hand, 
dehydration caused by skin failure may increase the concentration of minerals in the 
urine, resulting in nephrolithiasis. The accumulation of such crystals can form a plug, 
which causes a complete blockage of the urethra. The bladder became full of urine, which 
starts to go back into the kidney. This backflow of urine (vesicoureteric reflux) leads to 
infection, hydronephrosis and finally kidney damage (Tullus, 2015). The presence of 
proteins and haemoglobin in the urine - evaluated by the colorimetric test - confirmed 
the severe degenerative changes in kidneys. The presence of proteins in the urine may 
indicate damage of the filtration apparatus and the red blood cells were a sign of bleeding 
in the urinary system, caused by e.g. kidney stones. In turn, renal failure may interrupt 
the blood flow through the brain (Sims and Zaidan, 1995). The brain is particularly 
vulnerable to ischaemia (inadequate blood supply to a local area). Only 5 minutes of 
interruption in the blood flow to the brain triggers the death of neurons in several brain 
regions, while for example 20-40 minutes of ischaemia is required to destroy kidney cells 
or cardiac myocytes (Lee et al., 2000). Cerebral ischaemia is accompanied by a marked 
inflammatory reaction, which is initiated by ischaemia-induced expression of adhesion 
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molecules, cytokines and other inflammatory mediators, including prostanoides and nitric 
oxide (Iadecola and Alexander, 2001). These molecules activate the microglia, which is the 
resident macrophage population of the CNS responsible for the clearance of apoptotic 
neurons (Witting et al., 2000; Ginhoux et al., 2013). In light of this data, we performed 
immunostaining in Mocs2-/- brain sections using IBA1 (ionising calcium-binding adaptor 
molecule), a specific marker for microglia and macrophages (Ito et al., 2001). Although 
immunostaining for Casp3 (marker of apoptosis) showed massive apoptosis of neurons in 
brain sections of Mocs2-/- mice, IBA1 staining did not show increased activation of 
microglia. The rapid microglial response to local brain injury is mediated by extracellular 
ATP (Davalos et al., 2005). It can be hypothesised that the loss of mitochondria function 
due to the toxic effect of sulphite reduced the amount of extracellular ATP and thus 
abolished the over-activation of microglial cells. Finally, the observed phenotype may be 
an additive effect of the phenotypes observed in each tissue. Thus far, the brain 
phenotype has been considered the most severe, as the CNS is predominantly affected in 
patients. Indeed, this hypothesis was further confirmed in our study. Although Mocs2+/-
 mice do not present any abnormalities, we could identify slight neuron apoptosis in the 
hippocampus, cortex and brainstem. Since only the brain phenotype has been presented 
in Mocs2+/- mice, it seems to be a primary cause of premature death of Mocs2-/- animals. 
 
Tab. 8. Comparison of the phenotypes presented by Mocs1- and Mocs2- deficient mice 
Analysed features  Mocs1-/- Mocs2-/- 
Genetic background C57Bl/6J × 129sv C57Bl/6N 
Heterozygous animals  Normal and fertile Normal and fertile 
Number of homozygous mutant (-/-) 
mice 
~25% ~25% 
-/- pups Normal at birth  Normal at birth 
Suckling Normal Normal 
Survival rate 1-11 days 1-12 days 
Critical survival points 1 (82% died) 2 (47% and 51%) 
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Mean life span 6.3 4.7 
Impaired growth Yes Yes 
Curly whiskers Yes Yes 
Impaired hair growth Yes Yes 
Neuron apoptosis Yes (microarray) Yes (immunostaining) 
Activity of MoCo-dependent enzymes Diminished Diminished 
Sulphite level in the fresh urine Elevated Elevated 
Convulsions and ataxia No No 
Yellow deposits in the bladder Yes Yes 
Stones in kidney collecting ducts Not analysed  Yes 
 
In contrast to MoCo-deficient mice, patients present only progressive neurological 
damages. To date, the phenotype of isolated forms of aldehyde oxidase- and 
mitochondrial amidoxime reducing component-deficiency have not been described in 
humans. In most cases, xanthine oxidoreductase deficiency (xanthinuria) does not 
present any severe clinical symptoms and there is no specific treatment beyond 
maintaining a high fluid intake and avoiding foods that are high in purines (Gargah et al., 
2010). Xanthinuria is sometimes accompanied with xanthine deposition, which may rarely 
lead to renal failure (Ichida et al., 2012). In light of these findings, the phenotype 
observed in MoCo-deficient patients is mostly restricted to sulphite oxidase deficiency. In 
the first week of life, patients present feeding difficulties with tonic/clonic seizures. 
Additionally, they present symptoms such as metabolic acidosis, intracranial 
haemorrhage, exaggerated startle reaction, axial hypotonia and limb hypertonia (van der 
Knaap and Valk, 2005). Neuron damages are severe and progressive as a result of the 
accumulation of sulphite in the brain (Mechler et al., 2015). Magnetic resonance imaging 
(MRI) studies revealed a diffused pattern of brain atrophy with the arrested development 
of myelination (Appignani et al., 1996). Other observed features of MoCo deficiency in 
patients include dilated ventricles, hydrocephalus, brain hypodensity, spastic paraplegia, 
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myoclonus, ophisthotonus and ocular abnormalities (i.e. lens dislocation, spherophakia, 
iris coloboma, nystagmus or enophthalmos) (van der Knaap and Valk, 2005).  
 
4.4 Generation of isolated Mocs2a and Mocs2b knockout mice 
Although a Mocs2a knockout mouse line was successfully generated, it was not possible 
to establish a Mocs2b knockout, given that both MOCS2A transgenic lines failed to 
supplement the Mocs2a subunit in Mocs2-/- mice. In the first MOCS2A transgenic line 
(MOCS2A5) derived from the MOCS2A founder mouse #56, the MOCS2A transgene was 
expressed ubiquitously, although it was integrated in the third intron of the DnaJ (Hsp40) 
Homolog, Subfamily C, Member 24 (Dnajc24) gene (NCBI chr2:107210791-107210601). 
Heterozygous animals (MOCS2ATa/-) were fertile and had a normal appearance, while 
homozygous animals (MOCS2ATa/Ta) were embryonically lethal. qRT-PCR analyses showed 
a significant reduction of Dnajc24 expression in MOCS2ATa/- tissues in comparison to WT 
tissues. To date, the function of Dnajc24 gene is not well studied. Dnajc24m1Jkn mice (a 
chemically induced knockout mouse model of Dnajc24 gene) are retarded in growth and 
development and die before embryonic day 14 (E14) (Mouse Genome Informatics (MGI)). 
In the presented study, mating of heterozygous Dnajc24+/-mice with Mocs2+/- mice led to 
a formation of double heterozygous animals. The breeding of double heterozygous mice 
failed to generate offspring, although several females were pregnant. In accordance with 
the Mendelian ratio, approximately 6.25% of pups from the F1 generation should be born 
with a WT genotype. Most probably a cumulative effect of double knockout (DKO: Mocs2-
/-Dnajc24-/-, or Mocs2-/-Dnajc24+/-) caused severe malformation of DKO embryos, 
preventing the normal growing of other embryos and finally leading to abortion. In light 
of these results, a second transgenic line (MOCS2A6) was derived from the founder 
mouse MOCS2A #44. In this case, the integration site was identified on chromosome 6 
(NCBI chr6: 44712888). To date, no gene has been described in this area, although 
MOCS2A transgene expression was silenced. This problem seems to be common for 
transgenic mice generated via random transgene integration. A so-called position effect 
can influence the expression of the transgene (Robertson et al., 1995). The integration of 
foreign DNA into the heterochromatin region of genomic DNA often results in silencing of 
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the transgene. No additional MOCS2A founder animals were available to generate a 
Mocs2b knockout mouse model. 
By contrast, a MOCS2B transgenic line was successfully established, providing us the 
opportunity to generate a Mocs2a knockout mouse model. For this reason, Mocs2+/- mice 
were bred with MOCS2B transgenic animals and subsequently double heterozygous 
animals Mocs2+/-, Tb/- were selected and bred with each other. As expected, the Mocs2-/-, 
Tb/Tb and Mocs2-/-, Tb/- animals presented the same phenotype as Mocs2-/- mice, although 
the body weight during the postnatal period was higher compared to that presented by 
complete knockout mice. Additionally, most of the Mocs2-/-, Tb/Tb and Mocs2-/-, Tb/- 
presented only one critical time point and died between postnatal day 5 and 10, with a 
mean survival time of 5.9 ± 2.4 days. In light of these results, we can speculate that the 
Mocs2b protein has a dual function: besides the function which it performs together with 
the Mocs2a protein as a molybdopterin synthase, it may play additional role(s) that 
shortly after birth contributed to the reduction of growth retardation of Mocs2-/-, Tb/Tb and 
Mocs2-/-, Tb/- pups.  
 
4.5 Therapy for molybdenum cofactor deficiency 
The molybdenum cofactor deficiency is an example of a disease caused by a loss-of-
function mutation. There are three types of MoCo deficiency, namely A, B and C, which 
are distinguished based upon the mutations in genes regulating MoCo biosynthesis 
pathway. The type A of deficiency is attributed to the mutation in the MOCS1 gene, which 
protein products (MOCS1A and MOCS1B) are involved in the conversion of a guanosine 
triphosphate (GTP) to the cyclic pyranopterin monophosphate (cPMP). The cPMP is only 
one stable intermediate in the entire MoCo biosynthesis pathway (Schwarz et al., 2004). 
Schwarz and colleagues purified cPMP from Escherichia coli and used it for the 
substitution therapy in a mouse model of MoCo deficiency type A. Intrahepatic cPMP 
injection was sufficient to rescue the MoCo deficiency type A (Schwarz et al., 2004). Four 
years later (in year 2008), Veldman and colleagues used the cPMP for the treatment of a 
MoCo deficiency type A patient for the first time. Intravenous injections led to an efficient 
uptake of the cPMP, resulting in the restoration of activity of molybdenum cofactor-
dependent enzymes. It was not possible to rewind damages caused by the toxic sulphite, 
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although further neurodegeneration was retained (Veldman et al., 2010). This year, the 
patient will celebrate her 7th birthday. By contrast, substitution therapy cannot be 
employed for other types of MoCo deficiency, since other intermediates in the MoCo 
biosynthesis pathway are very unstable and purification is not possible. Therefore, 
development of potential therapy for MoCo deficiency type B and C is required. Figure 
4.5 presents a MoCo biosynthesis pathway in the context of possible therapy approaches 
for each type of MoCo deficiency. 
 
 
Fig. 4.5. Schematic representation of the molybdenum cofactor (MoCo) biosynthesis pathway together 
with potential therapies for the MoCo deficiency type A, B and C. A therapy for each type of MoCo 
deficiency depends on the biochemical character of missing intermediates. The green square represents 
MoCo deficiency type A, while the squares below present type B and C, respectively. Type A of the disease 
can be effectively cured by substitution therapy with purified bacterial cyclic pyranopterin monophosphate 
(cPMP), which is relatively stable in the lower pH. In contrast to cPMP, following intermediates, 
molybdopterin (MTP) and active MoCo are unstable. In this case, gene therapy is required to supplement 




D I S C U S S I O N  
 
4.5.1 Recombinant adeno-associated virus (rAAV)-based gene therapy 
Several considerations must be taken into account when designing a viral vector-based 
gene therapy, including a) infection efficiency, b) long-time expression of the therapeutic 
gene and c) a lack of toxicity (Daya and Berns, 2008). A growing body of evidence has 
shown that rAAV vectors fulfil all of these criteria.  
 
4.5.2 rAAV engineering and the route of delivery  
The first pre-clinical trials for MoCo deficiency gene therapy using recombinant adeno-
associated virus (rAAV) have been performed on a Mocs1-/- mouse model (Kugler et al., 
2007). Kugler and colleagues rescued the phenotype of a mouse model of MoCo 
deficiency type A by intrahepatic injections with rAAV serotype 1/2 carrying a MOCS1 
therapeutic gene under a ubiquitous CMV promoter. Based upon their results - as well as 
those obtained by Hahnewald and colleagues (Hahnewald et al., 2009) - we designed the 
rAAV-based gene therapy for MoCo deficiency type B. In order to increase the efficiency 
of viral infection and in turn the expression of the therapeutic gene, we used rAAV 
serotype 2/8 carrying the human MOCS2B gene under the control of a liver-specific, 
tyroxine binding globulin (TBG) promoter. To characterise the transduction efficiency and 
potential risk of rAAV induced tumour formation, we performed a long-term study. Table 
9 presents a summary of the strategy used in the present study in comparison to the 
strategy used by Kugler and colleagues (Kugler et al., 2007). 
 
Tab. 9: Comparison of strategies designed for the rAAV therapy of Mocs1 (Kugler et al., 
2007) and Mocs2 deficient mice 
GENE THERAPY PARAMETERS Mocs1-/- 
(Kugler et al., 2007) 
Mocs2-/- 
(Present study) 
SEROTYPE rAAV1/2 rAAV2/8 
PROMOTER CMV-ß-actin TBG 
EXPRESSION CASSETTE MOCS1 MOCS2B 
SCHEME OF INJECTIONS Day 1: 1×109 tu Day 1: 2×108 tu 
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Day 4: 3×109 tu Day 6: 8×108 tu 
ROUTE OF INJECTION Intrahepatic Intrahepatic 
PHENOTYPE RESCUE Yes n.a. 
PERSISTENCE n.a. 24 months 
RATE OF LIVER CELLS WITH TRANSGENE 
EXPRESSION  
100% to 5% 6.5% to 2% 
PATTERN OF EXPRESSION Ubiquitous Liver 
TUMORIGENIC POTENTIAL n.a. Strain dependent 
CMV = Cytomegalovirus, TBG = Tyroxine binding globulin, tu = transfecting units, n.a. = not analysed 
 
In the presented study, we chose the liver as a target organ for the gene therapy 
approach. Our choice was dictated by several factors: [1] all molybdenum cofactor 
(Moco)-dependent enzymes are active in the liver; [2] the liver is a highly vascularised 
organ, and thus a newly synthesised therapeutic protein can easily and efficiently gain 
access to the systemic circulation; [3] a growing number of studies have demonstrated 
that a liver-directed transfer can induce transgene product-specific immune tolerance 
(Mingozzi and High, 2007; LoDuca et al., 2009); and finally [4] the skin of newborn mice is 
transparent, which simplifies direct injection to the liver. Before the rAAV preparation, 
the appropriate tropism (viral affinity for specific tissue(s)) should be defined, since 
different serotypes of the virus interact with tissue-specific surface molecules (Rabinowitz 
and Samulski, 2000). A liver-specific tropism has been shown for serotype 8 of rAAV 
(rAAV8). This virus has been derived from the rhesus monkey (Gao et al., 2002) and the 
rAAV8 capsid has 82.8% homology with the capsid of best studied serotype 2 (AAV2) 
(Grieger and Samulski, 2005). Although the AAV2 is able to transduce hepatocytes, the 
expression of the therapeutic protein is low (Grimm and Kay, 2003). Most researchers 
employ so-called hybrid virions, which encode ITRs from the best described AAV2, as well 
as cap proteins derived from the AAV8, whose receptors appear highly prevalent in 
murine liver cells. It has been shown that such a hybrid virus achieves a 10- to 100-fold 
improvement in gene transfer efficiency compared with other vectors (Gao et al., 2002). 
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Many studies have shown successful gene transfer to the liver using rAAV2/8 
(Cunningham et al., 2008; Flageul et al., 2009; Laurence et al., 2009; Torres-Torronteras et 
al., 2014). Additionally, specific expression of a therapeutic gene can be triggered by an 
appropriate promoter (Papadakis et al., 2004). Kugler and colleagues showed that 
intrahepatic injection of neonatal mice with rAAV1/2 encoding EGFP under a CMV 
promoter leads to EGFP expression in different tissues, including the brain (Kugler et al., 
2007). In our study, we used a liver-specific tyrosine-binding globulin (TBG) promoter. It 
was shown that the TBG promoter-driven gene expression was restricted to the liver, with 
minimal invasion to other tissues (Yan et al., 2012). In agreement with this study, 
intrahepatic injection with rAAV2/8TBGMOCS2B-STOP-eGFP3 resulted in the expression 
of the MOCS2B protein exclusively in the liver of WT mice. At the same time, viral DNA 
could be detected in all other tissues analysed, except the brain. Although viral particles 
could be transported through blood vessels to different tissues, rAAV2/8 was unable to 
cross the blood-brain barrier.  
One of the drawbacks of intrahepatic injection is its restriction to a small volume 
injectable into a newborn liver. In order to test other routes of viral delivery, we 
performed intraperitoneal injection (IP). Although IP was sufficient to transduce the liver, 
it was not efficient enough to induce expression of the therapeutic gene. In light of these 
results, intrahepatic injection seems the most efficient route to deliver viral particles to 
the liver. These two aspects - rAAV engineering as well as the route of transduction - are 
very important to induce transgene expression for a long time in a tissue-specific manner.  
Modification of the strategy used by Kugler (Kugler et al., 2007), by changing the serotype 
and promoter and reducing the viral doses, was supposed to reduce the potential risk of 
the host immune response, which remains the greatest challenge facing AAV gene 
delivery. The host defence mechanism at the adaptive level comprises cell-mediated and 
humoral immunity. The cell-mediated response at the cellular level, eliminating the 
transduced cells using cytotoxic T cells, whereas the humoral response produces 
neutralising antibodies (NAb), preventing the re-administration of vector (Zaiss et al., 
2002). This first issue may be influenced by the route of viral administration (Brockstedt 
et al., 1999) and AAV serotype (Wang et al., 2007). Additionally, the cell-specific promoter 
might reduce the cellular response to rAAV (Cordier et al., 2001). A different route of 
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injection (intraperitoneal, intravenous, subcutaneous or directly to the tissue of interest) 
and packaging of a transgene to the distinct serotype of the rAAVs (Halbert et al., 2000) 
serve as potential factors that may allow re-administration of the virus. To overcome the 
problem of immune response in rodents, it is possible to use the window of vulnerability 
that encompasses the first days after birth, when the mature pattern of immune 
response to antigen is not yet achieved (Landreth, 2002). In contrast to human 
development, mice are born at an immunologically immature stage with few B cells and 
almost no T cells in the peripheral lymphoid tissues (Fadel and Sarzotti, 2000). Hahnewald 
and Hu showed in their studies that gene therapy in the neonatal period in mice avoid the 
development of immune responses and prolonged expression of the therapeutic gene 
(Hahnewald et al., 2009; Hu and Lipshutz, 2012). In terms of human, AAV-based gene 
therapy seems more complicated, given that humans do not present a window of 
vulnerability. Moreover, most human beings are serologically positive for antibodies 
against AAV particles (Boutin et al., 2010), thus significantly limiting rAAV gene transfer. 
However, it was shown that there might also exist in humans an ideal age interval for 
gene therapy intervention. Calcedo and colleagues studied the NAb titers to AAV2 and 
AAV8 in a cohort of 752 anonymous human subjects from different age groups (1 day to 
18 years), showing that NAb prevalence is moderate at birth, decreases markedly from 7 
to 11 months - probably due to a drop in maternal antibody levels - and subsequently 
progressively increases through childhood and adolescence (Calcedo et al., 2011). In light 
of this data, the age between 7 to 11 months seems the best period for rAAV treatment in 
humans. In case of patients who present the phenotype of disease earlier, an alternative 
strategy must be considered. Possible solutions to reduce the immune response include 
the administration of a short-term immunosuppression regimen concomitant with gene 
transfer or the development of more efficient vectors that can be administered at lower 
doses (Mingozzi and High, 2007). 
 
4.5.3 Efficiency of rAAV transduction 
The present long-term study has shown that a single injection of AAV2/8TBG-MOCS2B-
eGFP3 is sufficient to activate and maintain expression of the therapeutic gene for at least 
two years. As previously mentioned, several parameters (e.g. serotype, promoter or route 
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of viral delivery) should be considered before starting treatment. Another important issue 
includes the right time and amount of the virus used for injection. To optimise these 
parameters, we treated the animals with different virus concentrations with two 
temporally separated doses, both in the neonatal period. Through this strategy, we tried 
to find the balance between the injection volume restricted by the size of the animal and 
the potential immune response increasing with age. Three groups of animals obtained 
injection/injections with AAV2/8TBG-MOCS2B-eGFP3: the first group (I) obtained a single 
intrahepatic injection at the day of birth with 1×1010 GC (2×108 transfecting units (tu)); the 
second group (II) obtained a single injection at postnatal day 6 with 4×1010 GC (8×108 tu); 
and the last group (III) received a double injection, the first injection at the day of birth 
with 1×1010 GC, and a second injection at day 6 after birth with 4×1010 GC. The doses 
were chosen based upon the previous gene therapy study for molybdenum cofactor 
deficiency type A (Hahnewald et al., 2009). In this study, Hahnewald and colleagues 
showed that 4×108 tu (corresponding to 1×107 tu per g of body weight) is the minimal 
dosage required to rescue the phenotype of molybdenum cofactor deficiency type A. 
Under normal conditions, the AAV DNA can be detected in the cell nucleus as early as 2 
hours post-infection (Sanlioglu et al., 2000), and the AAV-mediated transgene expression 
is typically detected 2 to 3 weeks after vector infection (Miao et al., 1998). In our system, 
we were able to detect the MOCS2B-EGFP expression in hepatocytes as early as one week 
after injection, although the number of GFP-positive cells differed between different 
mouse groups. A single injection with 2×108 tu of AAV2/8TBG-MOCS2B-eGFP3 at the day 
of birth provided the best results, as 6.5% of liver cells were GFP-positive one week after 
injection. The number of positive cells gradually declined and maintained at 2%. In the 
other two groups (II and III) the initial efficiency was between 2-3% one week after 
injection and slightly decreased afterwards. In contrast to animals from group I and II 
(single injection), those from group III (double injection) did not present GFP-positive cells 
after 24 months. Because only one animal for each time point was used for the 
intrahepatic injection, technical problems during AAV injection cannot be ruled out. 
Therefore, it will be important to repeat this experiment with more animals to perform a 
solid statistical analysis. Interestingly, the first attempt to use AAV therapy for MoCo 
deficiency type A led to a transduction rate close to 100% one week after injection (Kugler 
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et al., 2007). In comparison to our study, Kugler and colleagues injected approximately 
60-fold more virus (5×109 tu) than we did. Unfortunately, there was no correlation 
between transduction efficiency and the number of GFP-positive cells, as only 5% of liver 
cells were GFP-positive one month after viral injection. The reason for such a dramatic 
decline of transgene expressing cells is due to the episomal nature of the rAAV genome, 
which can be easily lost during mitotical cell division (Beer et al., 2010). However, rAAV-
mediated gene therapy in a mouse model of molybdenum cofactor deficiency type A 
revealeds promising results after intrahepatic injection of newborn mice. Although less 
than 5% of hepatocytes expressed the therapeutic gene, most of the animals survived for 
20 weeks (Kugler et al., 2007). There are currently several clinical trials using AAVs for 
gene therapy approaches for the treatment of human disease. The long-term expression 
of the therapeutic gene was shown for example in a human haemophilia B patient, who 
obtained injection of rAAV encoding factor IX (F.IX) (Buchlis et al., 2012). Although the 
F.IX levels did not rise >1% and remained at a sub-therapeutic level, the patient survived 
10 years post-injection and died owing to causes unrelated to the gene transfer. The RT-
PCR analysis confirmed the expression of the F.IX transcript in the injected muscle tissue, 
reflecting an example of the longest transgene expression from a parenterally 
administered AAV vector and thus confirming that long-time expression is possible; 
rather, only the dosage has to be optimised to make the entire therapy approach highly 
efficient.  
 
4.5.4 Tumorigenic potential of rAAV-based gene therapy in mouse 
As mentioned at the beginning of this chapter, the ideal gene therapy approach should 
present a general lack of toxicity. In case of rAAV therapy, this aspect still prompts 
controversy. The wild type (WT) AAV is neutral for humans as it presents a site-specific 
integration on chromosome 19. This process is mediated by Rep proteins (Balague et al., 
1997). Unfortunately, the rAAV lost such ability during the process of its production, as all 
viral genes (including Rep) are replaced by the therapeutic gene (Linden et al., 1996). 
Although AAV vectors are predominantly non-integrating extrachromosomal episomes 
that serve as the major source for transgene expression, Nakai and colleagues showed in 
mice that after tail vein injection of recombinant AAV2 vectors expressing hF-IX at doses 
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of 2.4×1011 to 3.0×1011 vector genomes per mouse less than 10% of double-stranded 
rAAV genomes can be found inserted in the host chromosomal DNA (Nakai et al., 2001). 
Furthermore, a significant proportion of rAAV DNA integration events took place in 
transcriptionally active regions, as shown in the mouse liver (Nakai et al., 2003). We 
cannot exclude the possibility that long-term expression of the therapeutic gene in our 
study comes from integrated viral DNA rather than episomes. These findings prompt the 
question of whether there is any risk of insertional mutagenesis after rAAVs 
administration. The universal safety of rAAV was first questioned by a single study that 
described the development of hepatocellular carcinoma (HCC) in mice after rAAV-based 
gene therapy (Donsante et al., 2007). Using a murine model of β-glucuronidase 
deficiency, Donsante and colleagues identified an increased rate of HCC in mice treated 
with rAAV in the neonatal period. Subsequently, several groups investigated rAAV-
mediated genotoxicity in mice and failed to reproduce these results (Bell et al., 2005; Li et 
al., 2011). To investigate this issue, we performed the longitudinal study in which mice 
from two different strains - namely C57Bl/6N and 129sv mice - obtained two intrahepatic 
injections (first at the day of birth with 1×1010 GC, and second at the day 6th with 
4×1010 GC) with 1460 AAV2/8TBGMOCS2B-STOP-eGFP3 (n=50) or PBS (n=50) and were 
kept under sterile conditions to eliminate the risk of other infections (e.g. hepatitis virus 
infection). The cause of death of each animal was investigated by animal pathologists. The 
groups treated with PBS were used as a control showing a spontaneous tumour rate 
specific for each strain. We measured a tumour rate of 44% (22 mice, including 7 HCC) 
and 6% (3 mice, with 1 HCC) in C57Bl/6N and 129sv strain, respectively. Our results are in 
contradiction with previously published data showing the tumour incidences of 86% and 
14% in strain C57Bl/6 and 129sv, respectively (Smith et al., 1973; Blackwell et al., 1995). 
These discrepancies could be caused by differences in the housing condition (e.g. diet or 
SPF status) between experimental animal groups (Turturro et al., 2002). In contrast to 
previous studies, we also showed the differences in the frequency of spontaneous 
hepatocellular carcinoma (HCC). 10% and 2% of control animals from C57Bl/6N and 129sv 
strains developed HCC, respectively, which is significantly higher than <5% and 0% cited in 
the literature for the C57Bl/6N and 129sv strain, respectively (Smith et al., 1973; 
Drinkwater and Ginsler, 1986). Since the first onset of HCCs was manifested quite late 
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(17-27 months), they could not be due to premature experiment termination. Taken 
together, both studies present the same trend, whereby the C57Bl strain is considered 
susceptible to many tumours, including HCC. Compared to control groups, our 
experimental cohorts (mice treated with rAAV) showed slight increase in their tumour 
rate (48% and 14% in C57Bl/6N and 129sv strain, respectively). Based upon these results, 
it is extremely difficult to assess an influence of the rAAV infection on the global tumour 
formation. The differences became clearer when taking a closer look to tumour 
composition presented in each group. As expected, the highest differences were 
observed in the frequency of HCC, as 20% of C57Bl/6N and 6% of 129sv animals develop 
HCC after rAAV treatment. An increase of HCC frequency did not correlate with their 
earlier onset after rAAV infection, as the HCC latency period in rAAV treated mice was 
similar as in control mice (17-21 months). In agreement with our study, Chandler and 
colleagues showed that rAAV-mediated gene therapy activates genotoxicity. They found 
that rAAV integrate into the Rian (RNA imprinted and accumulated in nucleus) locus, 
resulting in overexpression of microRNAs and retrotransposon-like 1 (Rtl1), leading to 
HCC formation (Chandler et al., 2015). However, they described factors that may 
influence the frequency of HCC formation. They injected mice intrahepatically with 
1×1011GC to 2×1011GC or 1×109GC to 1×1010GC and revealed that there is a relationship 
between AAV dose and frequency of HCC following injection. They found that reducing 
AAV dose reduced the aggregate incidence of HCC at 22 months from 84% to 12%. 
Another factor that may trigger HCC formation is a promoter-driven therapeutic gene. 
They showed that AAV carrying a TBG or chicken β-actin (CBA) promoter developed HCC 
more frequently than those that contained a human alpha 1-antitrypsin (hAAT) promoter. 
Finally, they showed that the serotype may also modulate the hepatic tumour formation, 
as more mice presented HCC after treatment with AAV8 than after treatment with AAV2 
(Chandler et al., 2015). In light of these results, the dose of the virus as well as the 
serotype and promoter should be taken into consideration in future studies. Although 
Chandler and colleagues showed that the serotype 8 of AAV or usage of the TBG 
promoter are factors that increase genetoxicity, they only performed their analysis in 
mice with the C57Bl/6 background. Since I showed that background is a key factor that 
influences the HCC frequency - with C57Bl/6N mice developing HCC more frequently than 
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129sv mice (48% vs 14%) - a study of such factors as serotype, promoter or doses of the 
virus should be repeated in different mouse strains. From the non-malignant cause of 
death, the most frequent disease in the C57Bl/6N background was ulcerative dermatitis, 
whereby 18% animals from the group injected with rAAV and 18% from the group treated 
with PBS developed this disease. It is known from the literature that in some colonies 
from C57Bl/6N strain > 20% of animals may develop this skin lesion, while both the 
incidence and severity is higher in females (Kastenmayer et al., 2006; Brayton, 2009; 
Hampton et al., 2012). This trend was also observed in our colony (data not shown). 
Affected mice usually had pruritic leading to self-mutilation, disease progression and 
often euthanasia for ethical reasons. In the 129sv strain, the most frequent non-
malignant causes of death were retrobulbar abscesses with periocular swelling and 
urinary track obstruction with stones localised in the bladder. There is no information 
concerning the incidence of the eye lesion in the 129sv strain. Since the frequency was 
higher in the rAAV treated group than PBS (20% vs 8%), it can indicate that the virus may 
have an influence on the development of the disease. By contrast, urinary obstruction has 
been already described in animals from the 129sv strain (Brayton, 2009). Typically, it 
occurs in males and is a frequent non-malignant contributor to death.  
In conclusion, I have shown that the administration of rAAV2/8 carrying the MOCS2B 
therapeutic gene under the control of the TBG promoter can predispose to HCC 
formation, although the genetic background is a main factor that can influence the 
frequency of rAAV-mediated insertional mutagenesis and subsequent genotoxicity.  
 
4.6 Perspectives 
Therapies for most of the orphan diseases are challenging for the clinical study, given that 
the development of such therapy is extremely expensive and does not give sufficient 
profits for the pharmaceutical industry. A rAAV-based gene therapy seems a very 
promising tool for treatment of several diseases and it has been successfully used in many 
clinical trials, i.e. for haemophilia B (Hasbrouck and High, 2008), cystic fibrosis (Moss et 
al., 2004) or Leber’s congenital amaurosis (Simonelli et al., 2010). 
Deep knowledge about the exact expression of the Mocs2 gene will help to improve the 
strategy used for therapy. To date, very little is known about the exact expression pattern 
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of Mocs2 genes in the cell compartments. Although we showed that Mocs2 proteins are 
expressed in vesicle-like structures in the cytoplasm, an exact subcellular localisation 
should be performed. To identify the specific localisation of Mocs2 proteins, 
immunohistochemical analysis using a specific Mocs2 antibodies and organelle-specific 
marker antibodies should be conducted. This experiment can be performed for example 
in the neuronal cell line e.g. Neuro-2a or in liver sections. 
In the present study, I established the knockout mouse model for the complete Mocs2 
gene. The most severe phenotype caused by Mocs2 ablation was observed in the brain, 
kidney and skin. However, I was unable to point out the primary cause of the premature 
death of Mocs2-/- mice, given that damage occurring in one tissue may lead to a 
secondary effect in other organs, i.e. dehydration caused by impaired skin barrier can 
lead to stone formation in the urinary tract and parallel to kidney damage, resulting in 
decreased blood pressure, ischaemia and apoptosis in the brain. On the other hand, 
apoptosis in the brain can lead to kidney dysfunction, leading in turn to stone formation, 
etc. In future work, one should concentrate on the detailed characterisation of Mocs2 
knockout animals. To gain an overview of the general health condition of the knockout 
animals, basic examination of the blood and urine parameters should be performed. The 
analysis of the blood parameter should include the measurement of the blood activity of 
MoCo-dependent enzymes (aldehyde oxidase, xanthine oxidoreductase, sulphite oxidase 
and mitochondrial amidoxime reducing component (mARC), as well as level of liver 
transaminases (AST and ALT), triglycerides, glucose, total cholesterol, total protein, 
albumin and urea). Moreover, biochemical analysis of urine should include the specific 
gravity, pH, presence of proteins, bacteria, inflammatory markers, nitrite, ketones, 
leukocyte esterase, as well as the number of blood cells and the level of bilirubin, 
urobilinogen, sulphite, cystine, uric acid and xanthine. It will give the overall impression 
regarding the condition of all organs.  
Thus far, we have taken a closer look at the brain and kidney. In future studies, a 
histopathological analysis of the liver should be conducted. Since all MoCo-dependent 
enzymes are expressed in the liver, a severe phenotype in this organ is also expected. 
Furthermore, precise skin analysis should be performed. HE staining followed by 
histopathological analysis will show changes in the skin morphology. Identification of 
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severe changes could suggest that the skin barrier may be disturbed in Mocs2-/- pups. To 
measure the epidermal permeability barrier (EPB), simple techniques that monitor the 
diffusion of dyes (X-Gal or Lucifer Yellow) through the upper epidermis and measurement 
of transepidermal water loss (TEWL) resulting from a defective skin barrier could be 
performed. Finally, studying the influence of Mocs2 isoforms on mice fertility - especially 
in context of spermatogenesis - should be investigated. For this reason, a spermatogonial 
stem cell (SSC) culture from testis of Mocs2-/- mice should be established and 
transplanted to busulfan treated males. Busulfan treatment eliminates dividing cells from 
seminiferous tubules and only injected cells can colonise them. This technique is routinely 
used for testing the development potential of germ cells. After injection into recipient 
males, the spermatogenesis reconstitution should be investigated. Taking advantage of 
the LacZ reporter, one could easily identify cells derived from knockout mice. 
Although we detected crystal-like structures in the kidney and bladder of Mocs2-/- mice 
during phenotypical characterisation, the biochemical analysis failed to describe the 
composition of these structures. The analysis should be repeated using combined 
samples from more Mocs2-/- animals. 
To gain some ideas concerning whether Mocs2 depletion is able to induce neuron 
apoptosis, the siRNA approach to knockdown the Mocs2 gene in a neuronal cell line, e.g. 
Neuro-2a cells (ATCC), could be engaged. If Mocs2 knockdown will not induce massive 
apoptosis of Neur-2a cells, it means that apoptosis is rather a secondary effect caused by 
damages observed in the skin or the kidney. In parallel, an inducible conditional Mocs2 
knockout could be generated. Activation of the Cre-recombination in adult Mocs2flox/flox 
mice followed by pathological analysis of the skin, kidney and brain could give a clue 
about which tissue is first affected. If the primary phenotype will be present in the kidney, 
the symptoms can be cured and the condition of the brain and skin can be investigated. 
Moreover, the premature death of Mocs2-/- mice can be a result of the general weak 
condition of knockout animals, which hinders access to milk. To check whether the 
animals have an appropriate food intake, the stomach content should be measured in 
comparison to the wild type littermates. 
Gene therapy approaches for MoCo deficiency type B remain questionable due to the 
bicistronic structure of Mocs2 genes. It is unknown whether re-expression of Mocs2 
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genes in trans-configuration will lead to the production of functional subunits of Mocs 
proteins and finally to the formation of a molybdopterin synthase complex. To investigate 
this, we decided to supplement both Mosc2a and Mocs2b subunits by crossing a Mocs2 
knockout with transgenic animals. For this reason, I generated transgenic mouse lines 
overexpressing human MOCS2A or MOCS2B proteins. I obtained a MOCS2B transgenic 
line and successfully created a double transgenic mouse line Mocs2-/-, Tb/- (or Mocs2a-/-). 
As expected, double transgenic animals presented a similar phenotype to Mocs2-/- mice 
and died within the first 9 days after birth. Surprisingly, the re-expression of the MOCS2B 
gene significantly improved the body weight and mean life span of Mocs2-/-, Tb/- pups. In 
light of this result, I speculate that the Mocs2b protein can execute another function, 
independent from the Mocs2a protein function. As mentioned in the introduction 
section, there are at least three isoforms of the Mocs2b gene leading to translation of two 
different proteins: with complete or truncated (Mocs2bΔ) products encoded by exon 5. 
The part of exon 5 that is missing in Mocs2bΔ isoform is a part of the catalytic domain of 
Mocs2b protein. Thus far, Mocs2bΔ protein has not been detected in mice. In future 
studies, the characterisation of the tissue distribution on the RNA and protein level and 
its potential function should be elucidated. 
To rescue the phenotype of MoCo deficiency, double transgenic mice Mocs2-/-, Tb/- should 
be bred with a MOCS2A transgenic line. Since both established MOCS2A transgenic lines 
failed to express the transgene, generation of an additional MOCS2A transgenic line will 
be necessary. Furthermore, the MOCS2A mice should be crossed with Mocs2 knockout 
mice to generate the isolated form of Mocs2b knockout (Mocs2b-/-). For this model of the 
disease, we have already established a rAAV-based therapy. 
In the long-term study performed on wild type animals, we have shown that the virus can 
efficiently transduce hepatocytes, whereby around 2% of cells express the MOCS2B-eGFP 
fusion protein at least 2 years after injection. However, the efficiency of this therapy must 
be elucidated in isolated form of Mocs2b knockout. The process of transgenic line 
generation as well as the breeding of animals is time-consuming experiment. Since the 
isolated knockout of Mocs2a isoform has already been established, the viral particles 
encoding MOCS2A should be generated to check whether the design viral therapy will 
rescue the phenotype. Another possibility is viral treatment of complete Mocs2-/- mice, 
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although the virus encoding both Mocs2a and Mocs2b proteins is required. Essentially, 
these proteins are encoded from two different yet overlapping open reading frames 
(ORF). One option to produce two distinct proteins from the transcript delivered by the 
virus is to use a 2A peptide-based strategy for the therapeutic gene designing (Szymczak 
and Vignali, 2005). The 2A peptide is a self-processing peptide from the Foot-and-Mouth 
Disease Virus (FMDV). These peptides allow multiple proteins to be encoded as 
polyproteins, which dissociate into component proteins on translation. Using this 
technique, it will be possible to express both subunits of Mocs2 proteins from a single 
vector. 
In a final step, the phenotypical analyses of Mocs1 knockout animals in the context of the 
phenotype identified in Mocs2 knockout animals should be performed. In a previous 
study it was shown that the Mocs1 deficient mice die at postnatal day 0-11 and presented 
a phenotype with growth retardation, as well as curly whiskers. However, the histological 
analysis of the brain in Mocs1 deficient mice did not reveal any abnormalities. Because 
only nuclear staining of neuronal tissue of Mocs1 deficient mice was used in the previous 
study, precise immunohistochemical analyses of the brain as well as all other organs 
should be conducted and compared to the phenotype observed in Mocs2 deficient mice.  
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5 SUMMARY  
Main aims of this study were the generation of a mouse model for the molybdenum 
cofactor deficiency type B disease as well as the development of a potential recombinant 
adeno-associated virus (rAAV) gene therapy approach. The molybdenum cofactor 
deficiency type B disease occurs as a result of an impairment in the second step of the 
molybdenum cofactor (MoCo) biosynthesis pathway, including mutations in the MOCS2A, 
MOCS2B or MOCS3 genes (to date, no mutations have been found in the MOCS3 gene) 
(Reiss et al., 1999; Reiss and Hahnewald, 2011). Thus far, 26 cases of MoCo deficiency 
type B have been reported worldwide (HGMD Professional 2015.1). In 12 of these 
patients, the MOCS2A gene was mutated and in the rest of the patients the MOCS2B gene 
was affected. Accordingly, we decided to generate a knockout mouse model for the 
murine Mocs2b gene (Mocs2b-/-). In the first trial, Mocs2b knockout was generated using 
commercially available mouse embryonic stem cells (ESCs), in which one copy of the 
Mocs2b gene was targeted by a knockout first construct. Although ESC injections into 
C57Bl/6N blastocysts gave rise to chimeras, they did not transmit the knockout allele to 
the progeny. To overcome this problem, a knockout model of the entire mouse Mocs2 
gene was established. In this model, both Mocs2a and Mocs2b isoforms were deleted. 
Although Mocs2-/- mice were born in accordance with the Mendelian ratio and appeared 
normal at birth, a few hours later the body weights of Mocs2-/- mice were significantly 
reduced compared to their heterozygous (Mocs2+/-) and WT (Mocs2+/+) littermates. 
Moreover, during the first days of life, Mocs2-/- mice increased their body weights at a 
significantly slower rate than their WT and heterozygous littermates. Additionally, Mocs2-
/- mice presented skin problems, a defect in the overall hair growth and generally they 
were in a weaker health condition than Mocs2+/+ and Mocs2+/- pups. The Mocs2-/- animals 
died within 12 days after birth with a mean survival rate of 4.7 days. To select for 
potential tissues affected by the depletion of Mocs2a/b isoforms, Mocs2a/b expression 
analyses in different tissues of WT animals were performed. The results revealed 
ubiquitous expression of Mocs2a/b isoforms, with the highest expression levels detected 
in the mouse skin, liver, brain, lung and kidney. These findings can partially explain the 
skin phenotype observed in Mocs2-/- pups. Similar correlations were identified in the 
kidney and brain. All Mocs2-/- pups presented a urinary retention caused by the 
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accumulation of yellow deposits in the bladder. The histological analysis of kidneys 
derived from Mocs2-/- mice demonstrated the presence of crystals in the collecting duct 
system. Urine analysis revealed an elevated level of sulphite, proteins and extremely high 
concentrations of haemoglobin and/or damaged erythrocytes. The histopathological 
analysis of the brain showed severe neuronal apoptosis in the hippocampus, cortex and 
brainstem of Mocs2-/- mice. Despite being reduced as compared to the Mocs2-/- animals, 
Mocs2+/- mice also presented a statistical significant number of apoptotic neurons in the 
aforementioned brain regions, although Mocs2+/- animals developed normally and were 
fertile. I speculate that depletion of Mocs2 genes has a direct effect on the normal 
function of tissues presenting with high Mocs2a/b expression levels. In order to rescue 
the phenotype of Mocs2-/- mice, we decided to supplement missing proteins Mocs2a and 
Mocs2b through a transgenic mouse approach. For this reason, two different transgenic 
mouse lines expressing either the MOCS2A or the MOCS2B isoform were generated. The 
rescue experiment was designed to check whether both subunits expressed in trans-
configuration are able to form a functional complex. On the other hand, the generation of 
separate transgenic lines for MOCS2A and MOCS2B isoforms offered the possibility to 
breed them with Mocs2-/- mice and generate a pure knockout model for each isoform. 
The isolated knockout of either the Mocs2a or Mocs2b isoform could further serve as a 
model for testing a potential therapy approach. Unfortunately, due to several problems 
with transgenic MOCS2A mouse lines, it was not possible to create a rescue model for 
Mocs2b-/- knockout animals. To date, MOCS2B transgenic mice were successfully 
generated and subsequently bred with Mocs2+/- mice, giving rise to a mouse line 
corresponding to a knockout of the Mocs2a isoform. As expected, supplementation of 
Mocs2-/- mice with the transgenic MOCS2B protein (Mocs2-/-, Tb/- mice) did not rescue the 
phenotype of Mocs2-/- mice, although the body weight of Mocs2-/-, Tb/- pups and their 
mean life span significantly increased compared to their Mocs2-/- littermates. In parallel to 
the generation of an isolated form of the Mocs2 knockout model, a potential gene 
therapy approach was developed. Among many available vectors, we decided to use the 
recombinant adeno-associated virus (rAAV)-based vector system. rAAVs are currently 
among the most frequently used viral vectors for gene therapy approaches. We used the 
viral particles with serotype 2/8 encoding either the human MOCS2B protein or the 
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MOCS2B-EGFP fusion protein under the control of the liver-specific thyroxine-binding 
globulin (TBG) promoter. The virus was administered via intrahepatic injection, as we 
showed that this route results in the highest transduction efficiency. Using this system, 
we were able to transduce approximately 2-7% of mouse liver cells and maintain MOCS2B 
transgene expression for at least two years after a single injection into the mouse liver. In 
agreement with previous results, infection with rAAV2/8TBG-MOCS2B-STOP-eGFP3 did 
not rescue the phenotype of Mocs2-/- mice, but it was sufficient to increase the body 
weight of Mocs2 knockout pups after birth and prolong the mean life span of Mocs2-/- 
mice to 8 ± 0.7 days. Using a long-term study, we also investigated the potential 
malignancy risk of a viral-based gene therapy approach. We could demonstrate that the 
presence of tumours - and particularly hepatocellular carcinomas (HCC) - was mouse 
strain-specific, because HCC occurred more frequently in C57Bl/6N mice compared to the 
129sv mouse strain. Moreover, only in C57Bl/6N mice did rAAV administration into the 
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